SPRINGER BRIEFS IN FOOD, HEALTH, **AND NUTRITION**

Edurne Simón · Idoia Larretxi Itziar Churruca · Arrate Lasa María Ángeles Bustamante · Virginia Navarro María del Pilar Fernández-Gil Jonatan Miranda

Nutritional and Analytical Approaches of Gluten-Free Diet in Celiac Disease

SpringerBriefs in Food, Health, and Nutrition

SpringerBriefs in Food, Health, and Nutrition present concise summaries of cutting edge research and practical applications across a wide range of topics related to the field of food science, including its impact and relationship to health and nutrition. Subjects include: Food Chemistry, including analytical methods; ingredient functionality; physic-chemical aspects; thermodynamics Food Microbiology, including food safety; fermentation; foodborne pathogens; detection methods Food Process Engineering, including unit operations; mass transfer; heating, chilling and freezing; thermal and non-thermal processing, new technologies Food Physics, including material science; rheology, chewing/mastication Food Policy And applications to: Sensory Science Packaging Food Qualtiy Product Development We are especially interested in how these areas impact or are related to health and nutrition. Featuring compact volumes of 50 to 125 pages, the series covers a range of content from professional to academic. Typical topics might include: A timely report of state-of-the art analytical techniques. A bridge between new research results, as published in journal articles, and a contextual literature review. A snapshot of a hot or emerging topic. An in-depth case study. A presentation of core concepts that students must understand in order to make independent contributions.

More information about this series at<http://www.springer.com/series/10203>

Edurne Simón • Idoia Larretxi • Itziar Churruca Arrate Lasa • María Ángeles Bustamante Virginia Navarro • María del Pilar Fernández-Gil Jonatan Miranda

Nutritional and Analytical Approaches of Gluten-Free Diet in Celiac Disease

Edurne Simón Faculty of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz, Alava, Spain

Idoia Larretxi Faculty of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz, Alava, Spain

Itziar Churruca Faculty of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz, Alava, Spain

Arrate Lasa Faculty of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz, Alava, Spain María Ángeles Bustamante Faculty of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz, Alava, Spain

Virginia Navarro Faculty of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz, Alava, Spain

María del Pilar Fernández-Gil Faculty of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz, Alava, Spain

Jonatan Miranda Faculty of Pharmacy University of the Basque Country (UPV/EHU) Vitoria-Gasteiz, Alava, Spain

ISSN 2197-571X ISSN 2197-5728 (electronic) SpringerBriefs in Food, Health, and Nutrition ISBN 978-3-319-53341-4 ISBN 978-3-319-53342-1 (eBook) DOI 10.1007/978-3-319-53342-1

Library of Congress Control Number: 2017938122

© The Author(s) 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG

The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Contents

Chapter 1 Celiac Disease and Gluten-Related Disorders

Idoia Larretxi, Virginia Navarro, and Itziar Churruca

Abbreviations

Gluten is a complex mixture of proteins found in the endosperm of cereal, kernels, and grains in the *Triticeae* family (wheat, barley, rye, and their varieties) and, probably, from the *Aveneae* family (oats). Gluten comprises approximately 80% of these cereal proteins and includes two fractions: glutenins and prolamins. Although prolamins, soluble in alcohol, are the toxic fraction for celiac sufferers, celiac disease (CD) is usually known as gluten sensitivity instead of prolamin sensitivity.

A description of prolamins depends on the cereals' origin. In the case of wheat, they are called gliadins; regarding barley and rye, they are called hordeins and secalins, respectively, and the prolamins from oat are known as avenins.

Gluten is used as a gelling agent and emulsifier that binds water molecules and therefore works as a structural element; among other functions, it acts as a binding element that provides elasticity. It also provides adequate sensorial and technological characteristics, such as cohesiveness, firmness, moisture, and uniformity, to baked products. Because of these characteristics and its value as a source of protein in human nutrition, gluten is one of the essential ingredients for the food industry.

1.1 Celiac Disease

The definition of CD has been modified over the past two decades. Regarding the latest European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines, CD is defined as a systemic immune-mediated disorder caused by gluten and related prolamins in genetically predisposed individuals [[1\]](#page-18-0). In CD a combination of gluten-dependent clinical manifestations, specific antibodies, certain antigen-presenting molecules (HDL-DQ2 and HDL-DQ8 haplotypes), and enteropathy merge, with varying degrees of severity. This definition modified the prior concept of rare enteropathy, and CD has come to be considered a common and extended pathology, with multi-organ manifestations.

1.1.1 Epidemiology

In recent years, the epidemiology and symptomatology of CD have both considerably changed. Historically, this rare gastrointestinal disorder mainly affected the Caucasian population, and it usually appeared during the early years of life [[2\]](#page-18-0). Nowadays, it is known that CD affects all age groups, with a female-to-male ratio of 2:1. Available data suggest that its prevalence has significantly increased in the past 20 years, and it is currently one of the most common life-long heritable food intolerances worldwide [\[3\]](#page-18-0); this could, in part, be not only because of better diagnostic tools, but also because of the deeper understanding of the disease and its symptoms by health professionals.

The prevalence of CD is not well established, but in most of the Western world it affects approximately 1–2% of the population − even if wide differences have been found among countries [[2,](#page-18-0) [4\]](#page-18-0). Peña and Rodrigo [[4\]](#page-18-0) found significant differences between Northern Europe and Mediterranean countries, with a greater prevalence in the former (0.016–2.4%). The literature has shown that the average prevalence of CD in other developed countries, such as the United States, Australia, and New Zealand,

is similar to that seen in Europe [[2,](#page-18-0) [4\]](#page-18-0). On the other hand, Catassi et al. [\[5](#page-18-0)] found a prevalence of about 5.6% in the Western Sahara population in 1998. This might be linked to higher gluten consumption and to higher frequencies of HLA-DQ2 and HLA-DQ8 haplotypes in this population [\[6](#page-18-0)]. On the contrary, the prevalence of this condition in the Far East is almost anecdotal, probably because of the low consumption of gluten and the low prevalence of HLA-predisposing genotypes [\[2,](#page-18-0) [4,](#page-18-0) [6\]](#page-18-0). The epidemiology of CD is considered to have the characteristics of an iceberg, where symptomatic (both gastrointestinal and extraintestinal) CD is on the top, and a significant percentage of patients with silent or atypical CD are still undetected [[7,](#page-18-0) [8\]](#page-18-0).

It has been observed that the probability of developing CD increases in certain risk groups, such as first-degree relatives and patients with genetic alterations such as Down, Turner's, and William's syndromes, or selective immunoglobulin A (IgA) deficiency. It has also observed an increased CD prevalence in people suffering from autoimmune diseases, such as type 1 diabetes mellitus, autoimmune thyroid disease, chronic autoimmune liver disease, youthful chronic arthritis, Sjögren's syndrome, kidney disease, or idiopathic dilated cardiomyopathy. The understanding of these risk groups is important, and even though the conditions may not be pathogenically related to CD, the high prevalence of the disorder in these groups makes testing them serologically very necessary.

1.1.2 Pathogenesis and Clinical Presentation of CD

CD development requires the interaction of genetic, immunological, and environmental factors.

When gluten that is present in food is ingested, it is metabolized into peptides (prolamin). Taking wheat as an example, the gliadin crosses the epithelial barrier, which has an increased permeability in these patients, and it reaches the lamina propria. At this level, the peptide is deamidated by a tissue transglutaminase (tTG2), which allows its recognition by HLA DQ-2 or DQ8. The antigen-presenting cell presents deamidated gliadin to CD4 T cells. These immune cells, on the one hand, secrete pro-inflammatory cytokines that cause damage (villous atrophy and crypt hyperplasia) to the enterocytes but, on the other hand, activate B cells that produce antibodies against gliadin or other toxic prolamin. At the same time, deamidated gliadin induces IL15 production by the enterocyte, which stimulates the proliferation of intraepithelial lymphocytes (IEL) (Fig. [1.1](#page-9-0)).

Various factors have been proposed as possible triggers of later development of CD. On the one hand, feeding during early childhood has been studied. There is not enough evidence to provide general recommendations about breastfeeding (duration and breastfeeding at the time of gluten introduction) to prevent CD [[10,](#page-18-0) [11](#page-18-0)]. With regard to the association of the timing of gluten introduction and later development of CD, various results have been proposed [[10](#page-18-0)]; even so, the ESPGHAN recommends avoiding both an early (<4 months) and late (≥7 months) introduction of gluten, and introducing it while the infant is still being breastfed.

Fig. 1.1 Illustration of CD pathogenesis (Adapted from Moscoso and Quera [[9](#page-18-0)]). *IEL* intraepithelial lymphocytes, *TG2* transglutaminase 2, *DC* dendritic cell

Although a gluten-containing diet only supposes a risk of developing CD for persons carrying at least one of the CD risk alleles, recommendations are applied to all infants. With regard to the amount of gluten, avoiding the consumption of large quantities of gluten at the beginning of gluten introduction has been proposed; however, optimal amounts have not yet been established [\[11\]](#page-18-0). On the other hand, the relationship between CD and some gastrointestinal infections have been assessed; it seems that such infections increase the risk of celiac disease autoimmunity in people with a genetic susceptibility to CD [\[12](#page-18-0)], yet are reduced in people vaccinated against rotavirus. In the case of *Helicobacter pylori*, it has been suggested that gastric infection can confer protection against CD [\[13\]](#page-18-0). In summary, the literature indicates potential interactions among infections, genetic factors, and diet in the etiology of this pathology, but more studies are needed to shed light on this issue.

There is a wide variety of signs and symptoms, which makes it difficult for physicians to diagnose the disorder early and correctly. There are even no symptoms [\[3](#page-18-0)] in some cases and, when they appear, they can be distinguished as either gastrointestinal or extra-intestinal symptoms.

Symptomatic forms differ considerably, depending on the age, with gastrointestinal signs more characteristic in childhood, whereas adults endure extraintestinal symptoms (Table [1.1](#page-10-0)). In fact, less than 25% of the adult population diagnosed with CD presented with gastrointestinal symptoms [[14\]](#page-18-0).

As mentioned, symptomatic forms are just the tip of the iceberg regarding the broad spectrum of gluten sensitivity, as several epidemiological studies determined that CD without classic symptoms is more common than the symptomatic form [[15\]](#page-18-0).

Gastrointestinal symptoms		Extraintestinal symptoms		
Childhood	Adulthood	Childhood	Adulthood	
Lack of appetite	Irritable bowel	Arthritis	Anemia	
Chronic diarrhea	syndrome	Follicular keratosis	Early menopause	
Constipation	Constipation	Irritability/apathy	Osteoporosis/arthritis	
Recurrent	Recurrent	Menstrual irregularities/	Paresthesia	
abdominal pain	abdominal pain	delayed menarche	Ataxia/epilepsy/peripheral	
Vomiting	Dyspepsia	Stunted growth	neuropathy	
Abdominal	Chronic	Introversion/sadness	Irritability/apathy	
distension	diarrhea	Failure to thrive	Dermatitis herpetiformis	
	Malabsorptive	Osteopenia	Cold sores/peripheral edema	
	diarrhea	Enamel hypoplasia		
		Dermatitis herpetiformis		
		Cold sores		
		Headaches		
		Malnutrition/anemia		
		Muscle hypotrophy		

Table 1.1 Signs and symptoms of symptomatic CD

Some years ago, at the bottom of the iceberg, previously unknown symptoms were characterized as silent CD, latent CD, or potential CD [\[1](#page-18-0)].

Symptomatic CD is characterized by the onset of digestive, extra-digestive symptoms and/or associated diseases such as dermatitis herpetiformis. Silent CD or asymptomatic CD is a form of the disease in which the patient presents positive CD-specific antibodies, compatible HLA, and pathogenic small bowel as in classic CD. However, there are not enough symptoms to warrant clinical suspicion of CD. These cases are normally discovered by a serum analysis when belonging to any of the risk groups, such as being first-degree relatives.

Latent CD is defined as the presence of compatible HLA but without enteropathy (found in a normal small bowel biopsy) in a patient who has had, or will have, a gluten-dependent enteropathy at some point in his or her life. The patient may or may not have symptoms and may or may not have CD-specific antibodies.

Potential CD is characterized by the presence of positive specific antibodies and compatible HLA, but without abnormalities in duodenal biopsies. The patient may or may not have signs and symptoms and may or may not develop a gluten-dependent enteropathy later on.

1.1.3 Diagnosis and Treatment

Despite the increasing number of positive diagnoses for CD, this condition is frequently unrecognized. Information on variable clinical presentations has shown that only a clinical diagnosis (symptoms, associated diseases, and risk groups) is not enough for a suitable diagnosis of the disorder [\[16](#page-18-0)]. The advances and accuracy of new immunological diagnosis tests and the information on the genetic predisposition to CD have allowed the ESPGHAN to review the diagnostic criteria for this

			Antibodies	
	Genetic (HLA	Pathological	(anti-tTG, EMA,	
CD forms	DQ2, DQ8	anatomy	or anti-DGP)	Symptoms
Symptomatic	Compatible		$\,{}^{+}\,$	$\ddot{}$
Silent	Compatible		$^+$	
Latent	Compatible	$-{}^{\rm a}$	士	土
Potential	Compatible		$^{+}$	土

Table [1](#page-18-0).2 ESPGHAN diagnosis criteria [1]

a Could be + at some point of the evolution

disease [\[1](#page-18-0)]. ESPGHAN has determined that not only clinical suspicion is necessary for the diagnosis of CD, but also serological tests, genetic studies, and intestinal biopsy and histology (Table 1.2).

1.1.3.1 In Clinical Practice, CD Is Diagnosed Through Various Pathways Divided into Four Groups: Clinical Suspicion

Suspicion of CD emerges when the patient shows any of the wide range of symptoms and signs of the disease, as well as when she/he has a CD-associated disease or belongs to a high-risk group.

1.1.3.2 Serological Tests

CD-specific antibody tests are useful as indicators of CD. IgA autoantibodies against tissue transglutaminase are the test of choice for most populations. Currently, the IgA-type anti-tissue transglutaminase (anti-tTG) and IgA-type antiendomysial (EMA) antibodies, which are highly sensitive and specific for the diagnosis of CD, are the two most often-used biomarkers. In the last few years, these two tests have replaced the one that was based on anti-gliadin antibodies (anti-AGA), with less specificity.

Together with these serological tests, it is important to assess the total IgA of serum, given that up to 2–3% of patients with CD show a selective IgA deficiency, which may lead to false negatives − especially in adults. In these cases, an IgG-based test should be used, in particular IgG-type anti-tTG or IgG-type deamidated antigliadin peptide (anti-DGP) antibodies. Its use is also justified in toddlers less than 2 years old, as they also show a high rate of false positives for IgA antibodies [\[9](#page-18-0)].

Anti-DGP antibodies were introduced because they showed a similar sensitivity and specificity to the IgA-type anti-tTG antibodies. They are useful mainly for detecting CD in cases of IgA deficiency and in pediatric patients up to 2 years old, whose IgA antibody levels may lead to false negatives [\[17](#page-19-0)]. Moreover, it has been suggested that anti-DGP IgG assays may be useful to monitor mucosal damage and histological improvement in CD patients on a strict GFD [[18\]](#page-19-0).

Finally, it is noteworthy that negative results of these markers do not rule out the diagnosis; sometimes it is necessary to perform other tests when the suspicion is high. For example, a symptomatic first-degree relative with negative serology should be examined via a duodenal biopsy.

1.1.3.3 Genetic Test

Ninety-five percent of patients with celiac disease are HLA-DQ2 positive, and 5% HLA-DQ8 positive, while in the general population only 20–30% of individuals express these haplotypes. Therefore, the absence of HLA-DQ2 and HLA-DQ8 makes the diagnosis of CD unlikely [[19\]](#page-19-0).

1.1.3.4 Histological Analysis of Duodenal Biopsies

A biopsy of the proximal duodenum or jejunum has been used for the definitive diagnosis of CD. This test involves identifying structural changes and cell abnormalities of small intestine mucosa. According to ESPGHAN's latest guidelines, it is recommended to take at least five samples (one from the bulb and four from the second or third portion of the duodenum) because the lesions may be patchy [[1\]](#page-18-0). Biopsies must be taken either when patients are on a gluten-containing diet (at least 3 g of gluten/day for 2 weeks) or after a gluten challenge [\[20](#page-19-0)].

It is highly recommended that a pathologist´s report include a description of the orientation of the biopsy $[21]$ $[21]$ $[21]$; the presence/absence of normal villi; the degree of atrophy and crypt elongation; the villus-crypt ratio; the number of intraepithelial lymphocytes (IELs); and the interpretation according to the Marsh-Oberhuber classification, which is widely used in clinical practice [\[15,](#page-18-0) [22\]](#page-19-0).

Marsh classification of gluten-induced small-intestinal damage has four stages; Stage 0 indicates a normal mucosa, whereas Stage 3 includes a destructive lesion of a villus, including atrophy. This stage is the classic CD lesion. Stage 4 shows hypoplastic lesions that include full atrophy with crypt hypoplasia. This 4th stage is not described by World Gastroenterology Organization´s Global Guidelines [[23\]](#page-19-0). These Guidelines described only first three stages.

Histological presentation is compatible with the disease, but it is not specific. Hence the serological test and genetic study are needed to verify the diagnosis.

Although biopsy today is still major evidence of the diagnosis, the possibility of making a correct diagnosis of CD without intestinal biopsy is nevertheless being studied. In 2012, the ESPGHAN, in its new diagnostic guidelines, suggested that it is possible to avoid the biopsy in children whenever some requirements are achieved: suggestive clinic of CD; IgA antibodies (IgA anti-tTG) that exceed 10 times the used reference value; verification with anti-endomysial (EMA) antibodies in a different sample; and a positive genetic test (DQ2/DQ8 markers) [\[1](#page-18-0)].

The CD can be either silent or latent for several years. Therefore, careful clinical monitoring is required, mainly for first-degree relatives of patients and people in high-risk groups, including serological markers (IgA antibodies) and, if appropriate, an intestinal biopsy.

1.1.4 Treatment

Currently, the only effective treatment for CD is a strict, lifelong gluten-free diet (GFD). GFD consists of excluding wheat, barley, triticale, and rye from the diet, as well as all the food derived from these cereals. Some oat varieties do not have a harmful effect on celiac patients, but other varieties can produce the toxicity [[24\]](#page-19-0). Furthermore, many products containing oats can be contaminated by traces of flour of other cereals, which suggest limiting their use. For these collectives, a balanced diet should be based on naturally gluten-free (NGF) cereals such as rice, corn, quinoa, millet, and other pseudo-cereals and pulses. The diet will be rounded out with other NGFs such as vegetables and fruits, meat, fish, eggs, and milk and dairy products. It is recommended not to overuse the specific gluten-free products (GFP), as they used to have a different nutritional profile compared to their gluten-containing homologues. We found that these GFPs are usually fattier and contain less fiber [[25\]](#page-19-0).

Following a GFD is of vital importance, because after a few weeks or months of dietetic treatment, the symptoms of the disease are improved or even disappear in some cases. Between 6 and 12 months later, serological normalization is achieved and around 2 years are needed to attain complete recovery of the intestinal villus. In adult patients, the clinical improvement is usually slower than in children. Besides, it has been shown that following a strict GFD minimizes the risk of longterm complications such as osteoporosis, cancer of the intestines, and other associated autoimmune disorders (e.g., type 1 diabetes or thyroid disease). Clinical monitoring of patients is also important in order to observe the evolution of symptoms, control growth in children, and assessment of adherence to GFD. Developing complications when GFD is strictly followed is very unlikely; indeed, transgressions on the GF diet or undiagnosed conditions can arise, as can complications in a medium or long term, such hyposplenism, exocrine pancreatic insufficiency, osteoporosis, chronic ulcerative jejunoileitis, microscopic colitis, bacterial overgrowth, non-Hodgkin's lymphoma, and gastrointestinal carcinomas.

It is important to point out that even small amounts of gluten can be harmful to the intestinal villus. This shows the importance of avoiding gluten in diet, but that following a strict GFD is not easy, as gluten-containing grains and food are widespread. Moreover, aspects such as higher cost, poor sensorial quality, and low availability of gluten-free products and cross-contamination with gluten-containing cereals may enhance the difficulty in sticking to a GFD. As will be seen in Chap. [2](http://dx.doi.org/10.1007/978-3-319-53342-1_2), labeling rules differ from country to country, even if huge advances have been made during the last few years that reflect the awareness of authorities for the regulation of the labeling of manufactured products.

1.2 Gluten-related Disorders Other Than Celiac Disease

Even if during the last decade, gluten-related disorders have been found to have no relation to the diagnosis of CD, it is necessary to take into account the current knowledge about the toxic effects of gluten and the various disorders it is responsible for.

Gluten is not only the causative agent of CD, but it may be also for other pathologies such as wheat allergy (WA), dermatitis herpetiformis, gluten ataxia, or peripheral neuropathy [[26\]](#page-19-0). Besides, in recent years a disease called "non-celiac gluten sensitivity" (NCGS) has gotten more attention. While CD, gluten ataxia, and peripheral neuropathy have an autoimmune basis, wheat allergy is based on altered immune reaction and the source of NCGS is still unclear [\[27\]](#page-19-0). A diagram for gluten-related disorders' nomenclature is depicted in Fig. 1.2.

1.2.1 Wheat Allergy (WA)

WA is an adverse immunologic reaction to wheat proteins. Depending on the underlying mechanisms and the exposure type, WA could be classified into classic food allergy; wheat-dependent, exercise-induced anaphylaxis (WDEIA); occupational asthma (baker's asthma) and rhinitis; and contact urticaria (Fig. 1.2) [\[27](#page-19-0)]. The most frequent form of the disease is respiratory (baker's asthma), while the dietary allergy form is less widespread.

Allergens responsible for the respiratory form are slightly different from those related to food allergy. α-amylase inhibitors are the group of proteins responsible mainly for the respiratory form. However, other proteins have been reported to bind IgE from patients with baker's asthma, like germ agglutinin, peroxidase, and non-specific lipid transfer proteins (LTPs). The latter two are also related to the food

Fig. 1.2 Nomenclature and classification of gluten-related disorders (Adapted from Sapone et al. [[27](#page-19-0)])

allergy form [[28\]](#page-19-0); nevertheless, most patients with respiratory allergy to grasses consume cereals normally. It is interesting to note that deamidated forms of gluten (produced for their special technological properties) cause allergies too, but they are considered separate entities from WA [\[29](#page-19-0)].

Wheat-induced food allergies can be classified into two groups: WDEIA, and other allergic responses, such as urticaria, atopic dermatitis, and anaphylaxis. The major allergen of WDEIA is a specific type of gliadin (ω ₅-gliadin), whereas other allergic responses seem to be related to a range of wheat proteins [[27\]](#page-19-0). Studies of purified proteins using IgE-specific assays with patients' sera showed that all patients with anaphylaxis or WDEIA, and 55% of those with urticaria, produced IgE to ω_5 -gliadins [[28\]](#page-19-0). Other relatively well-documented allergens include α-amylase inhibitors, the response to which is associated with food allergy in children with atopic dermatitis. Wheat allergy prevalence varies, depending on the age and region, from 0.4% to 1% [[30\]](#page-19-0).

Food-dependent, exercise-induced anaphylaxis (FDEIA) is a peculiar form of food allergy in which food intake alone does not induce any symptom. Wheat is the predominant causative agent for FDEIA, and then it is called WDEIA; in this case, it is an allergic reaction caused by ingesting wheat, followed by physical exercise. Some other variables could be implicated, such as non-steroidal anti-inflammatory drugs (NSAIDS), alcohol, stress, or infections [[31\]](#page-19-0). Since both the amount ingested and the extent of exercise may vary from individual to individual, diagnosis becomes difficult. The reaction lasts several hours, and symptoms can change significantly. These include local or generalized [\[31](#page-19-0)]. Even if WDEIA is rare, it is difficult to diagnose, and the fatal consequences it causes deserve attention.

On the other hand, classic wheat allergy symptoms may include itching in the mouth; swelling of lips and tongue; hives; eczema; rhinitis; tightening of the throat or trouble breathing; drop in blood pressure; gastrointestinal symptoms such as vomiting, diarrhea, or abdominal cramps and pain; and, if severe, anaphylaxis [\[32](#page-19-0)].

Skin-prick tests are first-level diagnostics for WA. Nevertheless, they are prone to technical errors and false positives in some circumstances. The measurement of specific IgE levels is an alternative for the prediction of symptomatic allergies, but wheat-specific IgE is highly non-specific, detects only part of the wheat protein fractions, and the level required for clinical response is high [[30\]](#page-19-0). Figure [1.3](#page-16-0) shows the algorithm for the differential diagnosis of gluten-related disorders, adapted from Sapone et al. [\[27\]](#page-19-0).

1.2.1.1 Non-celiac Gluten Sensitivity (NCGS)

Although this disorder was first described in 1978 [[34\]](#page-19-0), nowadays it is gaining more interest, since GFD has been seen to be useful for the alleviation of symptoms of some non-celiac and non-wheat allergy disorders. In fact, it has been suggested that NCGS is a broad term that includes various clinical entities related to gluten. It is possible that innate immunity and intestinal permeability are implicated in this

Fig. 1.3 Algorithm for the differential diagnosis of gluten-related disorders [\[33\]](#page-19-0). *EMA* endomysial antibodies, *tTG* tissue transglutaminase, *DPG* deamidated gliadin peptides

disorder [[27,](#page-19-0) [35\]](#page-19-0); nevertheless, it may be that gluten is not the only responsible agent, or not responsible at all, as there is also some debate about the role that nongluten molecules such as FODMAPS (fermentable oligo-di-mono-saccharides and polyols) play in this syndrome $[26, 36]$ $[26, 36]$ $[26, 36]$ $[26, 36]$. It is not easy to identify the agent, since gluten-rich products are also usually rich in FODMAPS. In fact, some authors propose replacing the term "NCGS" with "wheat intolerance syndrome" [[26,](#page-19-0) [32\]](#page-19-0).

So far, the term NCGS applies to patients who do not meet the criteria for CD or WA, but react to gluten intake by intestinal (similar to irritable bowel syndrome), and/ or extra-intestinal symptoms that mostly occur soon after ingesting gluten-containing foods and disappearing quickly with a strict GFD [\[26](#page-19-0)]. In Table [1.3,](#page-17-0) differences

	Celiac disease	NCGS	Wheat allergy
Onset of symptoms since exposure	Week to years	Hours to days	Minutes to hours
Basis	Disturbances in the acquired immune response to gluten depend on the combination of HLA-DQ2 and HLA-DO8	Innate immunity?	IgE-mediated
Symptoms	Classical intestinal (e.g., chronic diarrhea, weight loss) or non-classical extra-intestinal (e.g., anemia, osteoporosis, neurological disturbances) features. Silent forms have been described	Resemble CD but with prevalence of extra-intestinal symptoms, such as behavioral changes, bone or joint pain, muscle cramps, leg numbness, weight loss, and chronic fatigue	Wheat-dependent, exercise-induced anaphylaxis (WDEIA); occupational asthma (baker's asthma) and rhinitis; and contact urticaria, atopic dermatitis, gastrointestinal symptoms and anaphylaxis
Morbidity	1%	Unknown (possibly $0.6 - 6\%)$	$0.4 - 1\%$
Antibodies in serum	tTG, EMA, DGP, AGA primarily in the IgA class, less frequently in the IgG class	In 50%: IgG-AGA	sIgE for wheat sIgE for w5-gliadin (in anaphylaxis) in 25%: IgG-AGA
Histology of duodenal mucosa	Marsh I-IV, prevalent Marsh III - IV	Marsh 0,I	Marsh 0,I,II
Atrophy of duodenal villi	Present	Absent	May be present

Table 1.3 Main differences between CD, NCGS and wheat allergy [[27](#page-19-0), [30, 37\]](#page-19-0)

tTG tissue transglutaminase, *EMA* endomysium antibodies, *DGP* deamidated gliadin peptide, *AGA* antigliadin antibodies

between CD, wheat allergy, and NCGS are detailed. Extra-intestinal symptoms vary from study to study, but some of them are unspecific, such as the lack of well-being or fatigue; others are psychiatric or neurological (anxiety, depression, schizophrenia, autism, attention deficit disorder, hyperactivity, sleep problems, etc.); and still others as dissimilar as skin rash, headache, or muscular problems [[26](#page-19-0)].

It is difficult to assess the prevalence of NCGS due to the lack of objective diagnostic criteria. There are no specific biomarkers, and diagnosis is made by the exclusion of wheat allergy and CD, and the effect of the withdrawal of gluten from the diet (Fig. [1.3](#page-16-0)). Moreover, many patients are self-diagnosed and start a GFD without medical advice, so some authors think that the incidence is even higher than in CD and WA [\[37](#page-19-0)]. Nevertheless, it is possible that a GFD followed with no exclusion diagnosis underestimates CD prevalence. What seems to be clear is that it is more common in females and in young/middle-aged adults [[38\]](#page-19-0). As mentioned, the expression of HLA-DQ2 or DQ8 genes are directly related to celiac disease (they

are present in 95% of celiac patients). In the case of NCGS, 50% of patients express them, whereas 30% of healthy people do [[37\]](#page-19-0).

More research is needed for the clear classification of wheat- and gluten-related diseases and for the identification of the causative agents. NCGS overlaps with CD, WA, and irritable bowel syndrome, lacking diagnostic criteria or biomarkers. Besides, epidemiology, diagnosis, and the efficacy of a GFD are still controversial. Moreover, labelling minor forms of CD as NCGS is a matter of concern, as both diseases have different levels of dietary restriction and prognosis if untreated [\[36](#page-19-0)].

References

- 1. Husby S, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, et al. European society for pediatric gastroenterology, hepatology, and nutrition guidelines for the diagnosis of celiac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136–60.
- 2. Lionetti E, Catassi C. New clues in celiac disease epidemiology, pathogenesis, clinical manifestations, and treatment. Int Rev Immunol. 2011;30(4):219–31.
- 3. Nevoral J. Celiac disease in children: what has changed? Int J Cel Dis. 2014;2(1):18–23.
- 4. Peña A, Rodrigo L. Epidemiology of celiac disease and non-celiac gluten-related disorders. In: Arranz E, Fernández-Bañares F, Rosell C, Rodrigo L, Peña A, editors. Advances in the understanding of gluten related pathology and the evolution of gluten-free foods. Barcelona: OmniaScience; 2015. p. 27–73.
- 5. Catassi C, Rätsch IM, Gandolfi L, Pratesi R, Fabiani E, El Asmar R, et al. Why is coeliac disease endemic in the people of the Sahara? Lancet. 1999;354(9179):647–8.
- 6. Lionetti E, Gatti S, Pulvirenti A, Catassi C. Celiac disease from a global perspective. Best Pract Res Clin Rheumatol. 2015;29(3):365–79.
- 7. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001;120(3):636–51.
- 8. Barton SH, Murray JA. Celiac disease and autoimmunity in the gut and elsewhere. Gastroenterol Clin North Am. 2008;37(2):411–28. vii
- 9. Moscoso JF, Quera R. Enfermedad celiaca: revisión. Rev Méd Clín Condes. 2015;26(5):613–27.
- 10. Silano M, Agostoni C, Sanz Y, Guandalini S. Infant feeding and risk of developing celiac disease: a systematic review. BMJ Open. 2016;6(1):e009163.
- 11. Szajewska H, Shamir R, Mearin L, Ribes-Koninckx C, Catassi C, Domellöf M, et al. Gluten introduction and the risk of celiac disease: a position paper by the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2016;62(3):507–13.
- 12. Kemppainen KM, Lynch KF, Liu E, Lönnrot M, Simell V, Briese T, et al. Factors that increase risk of celiac disease autoimmunity following a gastrointestinal infection in early life. Clin Gastroenterol Hepatol. 2016; doi:[10.1016/j.cgh.2016.10.033](http://dx.doi.org/10.1016/j.cgh.2016.10.033).
- 13. Narang M, Puri AS, Sachdeva S, Singh J, Kumar A, Saran RK. Celiac disease and H. pylori infection in children: is there any association? J Gastroenterol Hepatol. 2016; doi:[10.1111/](http://dx.doi.org/10.1111/jgh.13654) [jgh.13654.](http://dx.doi.org/10.1111/jgh.13654)
- 14. Vivas S, Ruiz de Morales JM, Fernandez M, Hernando M, Herrero B, Casqueiro J, et al. Agerelated clinical, serological, and histopathological features of celiac disease. Am J Gastroenterol. 2008;103(9):2360–5.
- 15. Ic P. Diagnóstico precoz de la enfermedad celiaca. Madrid: Ministerio de Sanidad y Consumo, Gobierno de España; 2008.
- 16. Vriezinga SL, Schweizer JJ, Koning F, Mearin ML. Celiac disease and gluten-related disorders in childhood. Nat Rev Gastroenterol Hepatol. 2015;12(9):527–36.
- 17. Leffler DA, Schuppan D. Update on serologic testing in celiac disease. Am J Gastroenterol. 2010;105(12):2520–4.
- 18. Spatola BN, Kaukinen K, Collin P, Mäki M, Kagnoff MF, Daugherty PS. Persistence of elevated deamidated gliadin peptide antibodies on a gluten-free diet indicates non-responsive celiac disease. Aliment Pharmacol Ther. 2014;39(4):407–17.
- 19. Arranz E, Garrote JA. HLA en la enfermedad celíaca. An Pediatr Contin. 2004;2(3):163–6.
- 20. Leffler D, Schuppan D, Pallav K, Najarian R, Goldsmith JD, Hansen J, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with celiac disease. Gut. 2013;62(7):996–1004.
- 21. Villanacci V, Ceppa P, Tavani E, Vindigni C, Volta U. Celiac disease: the histology report. Dig Liver Dis. 2011;43(Suppl 4):S385–S95.
- 22. Ic P. Libro blanco de la enfermedad celiaca. Madrid: Inutcam, Comunidad de Madrid, Salud Madrid; 2008.
- 23. GuidelinesWGOG. Celiac disease. 2016.
- 24. Comino I, MeL M, Sousa C. Role of oats in celiac disease. World J Gastroenterol. 2015;21(41):11825–31.
- 25. Miranda J, Lasa A, Bustamante MA, Churruca I, Simon E. Nutritional differences between a gluten-free diet and a diet containing equivalent products with gluten. Plant Foods Hum Nutr. 2014;69(2):182–7.
- 26. Guandalini S, Polanco I. Nonceliac gluten sensitivity or wheat intolerance syndrome? J Pediatr. 2015;166(4):805–11.
- 27. Sapone A, Bai JC, Ciacci C, Dolinsek J, Green PH, Hadjivassiliou M, et al. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012;10:13.
- 28. Tatham AS, Shewry PR. Allergens to wheat and related cereals. Clin Exp Allergy. 2008;38(11):1712–26.
- 29. Denery-Papini S, Bodinier M, Larré C, Brossard C, Pineau F, Triballeau S, et al. Allergy to deamidated gluten in patients tolerant to wheat: specific epitopes linked to deamidation. Allergy. 2012;67(8):1023–32.
- 30. Mäkelä MJ, Eriksson C, Kotaniemi-Syrjänen A, Palosuo K, Marsh J, Borres M, et al. Wheat allergy in children – new tools for diagnostics. Clin Exp Allergy. 2014;44(11):1420–30.
- 31. Scherf KA, Brockow K, Biedermann T, Koehler P, Wieser H. Wheat-dependent exerciseinduced anaphylaxis. Clin Exp Allergy. 2016;46(1):10–20.
- 32. Capili B, Chang M, Anastasi JK. A clinical update: non-celiac gluten sensitivity − is it really the gluten? J Nurse Pract. 2014;10(9):666–73.
- 33. Tonutti E, Bizzaro N. Diagnosis and classification of celiac disease and gluten sensitivity. Autoimmun Rev. 2014;13(4):472–6.
- 34. Ellis A, Linaker BD. Non-celiac gluten sensitivity? Lancet. 1978;311(8078):1358–9.
- 35. Sapone A, Lammers KM, Casolaro V, Cammarota M, Giuliano MT, De Rosa M, et al. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med. 2011;9:23.
- 36. Molina-Infante J, Santolaria S, Fernández-Bañares F. Non-celiac gluten sensitivity. In: Arranz E, Fernández-Bañares F, Rosell CM, Rodrigo L, Peña AS, editors. Barcelona. Spain: OmniaScience; 2015. p. 441–62.
- 37. Czaja-Bulsa G. Non-celiac gluten sensitivity a new disease with gluten intolerance. Clin Nutr. 2015;34(2):189–94.
- 38. Catassi C, Bai JC, Bonaz B, Bouma G, Calabrò A, Carroccio A, et al. Non-celiac gluten sensitivity: the new frontier of gluten-related disorders. Nutrients. 2013;5(10):3839–53.

Chapter 2 Gluten: General Aspects and International Regulations for Products for Celiac People

Virginia Navarro, María del Pilar Fernández-Gil, Edurne Simón, and María Ángeles Bustamante

Abbreviations

2.1 Introduction

Gluten is a complex mixture of proteins found in cereal kernels from the *Triticeae* family. This group includes wheat (*Triticum aestivum L*.), barley (*Hordeum vulgare L.*), and rye (*Secale cereale L.*), which are evolution-related and contain homologous peptide

Fig. 2.1 Taxonomic relationship of cereals (Modified from Belitz et al. [\[2](#page-29-0)])

Fraction	Wheat	Rye	Barley	Oat	Corn	Rice	Millet
Albumins	14.7	44.4	12.1	20.2	4.0	10.8	18.2
	Edestin						
Globulins	7.0	10.2	8.4	11.9	2.8	9.7	6.1
	Leukosin			Avenalin			
Prolamins	32.6	20.9	25.0	14.0	47.9	2.2	33.9
	Gliadin	Secalin	Hordein	Avenin	Zein	Oryzin	Cafirin
Glutelins	45.7	24.5	54.5	53.9	45.3	77.3	41.8
	Glutenin	Secalinin	Hordenin		Zeanin	Oryzenin	

Table 2.1 Protein distribution (%) and designations of fractions separated by Osborne

Adapted from Belitz et al. [\[2\]](#page-29-0)

groups. Although oats belong to the same sub-family, they come from the *Aveneae* family (Fig. 2.1). There is an ongoing debate concerning the toxicity of oat prolamins, which present some characteristics that are different than those from *Triticeae* [\[1\]](#page-29-0).

In 1907 Osborne [\[3](#page-30-0)] divided cereal proteins into four groups according to their solubility: water-soluble albumins; salt-soluble globulins (0.4 M) ; 60–70% aqueous ethanol-soluble prolamins; and glutelins, which are soluble in dilute acids or bases, detergents, and reducing agents. Each fraction takes different names, depending on the cereal from which it comes, and the content varies from one cereal to another (Table 2.1). Rye has the highest albumin content, and the prolamin content is highest in corn and wheat, whereas oat and rice have the lowest content, and glutelins are the major property in rice and oats.

Albumins and globulins are derived from the original cytoplasm of the cell and from other sub-cellular fractions, and they have metabolic and structural functions because of the presence of enzymes. Prolamins and glutelins are both proteins whose function is storing nitrogen, carbon, and sulfur in the endosperm of the kernel [[2,](#page-29-0) [4\]](#page-30-0). The term "prolamin" is used due to its high content in the amino acid

Fig. 2.2 Wheat protein classification

proline (Pro), and "glutelin" is used because of the content of glutamine (Gln). Proline has the ability to make β-turns, which has been shown to be more efficient than α -turns in packing proteins into a small space. This characteristic is very useful for storing amino acids, but the tight structure that is created hinders the hydrolyzation of the prolamin [\[5](#page-30-0)].

Gluten is a complex protein formed by a mixture of prolamins and glutelins at a ratio of 1:1 that represents around 80% of the total proteins of most cereals. These proteins can be found in cereals either as monomers or as oligomers and polymers linked by disulphide bonds – something that causes different physicochemical properties.

Wheat prolamin and glutelin are responsible for the rheological characteristics of dough; while gliadin brings viscosity, glutenin provides elasticity and strength for the dough. Gliadins form monomers with intramolecular disulphide bonds, and molecular weights ranging from 30 to 60 kDa that can be divided into α -, β -, γ -, and ω-gliadins (Fig. 2.2). Gliadins are also grouped by their N-terminal sequence: S-rich α/β-, γ-, and S-poor ω-gliadins that contain no cysteine residue [[6\]](#page-30-0). On the other hand, glutenins are found as polymers through interchain disulfide bonds as well as intramolecular bonds, with molecular weights ranging from 80 kDa to several million kilodaltons. These proteins are divided into two groups: low–molecular weight glutenins and high–molecular weight glutenins, as a consequence of their molecular weight range [\[7](#page-30-0), [8\]](#page-30-0). In other grains, like rye, gluten fractions are sub-grouped into ω-secalins, γ-secalins, and HMW glutelins. In barley, this heterogeneous protein is divided into B-, C-, and D-hordeins.

2.2 Toxicity Factors in Cereal Proteins

A great heterogeneity of peptides seems to be involved in the pathogenesis of celiac disease, although the characterization of all the relevant epitopes has not yet been achieved [\[9, 10\]](#page-30-0). Furthermore, the chemical diversity resulting from the various amino acid compositions makes the quantification of immunogenic peptide sequences difficult.

In order to develop an ideal antibody for gluten analysis in foods, it is important to take into account the fact that besides being able to determine various cereal prolamins, it should also recognize the specific intramolecular regions responsible for toxicity in CD [[1\]](#page-29-0). The toxicity of prolamins depends on their amino acid sequences and molecular properties. Celiac-harmful proteins are rich in glutamine and proline [\[11–13](#page-30-0)] and these aminoacids are located in the protein repetitive domains. Alfaand ω-gliadin-derived peptides are involved in immunological responses in adults, whereas other peptides, such as low–molecular weight glutenins and γ -gliadins, have been responsible for toxicity in children and occasionally in adults [\[14](#page-30-0), [15](#page-30-0)]. In this context, many protein regions had been proposed by their immunogenic properties, and even today some of them remain unidentified.

Accordingly, several approaches have been developed to identify the gluten peptides that can be recognized by T cells from the celiac population. The prolinerich repetitive region of gliadins is responsible for carrying epitopes for a respective lymphocyte receptor and is connected to CD. One of the most popular is 33-mer from α -gliadin, which contains three overlapping glutamine (Gln)-Pro rich epitopes (12,52,95): PFPQPQLPY, PQPQLPYPQ (3 copies), and PYPQPQLPY (2 copies) $[16]$ $[16]$ $[16]$.

A 33-amino acid peptide (LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF) from α/β-gliadin has been shown to be resistant to gastric and pancreatic hydrolysis and to exhibit celiac disease toxicity *in vivo* and *in vitro*. Furthermore, this 33-mer peptide acts as a strong stimulator to intestinal T-cells [\[16](#page-30-0)]. Nevertheless, other potential immunogenic peptides had been described (Table [2.2](#page-24-0)).

2.3 The Gliadin Standard

It is crucial for celiac patients to know the gluten content of the foods they eat, but detecting the toxic fraction of these molecules is not easy. Currently, immunochemistry is the most-used technology for food analysis, but some technical aspects remain to be solved. A critical point in this assay is the availability of a suitable reference standard in order to assess the results. The Working Group on Prolamin Analysis and Toxicity prepared the European Gliadin Standard (called PWG standard or PWG gliadin) from the 28 most common wheat cultivars grown in Europe [\[27](#page-31-0)]. These prolamins (gliadins) were separated from albumins and globulins using 0.4 M NaCl and then extracted with 60% ethanol. The gliadin extracts were finally concentrated, desalted by ultrafiltration, freeze-dried, and homogenized. This standard has been characterized by polyacrylamide gel electrophoresis, capillary electrophoresis, RP-HPLC, MALDI-TOF MS, and immunoassays, and its solubility and stability have been also evaluated.

However, the number of proteins in cereals is greater than those present in the PWG gliadin standard. Moreover, a great number of foodstuffs (produced using processes of fermentation and hydrolysis, like sourdough products, starch syrup,

Peptide	Amino acid sequence ^a Reference		
In vivo			
α -gliadin	LGQQQPFPPQQPY	Marsh et al. $[17]$	
	LGQQQPFPPQQPYPQPQPF	Sturgess et al. $[18]$	
	POPOPFPSOOPY	Marsh et al. $[17]$	
	LQLQPFPQPQLPYPQPQLPY	Fraser et al. [19]	
	LGQGSFRPSQQN	Mantzaris and Jewell [20]	
In vitro			
α -gliadin	VRVPVPQLQPQNPSQQQPQEQVP	De Ritis et al. $[21]$	
	LVQQQQF		
	VPVPQLQPQNPSQQQPQEQVPL	Wieser et al. $[22]$	
	QLQPFPQPELPY	Arentz-Hansen et al. [23]	
	POPELPYPOPOLPY	Arentz-Hansen et al. [23]	
	QYPSGQGSFQPSQQNPQA	Van de Wal et al. [24]	
	QYPSGQGSFQPSQQNPQA	Mazzarella et al. [25]	
γ -gliadin	QPFPQPQLPY, QPFPQPQQTF	Arentz-Hansen et al. [26]	
	LQPQQPFPQQPQQPYPQQPQ	Arentz-Hansen et al. [26]	
LMW glutenin	QQQQPPFSQQQQSPFSQQQQ	Vader et al. $[16]$	
	QQPPFSQQQQQPLPQ	Vader et al. [16]	
HMW glutenin	GQQGYYPTSPQQS	Van de Wal et al. [15]	
ω -prolamins	FPLOPOOP	Vallejo-Diez et al. [11]	

Table 2.2 Some immunogenic peptides found in wheat prolamins (modified from Kanerva [[5](#page-30-0)])

A alanine, *E* glutamic acid, *F* phenylalanine, *G* glycine, *L* leucine, *P* proline, *Q* glutamine, *S* serine, *T* threonine, *Y* tyrosine

malt extracts, or beer) can suffer a partial or total hydrolysis of proteins. In these cases, using a hydrolyzed standard and a competitive immunoassay to determine gluten in foods has been suggested. This hydrolyzed standard has been prepared with prolamin fractions from wheat (gliadin), barley (hordein), and rye (secalin) [\[28](#page-31-0)]. Although the results obtained with the PWG gliadin standard are comparable to those obtained using the partially enzymatically digested prolamin standard in a competitive assay, it is more difficult to prepare a reproducible hydrolyzed standard [\[29](#page-31-0)]. Other immunotoxic peptides of prolamin are being proposed as standard with a high degree of repeatability, reproducibility, and stability [\[30](#page-31-0), [31\]](#page-31-0), but they are still not widely used in routine analysis.

2.4 International Food Laws for Gluten-Free Products

Even if the promoter of CD was discovered in the twentieth century, with diet as the only treatment possible for these patients, food safety and food laws were not completely revised to meet their necessities until the twenty-first century. This is due, fundamentally, to the fact that CD and food allergies are becoming more prevalent with time. In the case of CD, it is probably because nowadays the diagnosis is more efficient, even if there is still a high percentage of under-diagnosed people; moreover, many potential celiac sufferers start diet treatment on their own, with no official diagnosis and without the supervision of doctors.

Food allergen management and control (including gluten) has become a food safety issue in recent years. In the case of gluten, it has been brought to light that even if naturally gluten-free ingredients are used, the final product could be crosscontaminated, and products apparently free of gluten could be made from ingredients that in the end bring a non-admissible gluten level not always reflected on the label. This situation leads to diet transgressions that ultimately affect the health of celiac sufferers and give little chance to reach nutritional balance with a true glutenfree diet. Many products labelled gluten-free have been launched on the market recently, and such a claim has been attempted to be regulated. Laws have been passed all over the world trying to make adequate labelling of gluten-free products mandatory in order to increase the variety of food these patients can use, thereby ensuring their safety.

The Codex Alimentarius (an international organization founded by the Food and Agriculture Organization and the World Health Organization) was established to develop coordinated international food standards. In 1979 this institution adopted a standard for foods for special dietary use for persons intolerant to gluten; the standard was revised and corrected both in 2008 and 2015 [\[32\]](#page-31-0). The document set the definition of gluten-free foods and foods specially processed to reduce gluten content as follows:

- 1. Gluten-free foods are dietary foods
	- (a) Consisting of or made only from one or more ingredients that do not contain wheat (i.e., all *Triticum* species, such as durum wheat, spelt, and khorasan wheat, which is also marketed under different trademarks such as Kamut), rye, barley, oats, or their crossbred varieties, and the gluten level does not exceed 20 mg/kg in total, based on the food as sold or distributed to the consumer, and/or
	- (b) Consisting of one or more ingredients from wheat (i.e., all *Triticum* species, such as durum wheat, spelt, and khorasan wheat, which is also marketed under various trademarks such as Kamut), rye, barley, oats, or their crossbred varieties, which have been specially processed to remove gluten, and the gluten level does not exceed 20 mg/kg in total, based on the food as sold or distributed to the consumer.
- 2. Foods specially processed to reduce gluten content to a level from above 20 to 100 mg/kg

are foods that consist of one or more ingredients from wheat (i.e., all *Triticum* species, such as durum wheat, spelt, and khorasan wheat, which is also marketed under different trademarks such as Kamut), rye, barley, oats or their crossbred varieties, which have been specially processed to reduce the gluten content to a level from above 20 to 100 mg/kg in total, based on the food as sold or distributed to the consumer.

Oats, or at least some varieties [[33,](#page-31-0) [34](#page-31-0)] of oats, can be tolerated by most but not all people who are intolerant to gluten. Taking this into consideration, the allowance of oats that are not contaminated with wheat, rye, or barley in foods covered by this standard may be determined at the national level. According to the document, nations are responsible for the decisions on the marketing of products, and the decision on whether or not to use the term "gluten-free" on the label lies with each manufacturer, so the product is only subject to the respective regulatory framework if a voluntary gluten-free claim is made.

Most nations have based their laws on this standard. Nevertheless, there are some differences between nations at the level of labelling.

In the European Union (EU), before the revision of the Codex Standard in 2008, the Council Directive 89/398/CEE of May 3, 1989, included gluten-free foods as food for particular uses [[35](#page-31-0)]. This directive forced the approval of other directives that would regulate any of these foods. In the case of gluten-free foods, Directive 2000/13/EC included by amendment a list of allergens in its annex IIIa [\[36](#page-31-0)], in which appeared cereals containing gluten (i.e., wheat, rye, barley, oats, spelt, Kamut, or their hybridized strains) and products thereof. The food containing any of the allergens listed in that annex had to be clearly labelled in the list of ingredients or by an indication that will include the word "contains" followed by the names of the ingredient(s) concerned. This list of allergens was recently modified in other directives in order to give details of the non-allergenic derivatives of the ingredients for which there were exemptions from the labelling requirement in force at that moment, such as wheat-based maltodextrins or glucose syrups based on barley.

Lately, and considering the fact that gluten is not introduced into an infant's diet until several months of age, Commission Directive 2006/141/EC of December 22, 2006, on infant formulas and formulas for infants when appropriate complementary feeding is introduced, prohibited the use of gluten-containing ingredients in such foods [\[37](#page-31-0)]. This prohibition extended to the use of the terms "gluten-free" or "low content of gluten" in these products. Even if the directive will be repealed in 2020, the prohibition on using gluten-containing ingredients in these foods will remain in the new regulation (Commission Delegated Regulation (EU) 2016/127 of September 25, 2015 [[38\]](#page-31-0)).

After the revision of the Codex Standard, and based on it, the European Union adopted Commission Regulation (EC) No. 41/2009 of January 20, 2009 [\[39](#page-31-0)]. This regulation was recently repealed and its framework is now under the Regulation (EU) No. 1169/2011, of October 25, 2011, *on the provision of food information to consumers* [[40\]](#page-31-0), and under the Commission Implementing Regulation (EU) No. 828/2014, which lays out the specific requirements for the provision of information to consumers on the absence or reduced presence of gluten in food [[41\]](#page-32-0). These regulations considered that gluten levels defined in the Codex were scientifically set and they regulated the indications related to gluten content that will be made in labelling in the EU, as seen before. They allowed the use of "very low gluten" and "glutenfree" wordings that enable celiac patients to find on the market a variety of foods suitable to their needs and to their level of sensitivity to gluten (Table [2.3\)](#page-27-0). Moreover,

Gluten-free	The label <i>gluten-free</i> may only be applied where the food as sold to the final consumer contains no more than 20 mg/kg of gluten
Very low gluten	The label very low gluten may only be applied where the food, consisting of or containing one or more ingredients made from wheat, rye, barley, oats or their crossbred varieties that have been specially processed to reduce the gluten content, contains no more than 100 mg/kg of gluten in the food as sold to the final consumer
Specifically formulated for people intolerant to gluten or specifically formulated for celiacs	If the food is specially produced, prepared, and/or processed to: (a) reduce the gluten content of one or more gluten-containing ingredients (b) substitute the gluten-containing ingredients with other ingredients naturally free of gluten.
Suitable for people intolerant to gluten or suitable for celiacs.	If requirements for <i>gluten-free</i> and <i>very low gluten</i> statements are compiled naturally.

Table 2.3 Statements on the absence or reduced presence of gluten in foods that are allowed to be made and conditions thereof by Regulation (EU) No 828/2014

Additional requirements for food containing oats

Oats contained in a food presented as gluten-free or very low gluten must have been specially produced, prepared, and/or processed in a way to avoid contamination by wheat, rye, barley, or their crossbred varieties, and the gluten content of such oats cannot exceed 20 mg/kg

according to this regulation, it is permitted to distinguish between foods that are naturally free of gluten and products that are specially formulated for celiac patients.

Outside the EU, before 2013 there were no standards for the food industry to use in labelling products as "gluten-free" in the U.S. That year, the Food and Drug Administration (FDA) established, among other criteria, a gluten limit of less than 20 ppm for foods that carry the label "gluten-free," "no gluten," "free of gluten," or "without gluten" [\[42](#page-32-0)]. The rule implements part of the Food Allergen Labelling and Consumer Protection Act of 2004 (FALCPA) [[43\]](#page-32-0). According to FDA opinion, messages such as "low gluten" or "very low gluten" are misleading, and if used, they will be studied case by case (Guidance for Industry, FDA, 2014). The rule excludes those foods whose labelling is regulated by the U.S. Department of Agriculture (USDA) and the Alcohol and Tobacco Tax and Trade Bureau (TTB), but includes supplements. Generally, the USDA regulates the labelling of meats, poultry, and certain egg products, while the TTB regulates the labelling of most alcoholic beverages, including all distilled spirits, wines that contain 7% or more alcohol by volume, and malted beverages that are made with both malted barley and hops.

The U.S.'s neighbor, Canada, for example, does not allow expressions such as "low gluten" or "reduced gluten" for the same reason, as seen in Section B.24.018 of the Canadian Food and Drug Regulations [[44\]](#page-32-0). The U.S., however, does not allow food that has less than 20 ppm gluten but contains a gluten-containing grain to use the claim "gluten-free," while Canada does. This claim will always be made if the manufacturer includes additional processing steps that are shown to be effective in removing gluten [\[45](#page-32-0)].

Furthermore, and as an example of the permanent evolution of the regulation, the FDA is at the moment proposing a rule to establish requirements concerning "gluten-free" labelling for foods that are fermented or hydrolyzed or that contain fermented or hydrolyzed ingredients [\[46](#page-32-0)]. The FDA proposes evaluating the compliance of such fermented and hydrolyzed foods that bear a "gluten-free" claim with the gluten-free labelling rule based on records that are made and kept by the manufacturer of the food with the "gluten-free" claim and made available to the agency for inspection. This is undoubtedly good news, as there is confusion in interpreting the results of current gluten test methods for fermented and hydrolyzed foods, as mentioned in Chap. [3.](http://dx.doi.org/10.1007/978-3-319-53342-1_3) This could also be a good guideline for international legislators to broaden the variety of food that celiac patients could consume safely.

According to this proposed rule, the records would need to provide adequate assurance that the food is "gluten-free" in compliance with the gluten-free foodlabelling final rule before fermentation or hydrolysis. In addition, the proposed rule would require the manufacturer of fermented or hydrolyzed foods bearing the "gluten-free" claim to document that it has adequately evaluated the potential for gluten cross-contact and, if identified, that the manufacturer has implemented measures to prevent the introduction of gluten into the food during the manufacturing process. Likewise, manufacturers of foods that contain fermented or hydrolyzed ingredients and bear the "gluten-free" claim would be required to make and keep records that adequately show that the fermented or hydrolyzed ingredients are "gluten-free" according to their regulations. Finally, the proposed rule would state that the FDA would evaluate the compliance of distilled foods by verifying the absence of protein using scientifically valid analytical methods that can reliably detect the presence of protein or protein fragments in the distilled food.

Other countries that are culturally close, such as Australia and New Zealand, regulate gluten-related labelling in their Food Standards Codes. This regulation states that while gluten-free mentions can only be made for products with no glutencontaining ingredients (even if they have been malted or hydrolyzed − including oats), "low gluten" mentions could be made for products with less than 200 ppm of gluten, which doubles the limit of the Codex Standard [[47\]](#page-32-0).

Other countries, such as Argentina, are stricter than the Codex, and set the limit for gluten-free products to 10 ppm. Moreover, Argentina defines gluten-free products as those that are naturally free of gluten, and manufacturers must apply GMP (Good Manufacturing Practices) in order to assure the absence of cross-contamination as set by Article 1383 of Chapter XVII of the Argentinian Food Code [[48\]](#page-32-0). In Japan, seven items are mandatory for labelling: shrimp/prawns, crab, wheat, buckwheat, eggs, milk, and peanuts, and another 20 are recommended for labelling. They are aware of allergies, but they do not regulate gluten content-related expressions regarding celiac disease. In fact, manufacturers must declare the presence of these allergens when their content is above 10 ppm, and precautionary expressions such as "may contain" are prohibited [[49\]](#page-32-0). Nevertheless, changes are rapidly being made all over the world.

Other countries have no regulations yet for gluten-free labelling or labelling for allergies and intolerances. Even if legislators have been working hard over the last few years, there is still much work to be done. Hydrolyzed and/or fermented products are an example, as previously mentioned, but industrial processes are complex and not always totally controlled to avoid cross-contaminations; this promotes the use of precautionary labelling (terms such as "may contain," "made in a factory that also uses...", or "not suitable for celiac patients"), prohibited in some countries for any allergen. This precautionary labelling is not properly regulated in most countries. It is confusing and turns over to the patients the responsibility of having a potential risk if they consume the product, or it narrows down the availability of products for this group even if, in some cases, the products are probably safe for them. Moreover, the inconsistent use of these messages leads to mistrust in the label and they are often ignored [[50,](#page-32-0) [51\]](#page-32-0).

For oats, the regulation is slightly different. The aforementioned Codex standard pointed out that even if most people with intolerance to gluten can include oats in their diets without any adverse effect on their health, the allowance of oats that are not contaminated with wheat, rye, or barley in foods may be determined at the national level. In the EU, Regulation (EU) No. 828/2014 includes additional requirements for products containing oats [[41\]](#page-32-0). These cereals, if used in products labelled as gluten-free or low-gluten content, must have been specially produced, prepared, and/or processed in a way to avoid contamination by wheat, rye, barley, or their crossbred varieties, and the gluten content of such oats cannot exceed 20 mg/kg. In the U.S., oats are not considered to be a "gluten-containing grain" [\[41](#page-32-0)], so oats can be used as an ingredient in foods labelled "gluten-free" as long as the oats contain <20 ppm gluten. Nevertheless, the rule encourages "manufacturers of foods labelled 'gluten-free' that use an oat-derived ingredient where the word 'oat' does not appear in the ingredient list to indicate in their labelling that an oat-derived ingredient is present."

It is necessary to label food products adequately, and it is obvious that important efforts have been made in recent years all over the world. Nevertheless, the "homogenization" of the rules worldwide will greatly enhance the quality of life for celiac sufferers. Globalization allows travelling and working in various parts of the globe, and it is difficult for celiac sufferers to follow a safe and varied diet if labelling rules remain different in each country. Nevertheless, it is very important to highlight that GMP in the food industry is fundamental for the production of food without any risk of cross-contamination. It is not only labelling, but also a new inclusive perspective of food-production that takes into account the reality for celiac and allergy sufferers, an ever-expanding group. For this new perspective, new technologies for gluten detection play a crucial role in the industry. Rapid, cost-effective, and reliable methodologies may allow manufacturers to detect gluten in any of the steps of the processes, without any inconvenient time lapses in their production.

References

- 1. Rosell CM, Barro F, Sousa C, Mena MC. Cereals for developing gluten-free products and analytical tools for gluten detection. J Cereal Sci. 2014;59(3):354–64.
- 2. Belitz H-D, Grosch W, Schieberle P. Food chemistry. 4th revised and extended ed. Berlin Heidelberg: Springer; 2009.
- 3. Osborne TB. The proteins of the wheat kernel. Publication No. 84. Washington D.C: Carnegie Institution of Washington, Press of Judd & Detweiler, Inc; 1907.
- 4. Shewry PR, Halford NG. Cereal seed storage proteins: structures, propertes and role ingrain utilization. J Exp Bot. 2002;53(370):947–58. doi:[10.1093/jexbot/53.370.947](http://dx.doi.org/10.1093/jexbot/53.370.947).
- 5. Kanerva P. Immunochemical analysis of prolamins in gluten-free foods (dissertation). EKT series 1530. University of Helsinki. Dep Food Environ Sci. 2011. p. 1–94. ISBN 978-952-10-7252-9.
- 6. Haraszi R, Chassaigne H, Maquet A, Ulberth F. Analytical methods for detection of gluten in food-method developments in support of food labeling legislatio. JAOACInt. 2011;94(4):1006–24.
- 7. Gimenez MJ, Gil-Humanes J, Ozuna CV, Barro F. Wheat varietes suitable for celiac patents. In: Rodrigo L, Pena AS, editors. Celiac disease and non-celiac gluten sensitvity. Barcelona: OmniaScience; 2014. p. 461–75.
- 8. Chirdo FG, Arranz E. Cereal proteins: immunostimulatory and toxic peptides. In: Arranz E, Fernández-Bañares F, Rosell CM, Rodrigo L, Peña AS, editors. Advances in the understanding of gluten related pathology and the evolution of gluten-free foods. Barcelona: OmniaScience; 2015. p. 141–62.
- 9. Camarca A, Anderson RP, Mamone G, Fierro O, Facchiano A, Costantini S, et al. Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease. J Immunol. 2009;182(7):4158–66.
- 10. Vallejo-Diez S, Bernardo D, de Lourdes MM, Munoz-Suano A, Fernandez-Salazar L, Calvo C, et al. Detection of specific IgA antibodies against a novel deamidated 8-Mer gliadin peptide in blood plasma samples from celiac patients. PLoS One. 2013;8(11):e80982.
- 11. Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AVS. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med. 2000;6(3):337–42.
- 12. Hausch F, Shan L, Santiago NA, Gray GM, Khosla C. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol-Gastr L. 2002;283(4):G996–G1003.
- 13. Breiteneder H, Radauer C. A classification of plant food allergens. J Allergy Clin Immunol. 2004;113(5):821–30.
- 14. van de Wal Y, Kooy YM, van Veelen P, Vader W, August SA, Drijfhout JW, et al. Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol. 1999;29:3133–9.
- 15. Vader W, Kooy Y, Van Veelen P, De Ru A, Harris D, Benckhuijsen W, et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology. 2002;122:1729–37.
- 16. Shan L, Molberg O, Parrot I, Hausch F, Filiz F, Gray M, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297:2275. [http://dx.doi.org/10.1126/](http://dx.doi.org/10.1126/science.1074129) [science.1074129](http://dx.doi.org/10.1126/science.1074129)).
- 17. Marsh MN, Morgan S, Ensari A, Wardle T, Lobley R, Mills C, et al. In-vivo activity of peptides 31-43, 44-55, 56-68 of *a*-gliadin in gluten sensitive enteropathy (GSE). Gastroenterology. 1995;108:A871.
- 18. Sturgess R, Day P, Ellis HJ, Lundin KEA, Gjertsen HA, Kontakou M, et al. Wheat peptide challenge in celiac-disease. Lancet. 1994;343(8900):758–61.
- 19. Fraser JS, Engel W, Ellis HJ, Moodie SJ, Pollock EL, Wieser H, et al. Celiac disease: in vivo toxicity of the putative immunodominant epitope. Gut. 2003;52(12):1698–702.
- 20. Mantzaris G, Jewell DP. In-vivo toxicity of a synthetic dodecapeptide from a-gliadin in patients with celiac-disease. Scand J Gastroenterol. 1991;26(4):392–8.
- 21. De Ritis G, Auricchio S, Jones HW, Lew EJL, Bernardin JE, Kasarda DD. In-vitro (organculture) studies of the toxicity of specific a-gliadin peptides in celiac disease. Gastroenterology. 1988;94(1):41–9.
- 22. Wieser H, Belitz HD, Idar D, Ashkenazi A. Celiac activity of the gliadin peptides CT-1 and CT-2. Z Lebensm Unters For. 1986;182(2):115–7.
- 23. Arentz-Hansen H, Korner R, Molberg O, Quarsten H, Vader W, Kooy YMC, et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med. 2000;191(4):603–12.
- 24. van de Wal Y, Kooy YM, van Veelen PA, Peña SA, Mearin LM, Molberg O, et al. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci U S A. 1998;95:10050–4.
- 25. Mazzarella G, Maglio M, Paparo F, Nardone G, Stefanile R, Greco L, et al. An immunodominant DQ8 restricted gliadin peptide activates small intestinal immune response in in vitro cultured mucosa from HLA-DQ8 positive but not HLA-DQ8 negative celiac patients. Gut. 2003;52(1):57–62.
- 26. Arentz-Hansen H, McAdam SN, Molberg O, Fleckenstein B, Lundin KEA, Jorgensen TJD, et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology. 2002;123(3):803–9.
- 27. Van Eckert R, Berghofer E, Ciclitira PJ, Chirdo FG, Denery-Papini S, Ellis J, et al. Towards a new gliadin reference material − Isolation and characterization. JCereal Sc. 2006;43:331–41.
- 28. Gessendorfer B, Koehler P, Wieser H. Preparation and characterization of enzymatically hydrolyzed prolamins from wheat, rye, and barley as references for the immunochemical quantitation of partially hydrolyzed gluten. Anal Bioanal Chem. 2009;395(6):1721–8.
- 29. Mena MC, Lombardia M, Hernando A, Mendez E, Albar JP. Comprehensive analysis of gluten in processed foods using a new extraction method and a competitive ELISA based on the R5 antibody. Talanta. 2012;91:33–40.
- 30. Comino I, Real A, Gil-Humanes J, Piston F, de Lorenzo L, Moreno ML, et al. Significant differences in celiac immunotoxicity of barley varieties. Mol Nutr Food Res. 2012;56(11):1697–707.
- 31. Comino I, Real A, Moreno ML, Montes R, Cebolla A, Sousa C. Immunological determination of gliadin 33-mer equivalent peptides in beers as a specific and practical analytical method to assess safety for celiac patients. J Sci Food Agric. 2013;93(4):933–43.
- 32. Codex Alimentarius. CODEX STAN 118–1979. Standard for Foods for Special Dietary Use for Persons Intolerant to Gluten. 2008 Revision.
- 33. Arentz-Hansen H, Fleckenstein B, Molberg O, Scott H, Koning F, Jung G, et al. The molecular basis for oat intolerance in patients with celiac disease. PLoS Med. 2004;1(1):84–92.
- 34. Pulido OM, Gillespie Z, Zarkadas M, Dubois S, Vavasour E, Rashid M, et al. Introduction of oats in the diet of individuals with celiac disease: a systematic review. Adv Food Nutr Res. 2009;57:235–85.
- 35. Council Directive 89/398/EEC of 3 May 1989 on the approximation of the laws of the Member States relating to foodstuffs intended for particular nutritional uses. Off J Eur Communities, L186; (June 30, 1989).
- 36. Directive 2000/13/EC of the European Parliament and of the Council of 20 March 2000 on the approximation of the laws of the Member States relating to the labelling, presentation and advertising of foodstuffs. Off J Eur Communities, L109; (May 6, 2000).
- 37. Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC. Off J Eur Union, L401; (December 12, 2006).
- 38. Commission Delegated Regulation (EU) No. 2016/127 of 25 September 2015 supplementing Regulation (EU) No. 609/2013 of the European Parliament and of the Council as regards the specific compositional and information requirements for infant formulae and follow-on formulae and as regards requirements on information relating to infant and young child feeding. Off J Eur Union, L25; (February 2, 2016).
- 39. Commission Regulation (EC) No. 41/2009 of 20 January 2009 concerning the composition and labelling of foodstuffs suitable for people intolerant to gluten. Off J Eur Union, L16; (January 21, 2009).
- 40. Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food information to consumers, amending Regulations (EC) No. 1924/2006 and (EC) No 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) No 608/2004. Off J Eur Union, L304; (November 22, 2011).
- 41. Commission Implementing Regulation (EU) No. 828/2014 of 30 July 2014 on the requirements for the provision of information to consumers on the absence or reduced presence of gluten in food. Off J Eur Union, L228; (July 31, 2014).
- 42. Food Labeling; Gluten-free Labeling of Foods, 21 C.F.R. 101. 2013.
- 43. Food Allergen Labeling and Consumer Protection Act of 2004, Pub. L. No. 108–282. 2004.
- 44. Food and Drug Regulations, section B.24.018, C.R.C., c. 870.
- 45. Health Canada's position on gluten-free claims. 2012. Available from: [http://www.hc-sc.gc.ca/](http://www.hc-sc.gc.ca/fn-an/securit/allerg/cel-coe/gluten-position-eng.php) [fn-an/securit/allerg/cel-coe/gluten-position-eng.php.](http://www.hc-sc.gc.ca/fn-an/securit/allerg/cel-coe/gluten-position-eng.php)
- 46. Food and drug administration. Proposed rule for food labeling. Gluten-free labeling of fermented or hydrolyzed foods. 80 FR 71990. (Nov. 18, 2015).
- 47. Australia New Zealand Food Standards Code. Schedule 4 nutrition, health and related claims, F2016C00189. 2016.
- 48. Código Alimentario Argentino. Ley 18284.
- 49. Akiyama H, Imai T, Ebisawa M. Japan food allergen labeling regulation − history and evaluation. Adv Food Nutr Res. 2011;62:139–71.
- 50. Marchisotto MJ, Harada L, Blumenstock JA, Bilaver LA, Waserman S, Sicherer S, et al. Global perceptions of food allergy thresholds in 16 countries. Allergy. 2016;71(8):1081–5.
- 51. DunnGalvin A, Chan CH, Crevel R, Grimshaw K, Poms R, Schnadt S, et al. Precautionary allergen labelling: perspectives from key stakeholder groups. Allergy. 2015;70(9):1039–51.

Chapter 3 Techniques for Analyzing Gluten

María Ángeles Bustamante, Edurne Simón, Itziar Churruca, and María del Pilar Fernández-Gil

Abbreviations

3.1 Introduction

Reliable and accurate methods for quantifying gluten in food are necessary to protect the gluten-sensitive consumer against exposure to this protein. According to the standard for gluten-free foods [\[1](#page-46-0)], the quantitative determination of gluten in food samples and ingredients must be based on an immunologic or other method that provides at least equal sensitivity and specificity.

In that sense, currently used analytical methods in gluten-free assessment and legal compliance testing are based on enzyme-linked immunosorbent assays (ELISAs). Nevertheless, other molecular techniques, such as mass spectrometry and chromatography, have also been used [\[2](#page-46-0), [3\]](#page-46-0). In addition, polymerase chain reaction (PCR) techniques are used as a complementary tool to identify the presence of gluten using a DNA pathway, and novel approaches such as aptamers, microarrays, and multi-analyte profiling are being developed [[4,](#page-46-0) [5\]](#page-46-0).

3.2 Immunological Techniques

Immunological methods are based on the antibodies (Abs) raised against the different prolamin fractions or specific sequences found in them. These assays should be able to measure the harmful proteins and peptides, regardless of the food matrix or manufacturing process. Nevertheless, as we will explain in the final section of this chapter, cereal proteins are modified during the elaboration process and they could make the detection analysis difficult [\[6](#page-47-0)].

ELISAs are most commonly used for routine gluten analysis, not only because of their specificity, sensitivity, and reproducibility, but also because of a lack of an independent reference method. Despite this, ELISA is the method recommended by the Codex [\[1](#page-46-0)], and other immunology-based methodologies are being developed, such as lateral flow devices, dipsticks, immunosensors, or immunomagnetic beads for multiplex analyses [\[7–10](#page-47-0)].

ELISA test kits provide rapid results, are easy to handle and, compared with other techniques, are usually cheaper and require simpler laboratory equipment. The gluten analysis assays are developed in several formats, although sandwich and competitive are more common than indirect methodologies. Either monoclonal or polyclonal Abs could be useful, and whereas monoclonal Abs (mAbs) recognize a single epitope that allows fine detection and quantification, polyclonal is often used to gather as much of the antigen as possible.

The sandwich ELISA quantifies prolamins – antigens – between two layers of Abs (i.e., capture and detection Abs) and they can be either monoclonal or polyclonal and can be the same or a different Ab. The capture Ab is well bound to the bottom of the microplate, and toxic fractions of prolamins are attached to this coating Ab. Later, a detection antibody conjugated to an enzyme (substrate) is added to the wells in order to join the capture Ab-prolamin mix together.

The prolamin to be measured must contain at least two antigenic epitopes capable of binding to both antibodies at the same time, since at least two antibodies take part in the sandwich. The Ab-linked enzyme used is usually horseradish peroxidase or alkaline phosphatase, and its purpose is to induce a color reaction involving chromogen, which can be measured by spectrophotometric methods. Figure [3.1](#page-35-0) summarizes these steps.

The competitive ELISA method is based on the competition between foodstuffs – i.e., a sample – prolamins and standard prolamins. This method uses only

Fig. 3.1 The Principles of ELISA: (1) Sandwich method; (2) Competitive method

one antibody, which makes it suitable for detecting small, hydrolyzed proteins and peptides as well. Taking into account that nonspecific binding is more likely to occur when only one binding site is needed for detection, this method may be less specific than the sandwich format (Fig. 3.1).

ELISA methods mostly use either gliadins or hordeins as reference standards, and antibody-specific for gliadins; they do not consider other possible toxic proteins, such as glutenins [[11\]](#page-47-0). Furthermore, based on an assumption that gliadins and glutenins are similar in proportion, ELISA estimates the total gluten content in foodstuffs using a conversion factor equal to 2 [[12\]](#page-47-0).

3.2.1 Antibodies and ELISA Test for Gluten Detection

Since the late 1980s, several immunochemical gluten analysis methods have been developed. They are based on mono- and polyclonal antibodies against prolamin proteins. Despite the fact that many of them have been built against wheat gliadin or its sub-fractions, and due to the structural homology of prolamins, they also recognize all the other prolamin fractions (hordein and secalin) to almost the same extent [\[13](#page-47-0), [14\]](#page-47-0). Nowadays, the most common are the monoclonal antibodies raised against multiple potential prolamin-specific antibodies. Several antibodies had been
developed, but only a few of them have been tested as ELISA and approved by a successful inter-laboratory study in accordance with AOAC guidelines.

3.2.1.1 Skerrit ELISA: Antibody Against ω-gliadin

This monoclonal mouse antibody (mAb), also referred as 401.21, was raised against ω-gliadins of the Australian Timgalen wheat variety [\[15](#page-47-0)]. This mAb was produced by Skerrit [[16\]](#page-47-0) and is able to recognize a gliadin fraction that does not denature during heating. This was an advantage to making it highly suitable for gluten detection in processed foods.

After a successful collaborative study, the sandwich ELISA based on this antibody was adopted as Official Method 991.19 by the Association of Official Analytical Chemists International (AOACI) [[16\]](#page-47-0). It underwent a very important development in the 1990s, but the use of ELISA based on this mAb is becoming less frequent because of the low validated sensitivity (limit of quantitation (LOQ): 160 mg gluten/kg), and also due to the high variability in the amount of ω-gliadins between cereal species and varieties. Consequently, the quantitative analysis can vary, depending on the relative ω-gliadins content; afterwards, it was replaced by other antibodies. Another disadvantage is that this method has only a low reactivity to barley hordeins.

3.2.1.2 R5 ELISA: Antibody Against Pentapeptide QQPFP (R5)

An mAb called R5 was developed against an ω-secalin extract [[17\]](#page-47-0) from rye, and it mainly recognizes the epitope QQPFP. The ELISA assay based on this antibody recognizes gliadins, hordeins, and secalins to a similar degree but does not recognize avenins [[18\]](#page-47-0). As QQPFP occurs in the repetitive domains of prolamins and has been found to occur numerous times in m-type prolamins [[19\]](#page-47-0), the antibody is a very good candidate for the detection of prolamins.

Since 2008, Codex Alimentarius [\[1](#page-46-0)] recommends ELISA methods based on the R5 antibody for gluten analysis. This antibody does not cross-react with proteins from inherently GF grains, but in some ethanol extraction conditions, not only harmful prolamins but also soy and lupin proteins [\[20\]](#page-47-0) might be detected. Later on, the use of a cocktail extraction, including reducing agents, solved these false positives.

The sandwich R5 ELISA, together with cocktail extraction, was validated by collaborative studies [\[18](#page-47-0), [21\]](#page-47-0) and subsequently adopted as an AACCI Approved Method 38–50.01 [[22\]](#page-47-0). A competitive R5 ELISA was developed for the determination of partially hydrolyzed gluten and, after a collaborative trial, it was accepted as AACCI Approved Method 38–55.01 [[23,](#page-47-0) [24\]](#page-47-0).

3.2.1.3 G12 and A1 ELISA Antibodies Against 33-mer (G12 and A1)

Two antibodies, G12 and A1, have been raised against 33-mer. The G12 antibody was developed by Morón et al. [\[25](#page-48-0)]; it particularly recognizes the hexapeptide QPQLPY. The antibody is highly selective for 33-mer and similar peptides found in

barley and rye. The A1 antibody recognizes the heptameric sequence QLPYPQP, which is also a part of 33-mer. A1 has a higher sensitivity for gluten detection than the G12 antibody, but G12 has a better affinity for 33-mer [[25,](#page-48-0) [26\]](#page-48-0).

Moreover, the advantage of these antibodies is their ability to recognize oat avenins [\[26](#page-48-0)] and this reactivity was proportional to the potential immunotoxicity of the oat cultivar [\[27](#page-48-0)]. The weakness came because it makes the G12 mAb unsuitable for detecting wheat, rye, or barley contaminations in oats. The sandwich assay was adopted as AACCI Approved Method 38–52.01 [\[28](#page-48-0)] after a collaborative study.

3.2.1.4 Others

Other immunological ELISA systems based on various antibodies have also been developed.

The Morinaga wheat protein ELISA method is based on the use of a polyclonal antibody to wheat $-$ gliadin $-$ that detects multiple epitopes. The antibody also cross-reacts with hordeins and secalins to a lesser degree than with wheat and, consequently, can underestimate barley and rye protein contamination.

Gabosská et al. (2006) [\[29](#page-48-0)] developed a gliadin ELISA kit based on two monoclonal antibodies against two different epitopes of gliadin and one polyclonal antibody. It recognizes wheat, rye, and spelt with the equivalent efficiency, but is lower for barley, where only about 20–30% is detected [\[30](#page-48-0)].

Ellis et al. [\[31](#page-48-0)] developed a competitive ELISA based on the PN3 antibody. PN3 is a monoclonal antibody raised against an epitope of 19 amino acids of A-gliadin (19mer), a harmful fragment of prolamins. The main recognition epitope is QQQPFP, and this mAb reacts strongly with a- and y-gliadins, but only weakly with ω-gliadins [\[11](#page-47-0), [32](#page-48-0), [33](#page-48-0)]. The antibody also detects LMW glutenins, secalins, and hordeins, but not HMW glutenins, avenins, or zeins. These and many other antibodies and ELISA methods have been assayed but none of them is commercially available.

3.3 Non-immunological Methods

3.3.1 Proteomic-Based Methods

3.3.1.1 SDS Polyacrylamide Gel Electrophoresis and Western Blotting

Gel electrophoresis has been largely used in protein analysis and, therefore, in cereal protein identification. Single and two-dimensional gel electrophoresis (both SDS-PAGE and A-PAGE) have been widely used to characterize prolamin subfractions based on their mobility.

The qualification of proteins by SDS-PAGE is further improved by adding another dimension based on isoelectric focusing, creating a two-dimensional system. Nevertheless, these techniques have not achieved enough sensibility for quantifying gluten at low levels. For this reason, complementary techniques have been associated as SDS-PAGE and Western blotting. Therefore, after electrophoretic separation by a one-dimensional SDS-PAGE, the proteins were transferred to polyvinylidene difluoride membranes where proteins are adsorbed. After transfer, the membranes were blocked with BSA (bovine serum albumin) and incubated with any of the monoclonal or polyclononal antibodies raised against toxic prolamins, already exposed. The western blot techniques allow a qualitative or semi-quantitative analysis of these immunogenic proteins [\[34](#page-48-0), [35](#page-48-0)].

3.3.1.2 RP or GP-HPLC

The protein profile has been characterized by reversed-phase or gel permeation high-performance liquid chromatography (RP- or GP-HPLC) with UV detection [\[19](#page-47-0)]. Nevertheless, this one-dimensional separation analysis is deficient for detecting gluten traces in complex food matrices due to low selectivity and sensitivity [[5\]](#page-46-0).

In that sense, in order to improve the prolamin analysis, new approaches have been designed that combine chromatography with mass spectrometry (MS) using soft ionization such as matrix-assisted laser desorption/ionization (MALDI) or electrospray ionization (ESI) followed by time-of-flight (TOF), ion trap, or triple quadrupole detection [\[19](#page-47-0), [36](#page-48-0), [37](#page-48-0)].

3.3.1.3 Mass Spectrometry, MALDITOF and LC/MS

As seen before, applying proteomics is interesting to complement immunological techniques. But when gluten-free products are being analyzed, where very low quantities of gluten are expected compared with the other major proteins, analysis becomes difficult [\[38](#page-48-0)]. Due to its high sensitivity for identification, characterization and quantification of proteins and peptides, mass spectrometry (MS) is one of the more important physical methods used in this field. MS is based in an ionization of the molecules of interest followed by ion separation. This separation is made according to their relation mass/charge, and finally, detection of the separated ions [[39\]](#page-48-0).

A type of MS method, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), has been proven to be an efficient tool for wheat gluten analysis [[18,](#page-47-0) [36\]](#page-48-0). Compared with the common separation methods, such as electrophoresis or HPLC, the MALDI-TOF-MS technique appears to be much more accurate and sensitive, requiring only a few minutes per sample to perform the measurement [[40\]](#page-48-0).

MALDI-TOF MS was the first technique used to identify toxic prolamins involved in celiac disease [[19,](#page-47-0) [36\]](#page-48-0) and to recognize the different patterns of toxic prolamins in grains, depending on the type of cultivar and variety studied. Nevertheless, as Mujico et al. have published [\[41](#page-48-0)], this system does not detect prolamins below 20–25 mg/kg and is, therefore, not appropriate for confirming the ELISA results in food samples with low gluten content. On the other hand, the complexity of the protein mixture, hydrolysis, or heating process carry out this methodology weakness, due to a possibly ambiguous gluten protein identification. The insufficient accuracy could be solved by a proteomic approach involving tandem mass spectrometry (MS/MS) or multi-stage MS experiments.

The classical workflow approach consists of separating protein mixtures by electrophoresis, digesting the sample by the enzyme trypsin breaking down proteins into peptides, and, finally, identifying those using MS. Other scientists overcome the protein separation stage by digesting the entire protein mixture into peptides and dividing them with one or two liquid chromatography (LC) steps [[6\]](#page-47-0). Furthermore, newly emerging technologies combine MS and proteomics, as well as the expanding field of bioinformatics tools and interactive databases (called "*in silico*"). These methods encompass the analysis of wheat protein extracts by MS with statistical methods such as artificial neural networks, partial least-squares regression, and principal component analysis in order to predict the variety or quality of unknown wheat samples [\[42](#page-48-0)].

3.3.2 Genomics-Based Methods

Genomics-based methods do not target gluten proteins, but rather a marker indicative of the presence of gluten: DNA or RNA. Methods relying on DNA have attracted great attention due to the high stability of DNA molecules.

As in protein-based methods, the success of the DNA-based methods for quantifying gluten in foods depends on the sensitivity and selectivity of the analysis. Moreover, in these kinds of methods, the efficacy of the DNA extraction, which should be valid for all food matrices and compatible with the selected analytical technique, and the use of a correct standard for calibration, are crucial [\[43](#page-48-0)].

DNA presents the advantage that it is efficiently extracted under harsh conditions, as well as being less affected by extraction from food matrices than proteins [\[44](#page-49-0)]; moreover, DNA analysis is more sensitive than protein analysis. However, it should be pointed out that genomics-based methods are indirect. This means that precise correlation between a DNA concentration or copy number and gluten protein concentration would be needed to use DNA-based methods for quantification purposes. Along these lines, legislation only establishes thresholds in terms of gluten concentration. Therefore, genomic-based methods are considered to be a complement or confirmation of the protein-based methods [\[43](#page-48-0), [45](#page-49-0)].

Food processing must be also taken into consideration. Highly processed foods are usually subjected to thermal and/or enzymatic transformations in which the DNA can be altered or even degraded. Nevertheless, DNA is much more stable than proteins, which is why DNA-based methods are a promising alternative in the analysis of these types of food.

Various DNA-based methods have been developed for detecting gluten; the PCR stands out among others. PCR is a technique that makes multiple copies of a segment of DNA using the ability of DNA polymerase to synthesize new strands of DNA complementary to a target sequence. DNA polymerase needs pre-existing

nucleotides to which to add new ones. Thus, short oligonucleotides, called primers, are used to initiate the amplification; this allows the use of complementary primers in order to detect specific DNA regions that they want to amplify, making PCR a very precise and specific technique. At the end of the reaction, the specific target sequence will be exponentially amplified in billions of copies.

After PCR, the amplified product can be completely identified by sequencing, or detected by gel electrophoresis subsequent staining and hybridization to a labeled version of the target DNA (southern blot) $[10]$ $[10]$. To quantify the target DNA, realtime PCR is used, which does not require post-PCR detection. In this case, fluorescent dyes that intercalate in double-stranded DNA, or probes specific to target DNA that are labeled with a fluorescent reporter, are used to detect the amplification of the DNA in real time [\[5](#page-46-0)]. The increase in fluorescence occurs at the same time that PCR is being carried out, and it is proportional to the amount of target DNA present in the sample [\[10](#page-47-0)].

With regard to gluten detection, the target DNA is any species-specific component of cereals that contain gluten and functions as a marker for the presence of a particular food ingredient. Commercial PCR kits for gluten detection mention that they include specific primer sequences developed for the amplification of DNA fragments solely present in gluten-containing cereals (wheat, spelt, kamut, rye, barley, triticale, and oat). However, they do not provide detailed information about their sequence.

Several targets have been proposed in the literature. Dahinden et al. [[46\]](#page-49-0) developed a PCR system as an indicator of celiac-toxic cereals' contamination of glutenfree food, simultaneously detecting a non-coding region of chloroplast *trnL* gene of wheat, barley, and rye. Afterwards, Olexová et al. used those primers satisfactorily, proving their suitability for the detection of gluten-containing cereals in flours and GF bakery products [\[47](#page-49-0)]. Similarly, in 2008, the applicability of those primers was validated in several food samples from various food groups (such as cereals and derivatives, chocolate, jam, meat extracts, commercially available gluten-free products, baby foods, and soy products), as well as heat-treated foods and partially hydrolyzed products [[45\]](#page-49-0).

The allergen-multiplex ligation-dependent probe amplification (MLPA) method for the detection of eight allergens − one of them gluten − proposed by Mustorp et al. must be also pointed out [\[44](#page-49-0)]. It consists of a 10-plex quantitative and sensitive ligation-dependent probe amplification method, in which ligated probes are amplified by PCR, and amplicons detected by capillary electrophoresis. Gluten probes were also based on a Dahinden-proposed sequence and tested positive for wheat, rye, barley, and oat.

Zeltner et al. [\[48](#page-49-0)] used primers specific for homologue sequences encoding highmolecular-weight glutenin sub-units in the case of wheat, spelt, kamut, and rye, the Hor3 gene for barley, and the gene-encoding 12S seed storage protein for oat. They obtained a satisfactory ruggedness in the detection, with a sensitivity of 2.5 mg/kg of wheat in vegetable food matrices, 5 mg/kg of wheat in meat, and 10 mg/kg for barley and oat. On the other hand, Mujico et al. [\[41](#page-48-0)] used a fragment of 51 base pairs of the intergenic region limited by the wheat ribosomal 25S and 18S genes to quantify wheat contamination. They obtained a PCR assay to confirm the presence of wheat in food even more sensitive than R5 ELISA. Martín-Fernández et al. [\[49](#page-49-0)] developed the real-time PCR method to assess three DNA sequences encoding wheat proteins $(\alpha^2$ -gliadin, agglutinin isolectin, and thioredoxin h). Results revealed high specificity to detect not only wheat, but also other gluten-containing cereals such as barley and rye. The most sensitive one was the α 2-gliadin marker sequencebased PCR.

Various outcomes have been published comparing DNA-based PCR methods results to those obtained by the Codex-approved protein-based R5 ELISA. Sandberg et al. [\[50\]](#page-49-0) used primers targeting prolamin genes of wheat, rye, barley, and oats in food samples. The PCR method provided a good correlation with the protein assay, as it was also rapid and sensitive. Similarly, a high correlation between PCR and R5 ELISA was noted by Mujico et al. [\[41](#page-48-0)]; however, while in some samples, prolamins were detectable by PCR and not by ELISA, in others, the DNA content was lower or higher than expected (high-temperature-treated samples and starch-based flours and foods respectively). Churruca et al. [\[45](#page-49-0)]observed a positive linear correlation between the gluten DNA and protein content in different food samples, including processed foods such as hydrolyzed beverages and heat-treated foods.

Proficiency tests were applied by Scharf et al. [\[51\]](#page-49-0) to assess the suitability of these methods. A total of 45 laboratories submitted PCR results and 170 laboratories submitted ELISA results between 2006 and 2011, showing agreements for both methods. Nevertheless, ELISA methods – but not PCR ones – gave 2% of false negatives in complex matrices such as pastries and sausage meat. Nevertheless, it must be pointed out that both methods were generally suitable for the detection of different gluten amounts in complex matrices, such as infant food.

Overall, these results show that PCR can be recommended as a highly sensitive screening method for the presence of gluten-containing cereals in food analysis, being confirmatory as well as complementary to the enzyme-immunoassay. In fact, DNA-based methods offer higher sensitivity and specificity than ELISA. However, PCR must be more deeply studied and developed for gluten detection in highly processed or hydrolyzed samples due to DNA degradation [[5\]](#page-46-0).

3.3.3 Novel Methods

3.3.3.1 Electrochemical Genosensors

DNA hybridization biosensors, also known as "genosensors," are analytical devices for the detection of specific DNA "target" sequences in solution, upon hybridization of the targets with complementary "probes" immobilized on a solid substrate [[52\]](#page-49-0). This is measured by the use of a reporter molecule and an electrode-based platform as transducer [[53\]](#page-49-0). Electrochemical genosensors have been proposed as an alternative to real-time PCR, yielding a rapid and specific amplicon post-PCR detection [[54\]](#page-49-0). The development of genosensors applied to complex biological samples, including food samples, has begun [\[52](#page-49-0), [53](#page-49-0)].

For celiac disease, an electrochemical genosensor to detect the oligonucleotide sequence encoding the CD immunogenic peptide 33-mer of gliadin in wheat was proposed, with an electrochemical sandwich assay [\[54](#page-49-0), [55](#page-49-0)]. It was able to selectively detect different varieties of wheat, barley, rye, and oats from other cereals, as low as 0.001% (10 mg/kg) of wheat flour in an inert matrix. Furthermore, even in highly processed food samples, a good correlation with the official immunoassay has been demonstrated [[53\]](#page-49-0).

3.3.3.2 SELEX

The systematic evolution of ligands by exponential enrichment, SELEX, is an *in vitro* selection process in which aptamers are identified from combinatorial libraries. Aptamers are structured, single-stranded nucleic acids [\[56](#page-49-0)] that bind with high affinity and specificity to their protein target. Later, aptamer-peptide complexes are detected by various techniques, such as PCR amplification, enzyme-linked assays, etc. Aptamers have been proposed as biomolecular recognition elements, an alternative to the use of antibody-detecting methods for many reasons: high affinity and specificity; high stability; they are chemically synthesized in a cost-effective way and with high reproducibility (obviating the requirement for host animals, as in the case of antibodies); and they can be easily combined with various chemical labels or groups for their adaptation to different analytical techniques [\[43](#page-48-0), [57](#page-49-0)].

There are few reports of aptamers selected against food allergens − in fact, not all targets are prone to generating useful aptamers. Gluten is the case, due to its hydrophobicity, that does not go well with the hydrophilic nature of nucleic acids [\[43](#page-48-0)]. Nevertheless, some researchers have developed a SELEX-based process for the selection of a DNA aptamer against the gliadin, called G33 aptamer, and its subsequent application for the detection of gliadin [\[57](#page-49-0)]. A competitive real-time apta-PCR was developed, where the bound aptamer was amplified for the detection of gliadin. Another SELEX process against α 2-gliadin led to different aptamers called anti 33-mer gliaptamers. Among them, Gli4 and Gli1 were selected. Gli4 was the aptamer with the highest affinity towards the target in the SELEX pool, while Gli1 was the most abundant one.

In 2014 Gli4 was used as a receptor for an electrochemical competitive enzymelinked apta-assay on magnetic particles. The results showed that besides gliadin, also detected were hordeins, secalins and avenins, with no cross-reactivity to corn, soy, or rice. Furthermore, this method was more sensitive than the reference immunoassay for detecting the same target [\[58](#page-49-0)]. The assay mentioned is compatible with the cocktail protein extraction method, allowing the quantification of gluten in heated foods. In 2015 the research group conducted a study with a Gli1 aptamer assay that allowed the detection of the allergen in different kinds of food samples, including hydrolyzed ones [[59\]](#page-49-0). The results revealed a good correlation with antibody-based assays, and G12-based and R5-based ELISAs.

3.3.3.3 Next-Generation Sequencing

Current commercial gluten analysis methods do not differentiate immunogenic and non-immunogenic CD epitope variants. It has been suggested that next-generation sequencing (NGS) may be used as a screening tool to classify wheat varieties according to phylogeny and their CD-immunogenic potential. Although it is not directly applicable to gluten detection, NGS could be a promising tool for differentiating between CD immunogenic epitopes and gluten sequences that are not CD active. This means that NGS could provide a correct selection of wheat varieties with low potential to cause CD [[60\]](#page-49-0).

Wheat α -gliadin proteins contain three major CD immunogenic peptides: $p31-$ 43, 33-mer, and DQ2.5-glia-α3 epitopes. An NGS study of α-gliadin genes from diploid and polyploid wheat revealed six types of α -gliadins with strong differences in the presence and abundance of these CD immunogenic peptides. Indeed, one of six contained all immunogenic peptides and epitopes [[61\]](#page-49-0). A 454 RNA-amplicon NGS was developed for α-gliadin transcripts encompassing the three major CD epitopes and their variants in various durum wheat varieties, all of which showed CD epitopes, but a few plants showed lower CD immunogenicity [[60\]](#page-49-0).

Taking into account all the published information, although novel methods are promising, more studies are needed to confirm their positive expectations.

3.4 Factors Affecting Gluten Analysis

Wheat gluten, obtained as a byproduct of the wheat starch industry, is a ubiquitous and relatively inexpensive source for the food industry. In the food processing industry sector, proteins like gluten are enzymatically modified as an effective tool to increase the functional properties, such as structure stabilization, and to enhance protein applications [\[62\]](#page-49-0). High temperatures during food processing could induce new intra- and intermolecular bonds, affecting toxic peptide detection. Furthermore, proteins can be modified by various techniques, such as deamidation, transamidation, and degradation by different types of hydrolysis. These modifications, which also occur naturally due to enzymatic mechanisms in cereal seeds, might mask or keep gluten hidden to some analytical tools [\[39,](#page-48-0) [63\]](#page-50-0).

3.4.1 Heating

During the processing of some foods, proteins are treated at high temperatures that induce new disulphide bonds between lysine and asparagines (Asp) and glutamine (Gln) residues. The α - and γ -gliadins contain high amounts of sulphur, increasing the heat-induced changes compared to those with a low sulphur content, as in

ω-gliadin. Furthermore, the heat-treatment of cooked and baked products produces protein aggregates forming an insoluble matrix that makes the extraction of gluten difficult, and, consequently, their analysis [[64,](#page-50-0) [65\]](#page-50-0).

Some extraction systems have been developed in order to solve these structural changes and ensure a complete recovery of prolamins and glutelins. In fact, ethanol solution extractions are insufficient, and solutions such as the cocktail that contains reducing and disaggregating agents, e.g., 2-mercaptoethanol and guanidine hydrochloride, are used. As mentioned, most spread is called cocktail [\[64\]](#page-50-0), but other similar compounds are suitable for that purpose. Nevertheless, β-mercaptoethanol can not be used in various tests -such as *ELISA competitive* test- because it interferes with the specific binding of the antibodies [[64](#page-50-0), [65\]](#page-50-0). Despite these approaches, a complete protein extraction cannot be guaranteed because they can form large aggregates that are hardly reducible and form new bonds to other types of polymers, such as starch or lipids [\[65, 66\]](#page-50-0).

3.4.2 Interference of Ingredients

Certain food ingredients may interfere in the gluten detection and prolamin analysis, giving lower or higher values than the real gluten content. It is known that polyphenol-containing foods such as chocolate, tannins, etc., may interfere in the gluten extraction process and, consequently, have detected less prolamin than was expected. This happens, for example, when spiked samples are prepared in order to determine recovery percentages, and the amount detected can be lower than assumed. It can be justified because these polyphenols are able to bind and precipitate proteins such as gliadins, and these complexes cannot be extracted for further analysis.

Cocoa and chocolate are one of the most common unwanted traps, but polyphenol sources are very varied among vegetables foods and includes spices and herbs (pepper, curry, oregano, parsley…), some nuts (peanut, pistachio…), pulses (lentils, beans, or peas), dried fruits (blueberries, plum…) and vegetables (artichoke, swiss chard leaves…). This problem has been solved by adding proteins to the extraction buffer that can capture these compounds, thereby avoiding catching gliadin or other prolamins. For this purpose, various options are available; these include adding fish gelatin and polyvinyl pyrrolidone (PVP) or skimmed milk to the cocktail solution.

Another conflictive matrix is soy; studies have shown that soy-based foods can give an overestimation of gluten content. Some authors have suggested that some soy epitopes could be recognized by gluten against raised antibodies [[20\]](#page-47-0). As a result, these sample analyses could carry some false positives or an increased recovery time when spiked controls are prepared with this matrix. In that sense, in our laboratory we also found that after a hydroalcoholic extraction at 60% in soy matrices, the ELISA sandwich method detected around 50 mg/kg of gluten but, surprisingly, these samples became negatives after adding the cocktail solution or after placing the samples at 80 °C for 24 hours and then carrying out the extraction.

3.4.3 Hydrolysis

In some hypersensitive conditions, such as allergies, the use of extensively hydrolyzed formulas might be an option instead of an allergenic protein substitution [[67](#page-50-0)]. Proteic hydrolysis during the processing of food might be a useful tool to reduce or abolish the harmfulness of prolamin proteins. Other strategies, such as fermentation of sourdough by lactic acid bacteria, might diminish prolamin toxic fractions because the majority of ethanol-soluble polypeptides could be mainly hydrolyzed and as a result, T cell stimulatory peptides would be broken [\[68\]](#page-50-0). Apart from adding lactic bacteria or fungal enzymes, endogenous cereal enzymes are most likely responsible for prolamin degradation during fermentation.

Other technological processes, like brewing, induce partial hydrolysis that produces smaller peptides and less secondary structure than the original proteins. Comparing them to the intact protein, these partial hydrolysates usually have enhanced physicochemical properties, whereas excessive hydrolysis might reduce some functionality [\[69–71](#page-50-0)].

In food processing, the enzymatic hydrolysis of wheat gluten is capable of improving its solubility and developing the emulsifying and foaming properties. In short, hydrolysis may decrease the toxicity of gluten [\[72](#page-50-0)], but this peptide fragmentation might complicate the analysis of gluten in these foods.

Reviewing some gluten analysis techniques, the ELISA sandwich is based on the requirement that at least two specific epitopes are recognized by the antibody. However, it is not appropriate when foods and beverages are treated with proteolytic enzymes, or when they are fermented because there may not be two of this sequence. Consequently, small hydrolyzed products with a single epitope cannot be reliably determined by using sandwich R5 ELISA [[23](#page-47-0), [24](#page-47-0), [73](#page-50-0)]. As competitive R5 ELISA requires only one antibody-binding epitope, it is more suitable for the detection of hydrolyzed gluten than sandwich R5 ELISA. The weakness of competitive assessment might appear because nonspecific binding is more likely to occur when only one binding site is needed for detection.

The hydrolyzed gliadin extraction process is also complex because some reducing agents used in the hydro-alcoholic solution interfere with the assay compounds. In order to solve this problem, another extraction solution called UPEX (universal prolamin and glutelin extractant solution) has been designed; it improves this analysis procedure, avoiding the problems previously mentioned [[64](#page-50-0)]. In other genomics-based techniques, such as the polymerase chain reaction (PCR) method, DNA extraction in hydrolyzed samples is difficult, and gluten-containing cereal DNA presence is not always related to gluten protein presence, probably due to the technological treatment of foods $[45]$ $[45]$ $[45]$.

3.4.4 Deamidation and Transmidation

Wheat gluten hydrophobic characteristics are due to the high percentage of uncharged amino acid residues such as glutamines (Gln) and asparagines (Asn). These amino acids are easily deamidated, changing to glutamic and aspartic acid, respectively. After deamidation, the solubility, emulsification and foaming properties of these proteins are improved under mild acidic-heating conditions [\[74](#page-50-0)]. Apart from the chemical approach, enzymatic reactions based on transglutaminase enzymes (tTG) are used in gluten deamidation processes. Furthermore, tTG could catalyze cross-linking between the glutamine residue and lysine, or another amine donor, by covalent bonding, in a process known as "transamidation." Taking these characteristics into account, in the food industry, the microbial TG (mTG) has become widely used as a food glue as well as in order to improve the baking qualities of weak wheat flours [[75–77\]](#page-50-0).

Although some authors suggested that the addition of microbial TG to wheat flours does not affect the prolamin analysis, [[78\]](#page-50-0), other researchers found that deamidation of toxic peptides decreases the antibody affinity in gluten analysis assays [\[63](#page-50-0)]. Indeed, gluten deamidation drastically depressed the antibody recognition compared to the intact gluten proteins [\[79](#page-50-0), [80](#page-50-0)].

On the other hand, the tTG present in the intestines induces deamidation and transamidation of prolamin toxic peptides, increasing their binding to HLA-DQ2 or -DQ8 molecules, and then the T-cell stimulating activity is increased [\[81](#page-50-0), [82](#page-50-0)]. In that sense, celiac sufferers develop increased levels of autoantibodies against tTG that become important in diagnosis. In this way, Lerner et al. [\[75](#page-50-0)] have suggested that the increased use of mTG in food processing may promote celiac pathogenesis *ex vivo*, possibly explaining the surge in the incidence of celiac disease. By contrast, other authors [[83\]](#page-50-0) have found that if cultured duodenal biopsies from celiac patients are tested, the enzymatic modification of gluten by transglutaminase could prevent the immunologic effects of CD.

References

- 1. Codex Alimentarius. CODEX STAN 118-1979. Standard for foods for special dietary use for persons intolerant to gluten. 2008 Revision.
- 2. Sealey-Voyksner JA, Khosla C, Voyksner RD, Jorgenson JW. Novel aspects of quantitation of immunogenic wheat gluten peptides by liquid chromatography–mass spectrometry/mass spectrometry. J Chromatogr A. 2010;1217(25):4167–83.
- 3. Allred LK, Sealey Voyksner JA, Voyksner RD. Evaluation of qualitative and quantitative immunoassays to detect barley contamination in gluten-free beer with confirmation using LC/ MS/MS. J AOAC Int. 2014;97(6):1615–25.
- 4. Ferre-Lopez S, Ribes-Koninckx C, Genzor C, Gamen S, Pena L, Ortigosa L, et al. Immunochromatographic sticks for tissue transglutaminase and antigliadin antibody screening in celiac disease. Clin Gastroenterol Hepatol. 2004;2(6):480–4.
- 5. Scherf KA, Poms RE. Recent developments in analytical methods for tracing gluten. J Cereal Sci. 2016;67:112–22.
- 6. Mena MC, Sousa C. Analytical tools for gluten detection. Policies andregulation. In: Arranz E, Fernández-Bañares F, Rosell CM, Rodrigo L, Peña AS, editors. Advances in the understanding of gluten-related pathology and the evolution of gluten-free foods. Barcelona: OmniaScience; 2015. p. 527–64.
- 7. Chu PT, Wen HW. Sensitive detection and quantification of gliadin contamination in glutenfree food with immunomagnetic beads based liposomal fluorescence immunoassay. Anal Chim Acta. 2013;787:246–53.
- 8. Chu P-T, Lin C-S, Chen W-J, Chen C-F, Wen H-W. Detection of gliadin in foods using a quartz crystal microbalance biosensor that incorporates gold nanoparticles. J Agric Food Chem. 2012;60(26):6483–92.
- 9. Rosales-Rivera LC, Acero-Sanchez JL, Lozano-Sanchez P, Katakis I, O'Sullivan CK. Electrochemical immunosensor detection of antigliadin antibodies from real human serum. Biosens Bioelectron. 2011;26(11):4471–6.
- 10. Haraszi R, Chassaigne H, Maquet A, Ulberth F. Analytical methods for detection of gluten in food–method developments in support of food labeling legislation. J AOAC Int. 2011;94(4):1006–25.
- 11. Dewar DH, Amato M, Ellis HJ, Pollock EL, Gonzalez-Cinca N, Wieser H, et al. The toxicity of high molecular weight glutenin subunits of wheat to patients with celiac disease. Eur J Gastroenterol Hepatol. 2006;18(5):483–91.
- 12. Shewry PR, Miflin BJ, Kasarda DD. The structural and evolutionary relationships of the prolamin storage proteins of barley, rye and wheat. Philos Trans R Soc Lond B Biol Sci. 1984;304(1120):297–308.
- 13. Brett GM, Mills ENC, Goodfellow BJ, Fido RJ, Tatham AS, Shewry PR, et al. Epitope mapping studies of broad specificity monoclonal antibodies to cereal prolamins. J Cereal Sci. 1999;29(2):117–28.
- 14. RumboM, ChirdoFG, FossatiCA, AnonMC. Analysis of anti-prolamin monoclonal antibody reactivity using prolamin fractions purified by preparative electrophoresis. 2010. [http://dx.doi.](http://dx.doi.org/101080/09540100099616) [org/101080/09540100099616](http://dx.doi.org/101080/09540100099616).
- 15. Skerritt JH, Smith RA. A sensitive monoclonal-antibody-based test for gluten detection: studies with cooked or processed foods. J Sci Food Agric. 1985;36(10):980–6.
- 16. Skerritt JH, Hill AS. Enzyme immunoassay for determination of gluten in foods: collaborative study. J Assoc Off Anal Chem. 1991;74(2):257–64.
- 17. Sorell L, López JA, Valdés I, Alfonso P, Camafeita E, Acevedo B, et al. An innovative sandwich ELISA system based on an antibody cocktail for gluten analysis. FEBS Lett. 1998;439(1–2):46–50.
- 18. Valdés I, García E, Llorente M, Méndez E. Innovative approach to low-level gluten determination in foods using a novel sandwich enzyme-linked immunosorbent assay protocol. Eur JGastroenterol Hepatol. 2003;15(5):465–747.
- 19. Rocher A, Calero M, Soriano F, Mendez E. Identification of major rye secalins as celiac immunoreactive proteins. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1996;1295(1):13–22.
- 20. Immer U, Haas-Lauterbach S. The question of extraction procedures. In: Stern M, editor. Proceedings of the 19th meetingof the working group on prolamin analysis andtoxicity. Zwickau: Verlag Wissenschaftliche Scripten. p. 45–52.
- 21. Méndez E, Vela C, Immer U, Janssen FW. Report of a collaborative trial to investigate the performance of the R5 enzyme linked immunoassay to determine gliadin in gluten-free food. Eur J Gastroenterol Hepatol. 2005;17(10):1053–63.
- 22. KoehlerP, SchwalbT, ImmerU, LacornM, WehlingP, DonC. AACCI approved methods technical committee report: collaborative study on the immunochemical determination of intact gluten using an R5 sandwich ELISA. 2014. [http://dx.doi.org/101094/CFW-58-1-0036.](http://dx.doi.org/101094/CFW-58-1-0036)
- 23. Haas-Lauterbach S, Immer U, Richter M, Oehler E. Gluten fragment detection with a competitive ELISA. J AOAC Int. 2012;95(2):377–81.
- 24. KoehlerP, SchwalbT, ImmerU, LacornM, WehlingP, DonC. AACCI approved methods technical committee report: collaborative study on the immunochemical determination of par-

tially hydrolyzed gluten using an R5 competitive ELISA. 2014. [http://dx.doi.org/101094/](http://dx.doi.org/101094/CFW-58-3-0402) [CFW-58-3-0402.](http://dx.doi.org/101094/CFW-58-3-0402)

- 25. Moron B, Bethune MT, Comino I, Manyani H, Ferragud M, Lopez MC, et al. Toward the assessment of food toxicity for celiac patients: characterization of monoclonal antibodies to a main immunogenic gluten peptide. PLoS One. 2008;3(5):e2294.
- 26. Moron B, Cebolla A, Manyani H, Alvarez-Maqueda M, Megias M, Thomas Mdel C, et al. Sensitive detection of cereal fractions that are toxic to celiac disease patients by using monoclonal antibodies to a main immunogenic wheat peptide. Am J Clin Nutr. 2008;87(2):405–14.
- 27. Comino I, Real A, Lorenzo L, Cornell H, López-Casado MÁ, Barro F, et al. Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in celiac disease. Gut. 2011;60(7):915–22.
- 28. DonC, Halbmayr-JechE, RogersA, KoehlerP. AACCI approved methods technical committee report: collaborative study on the immunochemical quantitation of intact gluten in rice flour and rice-based products using G12 sandwich ELISA. 2014.<http://dx.doi.org/101094/CFW-59-4-0605>.
- 29. Gabrovska D, Rysova J, Filova V, Plicka J, Cuhra P, Kubik M, et al. Gluten determination by gliadin enzyme-linked immunosorbent assay kit: interlaboratory study. J AOAC Int. 2006;89(1):154–60.
- 30. Sanchez D, Tuckova L, Burkhard M, Plicka J, Mothes T, Hoffmanova I, et al. Specificity analysis of anti-gliadin mouse monoclonal antibodies used for detection of gliadin in food for gluten-free diet. J Agric Food Chem. 2007;55(7):2627–32.
- 31. Ellis HJ, Rosen-Bronson S, O'Reilly N, Ciclitira PJ. Measurement of gluten using a monoclonal antibody to a celiac toxic peptide of A-gliadin. Gut. 1998;43(2):190–5.
- 32. Redondo MCB, Griffin PB, Ransanz MG, Ellis HJ, Ciclitira PJ, O'Sullivan CK. Monoclonal antibody-based competitive assay for the sensitive detection of celiac disease toxic prolamins. Anal Chim Acta. 2005;551(1–2):105–14.
- 33. van Eckert R, Bond J, Rawson P, Klein CL, Stern M, Jordan TW. Reactivity of gluten detecting monoclonal antibodies to a gliadin reference material. J Cereal Sci. 2010;51(2):198–204.
- 34. Gao L, Ma W, Chen J, Wang K, Li J, Wang S, et al. Characterization and comparative analysis of wheat high molecular weight glutenin subunits by SDS-PAGE, RP-HPLC, HPCE, and MALDI-TOF-MS. J Agric Food Chem. 2010;58(5):2777–86.
- 35. van Eckert R, Berghofer E, Ciclitira PJ, Chirdo F, Denery-Papini S, Ellis HJ, et al. Towards a new gliadin reference material–isolation and characterisation. J Cereal Sci. 2006;43(3):331–41.
- 36. Camafeita E, Alfonso P, Mothes T, Mendez E. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometric micro-analysis: the first non-immunological alternative attempt to quantify gluten gliadins in food samples. J Mass Spectrom. 1997;32(9):940–7.
- 37. Ferranti P, Mamone G, Picariello G, Addeo F. Mass spectrometry analysis of gliadins in celiac disease. J Mass Spectrom. 2007;42(12):1531–48.
- 38. Mamone G, Picariello G, Caira S, Addeo F, Ferranti P. Analysis of food proteins and peptides by mass spectrometry-based techniques. J Chromatogr A. 2009;1216(43):7130–42.
- 39. Rosell CM, Barro F, Sousa C, Mena MC. Cereals for developing gluten-free products and analytical tools for gluten detection. J Cereal Sci. 2014;59(3):354–64.
- 40. Li Liu AW, Appels R, Ma J, Xiab X, Lan P, He Z, Bekes F, Yan Y, Ma W. A MALDI-TOF based analysis of high molecular weight glutenin subunits for wheat breeding. Journal of Cereal Science. 2009;50(2):295-301.
- 41. Mujico JR, Lombardía M, Mena MC, Méndez E, Albar JP. A highly sensitive real-time PCR system for quantification of wheat contamination in gluten-free food for celiac patients. Food Chem. 2011;128(3):795–801.
- 42. Camarca A, Anderson RP, Mamone G, Fierro O, Facchiano A, Costantini S, Zanzi D, Sidney J, Auricchio S, Sette A, Troncone R, Gianfrani C. Intestinal T cell responses to gluten peptides are largely heterogeneous: implications for a peptide-based therapy in celiac disease. J Immunol. 2009;182(7):4158–66.
- 43. Miranda-Castro R, de-los- Santos-Álvarez N, Miranda-Ordieres AJ, Lobo-Castañón MJ. Harnessing aptamers to overcome challenges in gluten detection. Biosensors (Basel). 2016;6(2):16–27.

3 Techniques for Analyzing Gluten

- 44. Mustorp SL, Drømtorp SM, Holck AL. Multiplex, quantitative, ligation-dependent probe amplification for determination of allergens in food. J Agric Food Chem. 2011;59(10):5231–9.
- 45. Churruca I, Lasa A, Miranda J, Fernández-Gil P, Simón E. The usefulness of a complementary Real Time Polymerase Chain Reaction Technique in the determination of gluten in foods. In: Stern M, editor. Proceedings of the 23th working group on prolamin analysis and toxicity. Zwickau: Verlag Wissenschaftliche Scripten; 2008. p. 59–67.
- 46. Dahinden I, von Büren M, Lüthy J. A quantitative competitive PCR system to detect contamination of wheat, barley or rye in gluten-free food for celiac patients. Eur Food Res Technol. 2001;212(2):228–33.
- 47. Olexová L, Dovicovicová L, Svec M, Siekel P, Kuchta T. Detection of gluten-containing cereals in flours and "gluten-free" bakery products by polymerase chain reaction. Food Control. 2006;17(3):234–7.
- 48. Zeltner D, Glomb MA, Maede D. Real-time PCR systems for the detection of the gluten-containing cereals wheat, spelt, kamut, rye, barley and oat. Eur Food Res Technol. 2009;228:321–30.
- 49. Martín-Fernández B, Costa J, Oliveira MBPP, López-Ruiz B, Mafra I. Screening new gene markers for gluten detection in foods. Food Control. 2015;56:57–63.
- 50. Sandberg M, Lundberg L, Ferm M, Yman. Real Time PCR for the detection and discrimination of cereal contamination in gluten-free foods. Eur Food Res Technol. 2003;217(4):344–9.
- 51. Scharf A, Kasel U, Wichmann G, Besler M. Performance of ELISA and PCR methods for the determination of allergens in food: an evaluation of six years of proficiency testing for soy (Glycine max L.) and wheat gluten (Triticum aestivum L.). J Agric Food Chem. 2013;61(43):10261–72.
- 52. Tosar JP, Brañas G, Laíz J. Electrochemical DNA hybridization sensors applied to real and complex biological samples. Biosens Bioelectron. 2010;26(4):1205–17.
- 53. Martín-Fernández B, de-los- Santos-Álvarez N, Martín-Clemente JP, Lobo-Castañón MJ, López-Ruiz B. Challenging genosensors in food samples: The case of gluten determination in highly processed samples. Talanta. 2016;146:490-5.
- 54. Martín-Fernández B, Miranda-Ordieres AJ, Lobo-Castañón MJ, Frutos-Cabanillas G, de-los-Santos-Álvarez N, López-Ruiz B. Strongly structured DNA sequences as targets for genosensing: sensing phase design and coupling to PCR amplification for a highly specific 33-mer gliadin DNA fragment. Biosens Bioelectron. 2014;60:244–51.
- 55. Martín-Fernández B, de-los- Santos-Álvarez N, Lobo-Castañón MJ, López-Ruiz B. Hairpinbased DNA electrochemical sensor for selective detection of a repetitive and structured target codifying a gliadin fragment. Anal Bioanal Chem. 2015;407(12):3481–8.
- 56. Gold L, Janjic N, Jarvis T, Schneider D, Walker JJ, Wilcox SK, et al. Aptamers and the RNA world, past and present. Cold Spring Harb Perspect Biol. 2012;4(3):1–9.
- 57. Pinto A, Polo PN, Henry O, Redondo MC, Svobodova M, O'Sullivan CK. Label-free detection of gliadin food allergen mediated by real-time apta-PCR. Anal Bioanal Chem. 2014;406(2):515–24.
- 58. Amaya-González S, de-los- Santos-Álvarez N, Miranda-Ordieres AJ, Lobo-Castañón MJ. Aptamer binding to celiac disease-triggering hydrophobic proteins: a sensitive gluten detection approach. Anal Chem. 2014;86(5):2733–9.
- 59. Amaya-González S, de-los- Santos-Álvarez N, Miranda-Ordieres AJ, Lobo-Castañón MJ. Sensitive gluten determination in gluten-free foods by an electrochemical aptamer-based assay. Anal Bioanal Chem. 2015;407(20):6021–9.
- 60. Salentijn EM, Esselink DG, Goryunova SV, van der Meer IM, Gilissen LJ, Smulders MJ. Quantitative and qualitative differences in celiac disease epitopes among durum wheat varieties identified through deep RNA-amplicon sequencing. BMC Genomics. 2013;14:905–21.
- 61. Ozuna CV, Iehisa JC, Giménez MJ, Alvarez JB, Sousa C, Barro F. Diversification of the celiac disease α -gliadin complex in wheat: a 33-mer peptide with six overlapping epitopes, evolved following polyploidization. Plant J. 2015;82(5):794–805.
- 62. Wang J-S, Zhao M-M, Yang X-Q, Jiang Y-M, Chun C. Gelation behavior of wheat gluten by heat treatment followed by transglutaminase cross-linking reaction. Food Hydrocoll. 2007;21(2):174–9.
- 63. Kanerva P, Brinck O, Sontag-Strohm T, Salovaara H, Loponen J. Deamidation of gluten proteins and peptides decreases the antibody affinity in gluten analysis assays. J Cereal Sci. 2011;53(3):335–9.
- 64. Mena MC, Lombardia M, Hernando A, Mendez E, Albar JP. Comprehensive analysis of gluten in processed foods using a new extraction method and a competitive ELISA based on the R5 antibody. Talanta. 2012;91:33–40.
- 65. Kanerva P, Sontag-Strohm T, Brinck O, Salovaara H. Improved extraction of prolamins for gluten detection in processed foods. Agricultural and Food Science. 2011;20(3):206–16.
- 66. Lavelli V, NicolettaGuerrieri A, Cerletti P. Controlled reduction study of modifications induced by gradual heating in gluten proteins. J Agric Food Chem. 1996;44:2549–55.
- 67. Caffarelli C, Plebani A, Poiesi C, Petroccione T, Spattini A, Cavagni G. Determination of allergenicity to three cow's milk hydrolysates and an amino acid-derived formula in children with cow's milk allergy. Clin Exp Allergy. 2002;32(1):74–9.
- 68. De Angelis M, Coda R, Silano M, Minervini F, Rizzello CG, Di Cagno R, et al. Fermentation by selected sourdough lactic acid bacteria to decrease celiac intolerance to rye flour. J Cereal Sci. 2006;43(3):301–14.
- 69. Calderon de la Barca AM, Wall Medrano A, Jara Marini M, Gonzalez Cordova AF, Ruiz Salazar A. Enzymatic modification of the functional, nutritional and sensorial properties of soybeans for special feeding. Arch Latinoam Nutr. 2000;50(1):26–34.
- 70. Pena-Ramos EA, Xiong YLL. Whey and soy protein, hydrolysates inhibit lipid oxidation in cooked pork patties. Meat Sci. 2003;64(3):259–63.
- 71. Kuehler CA, Stine CM. Effect of enzymatic-hydrolysis on some functional properties of whey protein. J Food Sci. 1974;39(2):379–82.
- 72. Greco L, Gobbetti M, Auricchio R, Di Mase R, Landolfo F, Paparo F, et al. Safety for patients with celiac disease of baked goods made of wheat flour hydrolyzed during food processing. Clin Gastroenterol Hepatol. 2011;9(1):24–9.
- 73. Dostálek P, Gabrovská D, Rysová J, Mena MC, Hernando A, Méndez E, et al. Determination of gluten in glucose syrups. J Food Compos Anal. 2009;22(7–8):762–5.
- 74. Liao L, Zhao M, Ren J, Zhao H, Cui C, Hu X. Effect of acetic acid deamidation-induced modification on functional and nutritional properties and conformation of wheat gluten. J Sci Food Agric. 2010;90(3):409–17.
- 75. Lerner A, Matthias T. Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis. Nutr Rev. 2015;73(8):544–52.
- 76. Renzetti S, Rosell CM. Role of enzymes in improving the functionality of proteins in nonwheat dough systems. J Cereal Sci. 2016;67:35–45.
- 77. Caballero PA, Bonet A, Rosell CM, Gomez M. Effect of microbial transglutaminase on the rheological and thermal properties of insect- damaged wheat flour. J Cereal Sci. 2005;42(1):93–100.
- 78. Wieser H, Kahlenberg F, Kim J-J, Köhler P, Jimenez E, Hernando A, Méndez E, Mothes T. Is the quantification of gliadins in bread by R5 ELISA affected by the treatment of dough with bacterial transglutaminase? In: Stern M, editor. Proceedings of the 20thmeeting of the working group on prolamin analysis and toxicity. Zwickau: Verlag Wissenschaftliche Scripten; 2006. p. 75–9.
- 79. Tranquet O, Larré C, Denery-Papini S. Selection of a monoclonal antibody for detection of gliadins and glutenins: a step towards reliable gluten quantification. J Cereal Sci. 2012;56(3):760–3.
- 80. Gianfrani C, Siciliano RA, Facchiano AM, Camarca A, Mazzeo MF, Costantini S, et al. Transamidation of wheat flour inhibits the response to gliadin of intestinal T cells in celiac disease. Gastroenterology. 2007;133(3):780–9.
- 81. Arentz-Hansen H, Korner R, Molberg O, Quarsten H, Vader W, Kooy YMC, et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med. 2000;191(4):603–12.
- 82. Ellis HJ, Pollock EL, Engel W, Fraser JS, Rosen-Bronson S, Wieser H, et al. Investigation of the putative immunodominant T cell epitopes in celiac disease. Gut. 2003;52(2):212–7.
- 83. Elli L, Roncoroni L, Hils M, Pasternack R, Barisani D, Terrani C, et al. Immunological effects of transglutaminase-treated gluten in celiac disease. Hum Immunol. 2012;73(10):992–7.

Chapter 4 Gluten Content Change Over the Two Last Decades

Jonatan Miranda and Edurne Simón

Abbreviations

ppm parts per million

In recent years, the gluten-free (GF) food industry has become one of the most thriving industries. According to the Mintel Report on GF foods, in the U.S., the production of these foods has risen 136% between 2013 and 2105, with sales reaching \$11,609,000,000 [\[1\]](#page-60-0). However, the most remarkable aspect of this report is its GF market forecast of \$14,175,000,000 for 2018 in the worst-case scenario, while the best predictions could be around \$31,128,000,000 [\[1\]](#page-60-0). Reports by other companies portend a similar projection in Europe for 2015–2020 [\[2\]](#page-60-0). In the case of Canada, its government reported that 15.5% of newly launched food products in 2013 were GF [\[3](#page-60-0)]. According to the registered data, among GF food, snacks, bakery products, sauces and seasonings were the top categories in GF food launches. In addition to foodstuffs, around 200 new GF beverages were put on the market in Canada between 2007 and 2013 [\[3](#page-60-0)].

A clear example of this GF product expansion is easy to observe. While a few years ago, selling GF products was limited to specialty shops, today these products fill the shelves of grocery stores and supermarkets everywhere. However, this upsurge in the production and variety of GF products is not accompanied by an increase in the prevalence or awareness of celiac disease (CD). As Reilly [\[4](#page-60-0)] describes, searches for comments related to CD by Google Trend in the last decade remained constant, whereas those related to GF foods increased exponentially. Indeed, nowadays the search ratio is 1:8; that is, for each search for information on CD, there have been eight for gluten-free products [[4\]](#page-60-0).

Most American consumers of these products are not people who suffer from CD [\[5](#page-60-0)]. In these particular cases, their interest in GF foods appears to be similar to organic food conventionalization [\[6](#page-60-0)]. GF food for people without symptoms associated with gluten is motivated by a lifestyle based on cultural, ecological, civic, historical, ethical or health-related interest [[6\]](#page-60-0). The use of ancient GF grains, for instance, may contribute to a product's enchanting appeal.

Along these lines, a worldwide survey carried out in 2015 among 30,000 adults in 60 countries indicated that 21% of the interviewees found the term "GF" to be very important in their choice of buying food [[7](#page-60-0)]. However, it should not be forgotten that these types of products are more expensive than their counterparts that contain gluten, which also affects the purchasing decision [[8](#page-60-0)]; this has a great impact on the age of the potential buyers of gluten-free food. The same survey revealed how around a third of respondents under age 34 are willing to buy food without gluten, despite the higher price, while only 12% of the over-65s would do so [\[7\]](#page-60-0).

As mentioned in the chapter of this book concerning legislation, there are many countries that have accepted the definition of GF and the threshold of 20 mg of gluten per kg of food (or parts per million: ppm), proposed by the Codex Alimentarius to establish the foods that can be labeled "GF" (Chap. [2](http://dx.doi.org/10.1007/978-3-319-53342-1_2)). It is important to understand that many consumers rely on the labeling or claims of GF when making their purchases; nevertheless, gluten can be unintentionally introduced into the food through direct contact with raw materials containing gluten (wheat, barley, and rye). This gluten contamination can happen to product development beforehand (during harvest, transport, or storage of raw materials), during processing (adding meat sauces, beans or soups that are intended to improve the sensory and technological characteristics of the dish), or after product embellishment (e.g., a serving dish that has been cross-contaminated with gluten-containing products). Although for some GF product consumers there would not be any repercussions, it can lead to reactions and severe symptoms in patients with CD or related pathologies. For this reason, a precise and routine control of gluten content in food is necessary to ensure its safety in people who can have a reaction resulting from the intake of this protein.

Several studies have been carried out concerning gluten contamination in GF-labeled products (Table [4.1](#page-53-0)). In 2010, two interesting Brazilian researches revealed that around 13% of gluten-free samples contained more than 20 mg/kg of gluten [\[9](#page-60-0), [10](#page-60-0)]. Altogether, both studies analyzed 185 GF products, among them bread, flours, dough, sauce, cereal bars, and cereal-snack food groups.

Since 2010, the USA has been the country where most of the studies evaluating gluten content in GF labeled products have been carried out. Between 2011 and 2015, Thompson and Simpson (2015) collected 158 samples to analyze their gluten content [[11\]](#page-60-0). The results concluded that gluten was detected in almost 13% of the samples (>5 mg/kg of gluten). Furthermore, it is important to point out that 5.1% of the samples had over 20 mg/kg. Other research conducted by the same group indicated a similar ratio of samples over the pre-set threshold (4:112) [[12\]](#page-60-0).

(continued)

Table 4.1 (continued) **Table 4.1** (continued)

Unfortunately, none of the authors gave information on the food groups studied or positive samples classification.

With regard to Europe, during this same time period, an analysis of bread, pasta, pastry, biscuits, pizzas, and breakfast cereals from Italy, Spain, Germany and Norway was conducted, in which the researchers noted minimal gluten contamination [[13\]](#page-60-0). Although some traces were detected [\[17](#page-60-0)] in food samples (>5 mg/kg), only one sample (of pastry) from 205 GF products showed gluten levels over 20 mg/kg.

Some customers attribute the GF assumption of a product to reading the list of ingredients. As a consequence, research in which GF products were not labeled but appeared to be free of gluten-containing ingredients (no wheat, barley, or rye) have been carried out (Table [4.2](#page-56-0)). In the case of these kinds of foodstuffs, it can be said that Thompson promoted their analysis when she advised them about oats contamination with gluten in the USA [\[14](#page-60-0)]. In almost one-third of 12 studied oats, gluten levels were over 20 mg/kg. Later on, two studies conducted in two different countries (Brazil and Poland), declared similar percentages of gluten contamination above the standard limit (of 9.3 and 10.5%, respectively). The same year, Thompson et al (2010) published a study with 22 grains, seeds and flours [\[15](#page-60-0)]; according to the findings, millet flour and grain, white rice flour, buckwheat flour, sorghum flour, and soy flour were the most-contaminated raw materials [\[15](#page-60-0)].

With regard to bakery products, in research conducted in Brazil, positive samples were found in 6.1% of the products [\[16](#page-60-0)], and another study showed a cross-contamination by beans served in restaurants there [[17](#page-60-0)]. Their results showed that 16% of the samples and 45% of the restaurants suffered from gluten contamination. A recent study performed in the USA, involving 101 non-gluten-free-labeled samples concluded that five samples (breakfast cereals, spices, snacks, seasoning mixes, and oat fiber) contained more than 20 mg/kg of gluten [\[18](#page-60-0)].

In view of the above-mentioned results, as well as according to logic, it seems that gluten level control has been higher in GF labeled foods than in those that are apparently GF (by checking food labels or composition). In this regard, research conducted simultaneously in Canada and Greece with GF-labeled and non-labeled foods (but apparently GF) showed similar percentages of samples above 20 mg/kg gluten in both groups (about 20% in Canada and 10% in Greece) [\[19](#page-60-0), [20](#page-60-0)]. It is important to note that the sample sizes of both studies did not exceed 150 foodstuffs. On the contrary, in another study with a moderate sample size, but that took place in Poland, there was a higher ratio of positive samples in GF-labeled samples than in those that were apparently GF [\[21](#page-61-0)].

The first large-scale study evaluating gluten content not only in GF-labeled products but also in non-labeled ones, was carried out by Valdes et al (2003) [[22\]](#page-61-0) in which they analyzed 3,088 GF-labeled samples from several European countries. Their results indicated a high gluten detection (1,699 samples with >3.2 mg/kg) in these kinds of products, with almost one-third of the total samples having gluten over 20 mg/kg. For non-GF-labeled samples, this analysis found that in 1,366 samples, 66% were contaminated with gluten (>3.2 mg/kg of gluten) and 570 with more than 20 mg/kg. Moreover, in the samples studied, the authors observed that maize was the raw material most contaminated with gluten; therefore, it is possible to

Table 4.2 Summary of publications related to non-gluten-free labeled products **Table 4.2** Summary of publications related to non-gluten-free labeled products

Correspond to the publication year, due to the lack of information about when the study took place *Correspond to the publication year, due to the lack of information about when the study took place

conclude that according to Valdes et al (2003), around 30% of analyzed samples were over 20 mg/kg in GF-labeled products, as well as non-labeled ones.

By contrast, two recently published studies conducted on Spanish (Bustamante et al. 2017 [[27\]](#page-61-0)) and North American [[23\]](#page-61-0) on GF claimed products indicated that highly gluten-contaminated samples were more common in non-GF-labeled products. Indeed, the positive samples percentage of apparently GF products doubles the percentage of GF-labeled ones (around 10% vs. around 5%). The explanation that could justify the discrepancy between these two studies and that carried out by Valdes et al (2003) [[22\]](#page-61-0) could be the Codex Alimentarius revision, that was done in 2008. Since that year, the threshold proposal of 20 mg/kg or ppm of gluten to declare a food as GF was implemented by various government regulations. This guided the food industry toward stricter hazard analysis and critical control point implementation and, probably, to the development of new composition formulas. Figure 4.1 was created by the data collected from the gluten analysis of GF research previously mentioned.

Tables [4.1](#page-53-0) and [4.2](#page-56-0) show how before 2008 there was a marked reduction in glutenpositive samples (over 20 ppm of gluten). It is true that the decrease was even greater for GF- labeled products (reaching 3% of samples over 20 ppm of gluten) – which is logical, taking into account that the food industry must guarantee the GF claim. However, it must be emphasized that the "apparently GF" products (those without any gluten-containing ingredient shown on the label) have lowered the glutenpositive samples to half from 2008 until 2016. With regard to gluten-contaminated samples, an overview (from 1998 to 2013) of nearly 10,000 food products [\[24](#page-61-0)] sold in Spain, confirmed the presupposition that commercially GF-rendered food groups

Fig. 4.1 Evolution of gluten-positive samples (>20 mg/kg) sorted by 2003–2008 and 2009–2016 time periods for gluten-free labeled and non-labeled products. Data are expressed as the percentage of the total sample analyzed (*n*) in each period

Fig. 4.2 Evolution of gluten-detected samples, expressed as % of the total analyzed, in three food groups: cereals, additives, and meat derivatives (Modified from Bustamante et al. [\[24\]](#page-61-0))

represented by cereal-based foods, was the more contaminated with this prolamin than naturally gluten-free food in other food categories, represented by meat byproducts) [\[24](#page-61-0)] (Fig. 4.2). Taking into account the positive samples' description of Table [4.2](#page-56-0), this was also seen in other research. Apart from gluten contamination, it is well known that commercially GF-rendered products were poor from an organoleptic point of view, as well as extremely expensive when compared with homologous gluten-containing breads or baked products. It is worth noting that another frequently contaminated food group is that of additives, such as paprika, cinnamon, or curcumin powder, among others.

The different standards and regulations led the food industry toward stricter hazard analysis and critical control point implementation and, probably, to new composition formulas. After the Codex Alimentarius's proposed threshold [\[25](#page-61-0)], detected gluten was significantly down (Fig. [3.1\)](http://dx.doi.org/10.1007/978-3-319-53342-1_3). In that sense, gluten traces containing cereal-based foods were reduced to around 3% and then safer GF-labelled products were manufactured. Moreover, after the EU No. 1169/2011 standard was enforced, apparently GF, but not GF-labeled products, also became less contaminated.

The achievements attained have been essential to promote safe food consumption for celiac patients and groups with gluten-related disorders. Nevertheless, work must continue in this direction. Data shows that wheat consumption per capita has increased [\[26](#page-61-0)], which may contribute to gluten cross-contamination of "probably safe" foods (GF-labeled products and products apparently not containing gluten). In this sense, it is important to properly train food handlers, because sometimes their knowledge of the subject is not adequate enough. Moreover, it should keep on controlling the gluten content of the "apparently" GF food, because owing to economical aspects, many people include these products in their diet instead of GF-labeled ones.

References

- 1. Mintel. Gluten-free Foods US October 2015. [http://store.mintel.com/gluten-free-foods-us](http://store.mintel.com/gluten-free-foods-us-october-2015)[october-2015.](http://store.mintel.com/gluten-free-foods-us-october-2015) Accessed 22 Oct 2016.
- 2. Markets and Markets. Gluten-Free Products Market worth 7.59 Billion USD by 2020 2015. [http://www.marketsandmarkets.com/PressReleases/gluten-free-products.asp.](http://www.marketsandmarkets.com/PressReleases/gluten-free-products.asp) Accessed 2 Sept 2016.
- 3. Canada Go. "Gluten Free" Claims in the Marketplace 2016. [http://www.agr.gc.ca/eng/](http://www.agr.gc.ca/eng/industry-markets-and-trade/statistics-and-market-information/by-product-sector/processed-food-and-beverages/reports-and-resources-food-processing-innovation-and-regulations/gluten-free-claims-in-the-marketplace/?id=1397673574797) [industry-markets-and-trade/statistics-and-market-information/by-product-sector/processed](http://www.agr.gc.ca/eng/industry-markets-and-trade/statistics-and-market-information/by-product-sector/processed-food-and-beverages/reports-and-resources-food-processing-innovation-and-regulations/gluten-free-claims-in-the-marketplace/?id=1397673574797)[food-and-beverages/reports-and-resources-food-processing-innovation-and-regulations/](http://www.agr.gc.ca/eng/industry-markets-and-trade/statistics-and-market-information/by-product-sector/processed-food-and-beverages/reports-and-resources-food-processing-innovation-and-regulations/gluten-free-claims-in-the-marketplace/?id=1397673574797) [gluten-free-claims-in-the-marketplace/?id=1397673574797.](http://www.agr.gc.ca/eng/industry-markets-and-trade/statistics-and-market-information/by-product-sector/processed-food-and-beverages/reports-and-resources-food-processing-innovation-and-regulations/gluten-free-claims-in-the-marketplace/?id=1397673574797) Accessed 1 Nov 2016.
- 4. Reilly NR. The gluten-free diet: recognizing fact, fiction, and fad. J Pediatr. 2016;175:206–10.
- 5. Topper A. Gluten-free foods report: Mintel 2013. [http://store.mintel.com/gluten-free-foods](http://store.mintel.com/gluten-free-foods-us-september-2013)[us-september-2013](http://store.mintel.com/gluten-free-foods-us-september-2013). Accessed 2 Sept 2016.
- 6. Worosz MR, Wilson NLW. A cautionary tale of purity, labeling and product literacy in the gluten-free market. J Consum Aff. 2012;46:288–318.
- 7. Company TN. We are what we eat: healthy eating trends around the world. [http://www.nielsen.](http://www.nielsen.com/content/dam/nielsenglobal/eu/nielseninsights/pdfs/Nielsen Global Health and Wellness Report January 2015.pdf) [com/content/dam/nielsenglobal/eu/nielseninsights/pdfs/Nielsen%20Global%20Health%20](http://www.nielsen.com/content/dam/nielsenglobal/eu/nielseninsights/pdfs/Nielsen Global Health and Wellness Report - January 2015.pdf) [and%20Wellness%20Report%20-%20January%202015.pdf.](http://www.nielsen.com/content/dam/nielsenglobal/eu/nielseninsights/pdfs/Nielsen Global Health and Wellness Report - January 2015.pdf) Accessed 1 Nov 2016.
- 8. Burden M, Mooney PD, Blanshard RJ, White WL, Cambray-Deakin DR, Sanders DS. Cost and availability of gluten-free food in the UK: in store and online. Postgrad Med J. 2015;91:622–6.
- 9. Laureano A. Análise da presença de glúten em alimentos rotulados como livres de glúten através de ensaioimunoenzimático e de fitas imunocromatográficas. Masters Dissertation. Brazil: Federal University of Rio Grande do Sul; 2010.
- 10. Plaza-Silva R. Detection and Quantification of Gluten in Processed Food by ELISA. Masters Dissertation. Brazil: University of São Paulo; 2010.
- 11. Thompson T, Simpson S. A comparison of gluten levels in labeled gluten-free and certified gluten-free foods sold in the United States. Eur J Clin Nutr. 2015;69:143–6.
- 12. Thompson T, Grace T. Gluten content of selected labelled gluten-free foods sold in the US. Pract Gastroenterol. 2013;37:14–6.
- 13. Gibert A, Kruizinga AG, Neuhold S, Houben GF, Canela MA, Fasano A, et al. Might gluten traces in wheat substitutes pose a risk in patients with celiac disease? A population-based probabilistic approach to risk estimation. Am J Clin Nutr. 2013;97:109–16.
- 14. Thompson T. Gluten contamination of commercial oat products in the United States. N Engl J Med. 2004;351:2021–2.
- 15. Thompson T, Lee AR, Grace T. Gluten contamination of grains, seeds, and flours in the United States: a pilot study. J Am Diet Assoc. 2010;110:937–40.
- 16. Farage P, de Medeiros Nóbrega YK, Pratesi R, Gandolfi L, Assunção P, Zandonadi RP. Gluten contamination in gluten-free bakery products: a risk for coeliac disease patients. Public Health Nutr. 2017;20(3):413–16.
- 17. Oliveira OMV, Zandonadi RP, Gandolfi L, de Almeida RC, Almeida LM, Pratesi R. Evaluation of the presence of gluten in beans served at self-service restaurants: a problem for celiac disease carriers. JCulinary SciTech. 2014;12:22–33.
- 18. Thompson T, Lyons TB, Jones A. Allergen advisory statements for wheat: do they help US consumers with celiac disease make safe food choices? Eur J Clin Nutr. 2016;70(12):1341–7. doi:[10.1038/ejcn.2016.155.](http://dx.doi.org/10.1038/ejcn.2016.155)
- 19. Gélinas P, McKinnon CM, Mena MC, Méndez E. Gluten contamination of cereal foods in Canada. Int J Food Sci Tech. 2008;43:1245–52.
- 20. Agakidis C, Karagiozoglou-Lampoudi T, Kalaitsidou M, Papadopoulos T, Savvidou A, Daskalou E, et al. Enzyme-linked immunosorbent assay gliadin assessment in processed food

products available for persons with celiac disease: a feasibility study for developing a glutenfree food database. Nutr Clin Pract. 2011;26:695–9.

- 21. Daniewski W, Wojtasik A, Kunachowicz H. Gluten content in special dietary use of gluten-free products and other food products. Rocz Panstw Zakl Hig. 2010;61:51–5.
- 22. Valdés I, García E, Llorente M, Méndez E. Innovative approach to low-level gluten determination in foods using a novel sandwich enzyme-linked immunosorbent assay protocol. Eur J Gastroenterol Hepatol. 2003;15:465–74.
- 23. Sharma GM, Pereira M, Williams KM. Gluten detection in foods available in the United States – a market survey. Food Chem. 2015;169:120–6.
- 24. Bustamante MA, Fernández-Gil MP, Larretxi I, Lasa A, Churruca I, Miranda J, Simón E. Enfermedad celiaca y dieta sin gluten: avances en la producción de los alimentos libres de gluten. Revista Alimentaria. 2014;456:66–70.
- 25. Codex Alimentarius. CODEX STAN 118–1979. Standard for Foods for Special Dietary Use for Persons Intolerant to Gluten. 2008 Revision.
- 26. Kasarda DD. Can an increase in celiac disease be attributed to an increase in the gluten content of wheat as a consequence of wheat breeding? J Agric Food Chem. 2013;61:1155–9.
- 27. Bustamante MÁ, Fernández-Gil MP, Churruca I, Miranda J, Lasa A, Navarro V, Simón E. Evolution of Gluten Content in Cereal-Based Gluten-Free Products: An Overview from 1998 to 2016. Nutrients. 2017;9(1). doi: [10.3390/nu9010021.](http://dx.doi.org/10.3390/nu9010021)

Chapter 5 Nutritional and Sensorial Aspects of Gluten-Free Products

Arrate Lasa, María del Pilar Fernández-Gil, María Ángeles Bustamante, and Jonatan Miranda

Abbreviations

GF Gluten-free

5.1 Introduction

Gluten, as a general concept, is a protein responsible for elasticity and viscosity of dough, enhancing the retention of gas, and making structured, baked end-products [\[1](#page-78-0)]. Whereas the forced removal of this protein in gluten-free (GF) products can lead to reduced palatability and acceptance, many alternative proposals are available to keep this from happening.

During the creation of GF products, it is common to use GF raw materials. In most cases, gluten-free cereals (mainly corn and rice) are the major ingredients of these products. However, pseudo-cereals, vegetables, or other ingredients (milk and egg protein) represent another possibility. When using GF cereals, substances that mimic the properties of gluten are often added. Among these, hydrocolloids (guar and xanthan gums, alginate, carrageenan, hydroxypropyl methylcellulose, carboxymethyl cellulose), emulsifiers, isolated proteins (from egg, legumes, or dairy products) or enzymes (cyclodextrin glycosyl transferases, transglutaminase, proteases, glucose oxidase, and laccase) are those that are most often used [[2\]](#page-78-0).

In the particular case of bread, other approaches have been undertaken to improve its organoleptic quality; among them, sourdough technology and high hydrostatic pressure are the most important. Although these mechanisms have been designed for the organoleptic improvement of GF products, they can also affect the nutritional composition. Throughout this chapter, in many cases bread will be used as a reference. It is important to point out that among all GF foods, bread is the most widely studied [\[3](#page-78-0)].

On the other hand, some foods originally contained gluten, but after various treatments in the elaboration process, are no longer toxic for celiac patients; this is the case in GF wheat starches or enzyme-treated barley beers, among others. Although there is growing scientific and academic interest in the improvement of the organoleptic characteristics of GF products [\[4](#page-78-0), [5\]](#page-78-0), studies of the celiac population show that the degree of satisfaction of these people with products actually available on the market is poor [[6\]](#page-78-0).

5.2 Non-gluten-Containing Grains and Pseudo-cereals

Two main food groups are mostly used for replacing cereals containing gluten: (1) GF grains or true cereals (maize, rice, sorghum and teff), and (2) pseudo-cereals (amaranth, quinoa, buckwheat, etc.).

Corn (*Zea mays* L.) and cornstarch are commonly used in the preparation of GF Foodstuffs alone or with xanthan gum. In the case of bread, the product obtained has an appropriate volume, but lacks of taste and has an unsuitable crumb structure [[7\]](#page-78-0). Because of the absence of color, easy digestion and hypoallergenic effect, rice (*Oryza sativa*) is one of the most appropriate cereal grains for GF foods. However, rice lacks the elastic and plastic properties to retain the gas formed during fermentation.

Tables [5.1](#page-64-0) and [5.2](#page-65-0) show the nutritional composition of the most commonly used raw materials in GF and gluten-containing food preparation. The data were obtained from the online database of the U.S. Department of Agriculture [8].

When comparing the two traditionally used cereals in GF foodstuffs (corn and rice) with cereals containing gluten (wheat, barley, and rye), it can be observed that rice and corn have smaller amounts of protein and fat and larger amounts of carbohydrates (Table [5.1\)](#page-64-0). Meanwhile, the general contribution of micronutrients is lower when comparing wheat with corn.

Sorghum (*Sorghum vulgare)* is quite similar to corn in that the primary component is starch. However, sorghum protein and starch are less digestible [[9\]](#page-78-0). This GF cereal has some limited properties for bread-making; its temperature for gelatinization is high, and it forms cracks in the bread and large holes in the crumbs [[7\]](#page-78-0). This cereal has the lowest caloric intake compared to wheat, due to a lower content of lipids and carbohydrates (Table [5.1](#page-64-0)).

Teff (*Eragrostis teff*) is a GF cereal used primarily in Ethiopia and Eritrea. Although its use as a raw material is not widespread due to its high protein and

– with no value, *FA* fatty acids

aOats can be contaminated with gluten

5 Nutritional and Sensorial Aspects of Gluten-Free Products

Table 5.2 Micronutrient composition of gluten-containing and gluten-free grains according to USDA Food Composition Databases **Table 5.2** Micronutrient composition of gluten-containing and gluten-free grains according to USDA Food Composition Databases

62

-with no value, IU international units
40 ats can be contaminated with gluten –with no value, IU international units a_0 ats can be contaminated with gluten

micronutrient content, new formulations based on this cereal are increasing. In this sense, it is very important to highlight its excellent balance in the amino acid composition (eight of them essential for humans). According to the literature, the amounts of isoleucine, leucine, valine, tyrosine, threonine, methionine, phenylalanine, arginine, alanine, and histidine in teff are higher than those in wheat or barley [\[10](#page-78-0)]. Furthermore, this amino acid profile gives teff high levels of properties for malt and beer production [[10\]](#page-78-0). As described in Table [5.2,](#page-65-0) its high mineral content (of calcium, iron, magnesium or zinc) must be emphasized.

Millets are small cereal grains widely used for brewing traditional beers as well as a staple food in the form of porridges and couscous. Under "millet" are included several genera and species such as *Pennisetum typhoides*, *Pennisetum glaucum*, *Eleusine coracona*, *Setaria italica*, etc. [[11](#page-78-0)]. Millets are rich in polyphenols with antioxidant capacities [\[12](#page-78-0)]. The protein and carbohydrate content is similar to the quantity of these macronutrients in wheat and rye, with a higher concentration of lipids, but their fat content is lower than in oat. Millet has a nutritional composition very close to teff, at least in terms of macronutrient content (Table [5.1\)](#page-64-0); however, micronutrient deficiencies can be observed when comparing millet with teff (Table [5.2](#page-65-0)).

Oats (*Avena sativa*) are special cereals, and their use in the Scandinavian countries as GF cereals is widespread. Nevertheless, using oats in a GF diet is still a controversial subject. Some authors maintain that avenins can trigger an immunogenic response in celiac patients [[13\]](#page-78-0), and other researchers have found that the immunogenicity of oats varies, depending on the cultivar consumed [[14–16\]](#page-78-0). Furthermore, in order to assure the lack of contamination from the point of view of celiac disease, it is necessary to take particular care. Some oats are grown, stored, transported, or processed with gluten-containing cereals, thereby becoming glutencontaminated products. A clear example of this cross-contamination is reflected in the publication of Thompson et al. [\[17](#page-78-0)], in which the authors found that 32% of analyzed GF samples contained gluten.

However, numerous benefits have been attributed to oats in recent years. Its calcium, phosphorus, potassium, and zinc content is high, as is the contribution of unsaturated fatty acids, thiamine, or folate (Tables [5.1.](#page-64-0) and 5.2). Its high level of fiber, mainly beta-glucans, is noteworthy [\[18](#page-78-0)]. Meanwhile, in the production of oat bread, unlike what happens when baking other GF cereals (e.g., sorghum), the end product has a nice appearance with a proper soft crumb structure or volume [[19\]](#page-78-0).

As a last raw material related to GF grains, it is necessary to speak of wheat starch, a product extracted from processed wheat flour. After several optimized processes for separating the protein from the starch, a pure, and gluten-free element is obtained, which needs to have certification. Its nutritional value is minimal, as it is just a source of carbohydrates.

Unlike monocotyledonous cereals, pseudo-cereals are dicotyledonous and do not belong to the *Gramineae* family. However, its seeds are rich in starch and can be used as cereal alternatives [[7\]](#page-78-0). Due to its botanical origin, their nutritional properties share similarities with legumes and grains [[20\]](#page-78-0).

Amaranth (*Amaranthus* spp) has been consumed by the Inca, Mayan and Aztec civilizations for many years. It has high levels of both fiber and protein, with equally significant levels of methionine and lysine. With respect to fiber, it has a considerable percentage of insoluble fiber. Escudero et al. (2004) reported that from the total dietary fiber in *A. cruentus*, 4.2% was soluble [[21\]](#page-78-0). Similar to quinoa, its fatty acid profile is beneficial for health, with a large amount of unsaturated fatty acids (Table [5.1](#page-64-0)). As is shown in Table 2, and in the literature [\[22](#page-78-0)], amaranth is very rich in micronutrients. Although the content of minerals as calcium, phosphorus, iron, potassium, magnesium, and zinc must be highlighted, ascorbic acid, riboflavin, or thiamine could be found at an acceptable level.

The introduction of buckwheat (*Fagopyrum esculentum*) as a raw material for GF foodstuffs has improved their nutritional qualities [\[23](#page-79-0)]; however, problems have been detected for these kinds of breads, limiting their use. The disadvantages include flavor intensity and brittleness after 2 days of storage [\[7](#page-78-0)].

Quinoa, *Chenopodium quinoa* is an *Amaranthacean*, stress-tolerant plant that has been cultivated in the Andes for the last 7,000 years. As in the case of amaranth or teff, the protein content of quinoa is higher than that of gluten-containing grains. In addition, the amino acid profile of this pseudo-cereal is very beneficial. According to Vega-Galvez's review, quinoa provides levels of FAO/ WHO recommendations for histidine, isoleucine, lysine, methionine + cysteine, phenylalanine + tyrosine, threonine, tryptophan, and valine [\[24\]](#page-79-0). Comparing it with other GF raw materials, the carbohydrate amount in quinoa is lower (Table [5.1](#page-64-0)); however, due to its high proportion of d-xylose and maltose, and low levels of glucose and fructose, this pseudo-cereal has appropriate properties for malted drink formulation [[24](#page-79-0)].

The vitamin content of quinoa is especially significant for riboflavin, vitamin E and vitamin B6 (Table [5.2\)](#page-65-0). With regard to minerals, its calcium and phosphorus content is higher than that of wheat and barley. Moreover, quinoa's contribution in oleic and linoleic acid is also relevant [[24\]](#page-79-0).

5.3 Other Ingredients Used in the Preparation of GF Foods

The research conducted by do Nascimiento et al. (2013) relating to the composition of gluten-containing and GF products, revealed that although there were ingredients common to both formulations, there were some differences [\[25](#page-79-0)]. The study was carried out in Portugal with a total of 324 products (162 of them GF), and 12 terms found on the product labels were on products both with and without gluten. Meanwhile, the most common terms found only on the labels of GF foods were rice flour, egg, cassava starch, lecithin, natural corn starch, soy and rice flour, and vanilla [\[25](#page-79-0)]. Some of these ingredients are the basis of GF foodstuffs, but others are only assistants, to add to the characteristics of GF foods.

In baking, dairy ingredients set up nets that improve the texture and besides they reduce the staling and increase the flavor and crust color [\[7](#page-78-0)]. This type of ingredient can be found in various forms, with isolated milk protein or caseinate the most common. It is important to point out that the presence of lactose in celiac patients can lead to health problems. The damage caused by celiac disease in intestinal villi, in many cases causes the patients to have temporary lactose intolerance [\[26](#page-79-0)].

In their publication on breads, Matos and Rosell reported that one of the main ingredients found is egg protein [[27](#page-79-0)]; this has high cohesive viscoelastic power, is essential for stable foaming, and improves gas retention in bread [\[7](#page-78-0)]. Moreover, it improves protein content and the amino acid profile of GF foods, just as soy can do. In fact, soybean protein and lupine are two other ingredients that are very often used, as Matos and Rosell found in their study conducted on 11 GF breads [\[27\]](#page-79-0).

The addition of starches or hydrocolloids is also quite common in GF products. In the case of starches, as shown in the study of do Nascimiento et al. (2013), one of the most often used is corn [\[25](#page-79-0)]. Due to the starch pastes formed that can trap air bubbles, starch gelatinization plays an important role. For example, prolamin corn (zein), combined with starch and water, form a viscoelastic mass close to that of wheat dough [[28\]](#page-79-0). In the case of hydrocolloids, these are polysaccharides with a high molecular weight and hydrophilic characteristics, extracted from plants, seaweed, and bacterial sources. They are used as structuring agents to mimic the viscoelastic properties of gluten. These agents have an additional value; taking into account that they are soluble fiber, their inclusion in GF foods increases the nutritional quality of the products [\[2](#page-78-0)].

5.4 Gluten-Free Rendered Foods vs. Gluten-Containing Rendered Foods

5.4.1 Differences in Nutritional Composition

Researchers working in the field of celiac disease and GF diet have increased their interest in the nutritional composition of the GF diet and the adequacy of GF foods as healthful products. In fact, a detailed analysis of the nutritional composition of GF foodstuffs, and the design of databases considering these foods and their composition, have recently been carried out by several groups in Italy, Austria, Canada, Australia, and Spain [\[29–33](#page-79-0)].

Miranda et al. (2014) previously reported a comparison between 206 GF foodstuffs vs. 289 equivalent foods containing gluten [\[33](#page-79-0)]. Information from the panels and product labels was compared, and differences in calories, macronutrients, fiber, sodium, salt, and cholesterol were described. Other authors estimated the full nutrient composition of GF products by using the nutritional composition of each ingredient of a GF product and estimating the quantity of each ingredient in the final recipe of the product [[29,](#page-79-0) [30](#page-79-0), [32\]](#page-79-0). As a result, in these studies the energy content, macronutrients, fiber, cholesterol, and mineral and vitamin content were analyzed and compared to that of gluten-containing foodstuffs. Nevertheless, to compare the results obtained in different studies is difficult, due to the fact that not all of them show the same classification of food categories. Most of the studies analyze and compare the nutritional composition of gluten-free flours, breads, bakery products, pasta, cereals, cookies, and snacks, and some also report results obtained in other food groups such as frozen foods or processed meats [\[31](#page-79-0)], or convenience foods (chicken nuggets, fish sticks, soups, etc.) [[30\]](#page-79-0).

Differences in calorie content between GF and gluten-containing counterparts were not observed in most of the analyzed food groups. Only GF flours, breads, and the dough/pastry/ pizza group showed more calories than their analogues containing gluten. According to these results, when the calorie content of GF and glutencontaining foods was compared, as well as in other studies, no differences were observed [[30,](#page-79-0) [31\]](#page-79-0).

However, and according to the macronutrient content, results obtained in different studies agree that GF products have higher amounts of fat [\[31](#page-79-0), [33\]](#page-79-0), especially saturated fats, and a lower amount of protein [[30, 31](#page-79-0), [33](#page-79-0)] than their regular counterparts. These differences may be due to the formulations of GF products. On the one hand, differences in lipid content could be due to the fact that frequently, lipid-rich ingredients, such as animal or vegetable oils and emulsifiers (mono- and diglycerides of fatty acids) are added in order to improve the palatability of GF foodstuffs [\[34](#page-79-0)]. Such ingredients are indeed useful in bakery products for the stabilization of gas bubbles and the reduction of kneading resistance and swelling of starch granules [\[35](#page-79-0)]. Moreover, emulsifiers can be used to increase the dough stiffness, improve the bread structure, and decrease the speed of staling. In pasta products, emulsifiers act as lubricants in the extrusion process and provide firmer consistency and a less sticky surface because they control starch swelling and leaching phenomena during cooking [[36\]](#page-79-0). Thus, although emulsifiers can be avoided in pasta products, they are necessary for baked products. On the other hand, the lower protein content could be due to the use of starches, flours from low protein cereals such as rice or corn, or the use of gums or enzymes in their elaboration [[34\]](#page-79-0).

Some of the GF foods analyzed in the studies mentioned differed in their carbohydrate content as well. Miranda et al. (2014) saw a higher amount of them in flour, whereas Kulai et al. (2014) observed these results in the pasta group [[31,](#page-79-0) [33\]](#page-79-0). However, a lower amount of sugar was observed in foods from the pasta group by both authors, and this suggested that starches represent the largest component of carbohydrates in GF pasta. Indeed, a low intake of non-starch carbohydrates in people following a GF diet has been reported [[37,](#page-79-0) [38\]](#page-79-0).

GF foodstuffs showed a low amount of fiber [[31,](#page-79-0) [33](#page-79-0)], especially when various pastas or flours were analyzed; this could be due to a lack of whole grain cereals in the production of GF pastas or flours. Salt and sodium content in GF products is also higher [[29, 30](#page-79-0), [33](#page-79-0)]. The use of sodium stabilizes the structure and enhances the taste of GF products, which is especially important when the main ingredient in these products is tasteless starch.

Table [5.3](#page-71-0) summarizes the results obtained in four different studies where GF products' nutritional composition was analyzed and compared to that of glutencontaining counterparts.

68

- Data not available, NA not analyzed, † GF products contain more than gluten-containing products, \downarrow GF products contain less than gluten-containing prod-
ucts, = GF products and gluten-containing products contain the – Data not available, *NA* not analyzed, ↑ GF products contain more than gluten-containing products, ↓ GF products contain less than gluten-containing products, *=* GF products and gluten-containing products contain the same amount

With regard to vitamins and minerals, Thompson was the first researcher to report that GF products (breads, pasta, breakfast cereals, and flours) had less niacin, riboflavin, thiamin, folate, and iron than their gluten-containing reference products [\[39](#page-79-0), [40\]](#page-79-0). Afterwards, other studies followed the research line, and they have confirmed or suggested lower amounts of zinc, iron, calcium, phosphorus, B vitamins and folate in GF foodstuffs [\[29–31](#page-79-0)]. This deficiency could be partly due to the fact that in some countries, such as the U.S. and U.K., fortification of wheat flour with some minerals and B vitamins is mandatory, whereas the GF analogue products are not enriched or fortified [[39\]](#page-79-0). In fact, when, for example, fortified GF cereals were analyzed and compared to those containing gluten, a similar nutrition profile was observed [[31\]](#page-79-0).

In the particular case of folate, its reduced presence in GF products can be due to their using the elaboration of starches or corn and rice flours, which usually had low folate content. Besides, folate is a vitamin that binds to cereal proteins and thus, when protein fractions are removed from the cereal matrix, it may cause the depletion of folates [[41\]](#page-79-0). However, folate content can vary − depending on the kind of GF product. Yazynina et al. (2008) showed − after the direct analysis of eight GF foodstuffs – that breads had higher amounts of folate than the others. In the case of breads, the author attributed the higher folate value of bread to yeast, which is rich in this vitamin [\[41](#page-79-0)].

It must be pointed out that data concerning vitamin and mineral content of GF products were just estimations; indeed, authors from the studies mentioned used data for nutrient comparison based on the ingredient list reported on the label or the nutrition information of each product. However, Suliburska et al. (2013) directly analyzed the content and release of calcium, magnesium, iron, zinc, and copper from five GF products [\[42\]](#page-79-0). According to these authors, their results indicated that the content of the analyzed mineral was lower in GF products than that in gluten-containing oat and barley products. Additionally, they reported low bioavailability for minerals in GF foodstuffs (in pasta, from 7% for calcium to 27% for iron).

All the differences between GF and gluten-containing products would suggest that a GFD rich in these kinds of GF products could also be very different from diets containing gluten. In fact, when studies focused on analyzing the nutritional composition and eating patterns of celiac patients were carried out, differences in macronutrient and micronutrient intake between celiac and control patients were observed [[43–](#page-79-0)[45\]](#page-80-0). Concretely, higher fat intake and lower protein, carbohydrates and fiber intake, have been observed among celiac patients, as well as some potential deficiencies in vitamins and minerals. An unbalanced GF diet could lead to a harmful nutritional status and could determine a celiac patient's quality of life. The latest outcomes related to the evaluation and analysis of a GF diet are described in Chapter [6](http://dx.doi.org/10.1007/978-3-319-53342-1_6).

5.4.2 Differences in Other Characteristics

Other differences among GF and gluten-containing foods − not related to nutritional value − have been observed. Apart from the price of the products, their physicochemical properties, sensory properties, starch digestibility or glycemic index have been the focus of the attention of researchers working in this field.

Several studies have analyzed the differences between the prices of GF foods and those of their gluten-containing counterparts; all the studies conclude that GF products are between two and three times more expensive than their conventional analogues. In two of the studies mentioned above, the prices of GF products were analyzed apart from their nutritional composition [[30,](#page-79-0) [31\]](#page-79-0). Missbach et al. (2015) observed that prices were higher in all GF product groups, varying from +267% in breads and bakery products to +205% in cereals. Results of a study conducted in the U.K. in 2014 are significant [\[46](#page-80-0)]; it not only confirms the elevated price of GF foodstuffs but also shows that budget supermarkets that tend to cater to patients from lower socioeconomic classes stocked no GF foods. According to the researcher, this could have a negative impact on GF diet adherence.

Carini et al. (2015) analyzed the physicochemical (volume, crumb grain, and color), sensory, and starch *in vitro* digestion properties in four GF breads produced using GF commercial mixes [[47\]](#page-80-0). Mixes from various formulations and elaboration parameters led to the production of breads with different crumb grains, specific volume, and crust and crumb color that affected the product's sensory acceptability. In general terms, the judges preferred those with a heterogeneous and coarser crumb grain and darker color. Moreover, in that study, the authors saw that the starch's availability to hydrolytic enzymes in the GF breads was not influenced by a variation in ingredients and nutritional composition, but was related to the physical structure in terms of specific volume. When the specific volume was higher, the starch-digested fraction was also larger.

Flores-Silva et al. (2015) tried to improve starch digestibility in GF snacks by using a blend of unripe plantains, chickpeas, and maize. The authors saw that the snack with the highest amount of unripe plantain flour showed higher amounts of slowly digestible starch [[48\]](#page-80-0).

Only a few studies have analyzed the glycemic index of GF products, and controversial results have been obtained. It has been seen that the glycemic index changes not only according to the food formant carbohydrate content, but also when using the same GF product in healthy people as opposed to celiac sufferers [[49\]](#page-80-0). In theory, GF products might cause a higher increase in glycemia due to the fact that, as stated above, starches are commonly added while GF products elaboration. Studies in the literature have shown [[49,](#page-80-0) [50\]](#page-80-0) that there is a higher glycemic index in GF breads or pastas than in their traditional counterparts. Nevertheless, other studies have observed the opposite results in GF biscuits, pastas, and breads [\[51](#page-80-0)]. Thus new strategies in the GF food industries (especially breads and pastas) are being carried out in order to reduce the glycemic indexes in GF products – for example, increasing fiber content or using sourdough fermentation. Strategies such as substituting carbohydrates by lipids or proteins should be avoided since these foods are the main carbohydrates/contributors in the diets of celiac patients.

5.5 New Approaches to Improving the Characteristics of GF Foods

As noted in the previous section, one of the biggest differences between GF foods and gluten equivalents is the nutritional composition. In this scenario, trials with new formulations for GF foods have cropped up. Although most of the formulations were for the development of new baked products, tests on pasta, biscuits, and cakes have also been carried out.

In the first section of this chapter, it was reported that there are raw materials whose nutrient density is higher than that of the traditionally used GF cereals (rice or corn). Most research aimed at increasing nutrient density, combining in their formulations flour or traditional starches (flour and starch, rice flour and cornstarch, or starches of cassava, potato and wheat) with alternative flours such as amaranth, teff, or brown rice. The justification for this is that these kinds of formulations not only have greater nutritional density, they also have an organoleptic acceptance by the consumer [\[3](#page-78-0)].

A clear example can be the studies carried out by the research group of Alvarez-Jubete et al. [[52,](#page-80-0) [53\]](#page-80-0) replacing potato starch by flour from buckwheat, amaranth, and quinoa flour. These pseudo-cereals increased their content of vitamins, protein, fiber, and iron, showing no differences in acceptability compared to the control. Capriles et al. (2016) focus their work on the variation in the proportion of the main ingredients in their formulations (rice flour, potato starch, and flours with high nutritional value), to obtain products with good physical properties, acceptable sensory qualities, and high nutritional value [\[3](#page-78-0)]. Thus, the Alvarez-Jubete research team has managed to make breads with an acceptance that is equivalent to those made by wheat breads.

Apart from breads, other foods have also been tested with pseudo-cereal flours, and better nutritional properties have been observed [\[54](#page-80-0)]. For example, when breakfast cereals and snacks, among others, have been formulated with amaranth, teff, or quinoa, the levels of selenium increased to $10.8 \mu g/100 \text{ g}$ as opposed to the 2.8 μg/100 g in traditional GF cereal formulations [\[55](#page-80-0)].

A study reflecting partial substitution of cornflour by amaranth and buckwheat flour to obtain cakes (sponge, coconut, and carrot cake) and biscuits showed that alternative products had better quality and nutritional value than controls made only with cornflour. In general terms, cakes and biscuits from pseudo-cereals had a higher amino acid content (in the case of biscuits, this increase was due to an elevation of

essential amino acids), and fiber and lipids content (especially polyunsaturated fatty acids), as well as increased magnesium, zinc, manganese and copper level, than corn formulations. Additionally, all products had a high degree of acceptance by consumers [\[54\]](#page-80-0). Other research on the elaboration of GF cookies conducted with rice, buckwheat, sorghum, and pearl millet, indicated that the resulting products increased the amount of ash, lipids, fiber, and protein content [\[56](#page-80-0), [57\]](#page-80-0).

It is also possible to combine the use of alternative cereals to corn and rice with another way of improving the nutrient density: the addition of dairy products. Following this line, in 2012 Lemos et al., found that cheese bread with 10% amaranth flour increased fiber and iron levels, thereby maintaining consumers' acceptance [\[58\]](#page-80-0).

The partial substitution of cereal by legume flours has also been used to improve GF breads, especially in the amount of fiber and protein. Along these lines, Tsatsaragkou et al. (2012) conducted a study in which 15% of rice flour was replaced by carob germ [[59\]](#page-80-0); the strategy was also used for pasta. Several approaches were tried in the pasta group, partially replacing cornflour with chickpea or broad bean flour [\[60](#page-80-0), [61\]](#page-80-0). Both studies resulted in pasta with high fiber, lipid, and protein levels. It is important to note that the increase of dietary fiber has a direct impact on reducing the glycemic index of foods. Therefore, the formulated pasta could have great implications for diabetics. In the case of corn pasta enriched with broad bean flour, this product had also added quinoa, leading to iron and zinc content increase. Both minerals are very relevant among celiac patients because deficiencies in zinc and iron serum levels have been observed [\[60](#page-80-0)].

Similar research was carried out with nut flour. For instance, Brazilian almonds were used to enhance gluten-free cakes [\[62](#page-80-0)].The final product not only had good general acceptability (aroma, flavor, and texture similar to those of gluten), it also contained low carbohydrate values and high protein and lipid levels. Considering the deficiencies reported in the previous section of this chapter where the GF foodstuffs and their counterparts with gluten were compared, one of the most relevant findings of this study was the high content of fiber, zinc, copper, and iron that Brazilian almond cakes showed [\[62](#page-80-0)].

A new and hopeful horizon has opened up in the world of GF formulations, including fruit- and vegetable-based ingredients. Studies such as Korus and O'Shea's, formulating GF breads with de-fatted strawberry and black currant seeds, and orange pomace, showed an improvement in the nutritional composition of the final products [\[63, 64](#page-80-0)].

Apart from the addition of raw materials, there are other methods for improving the nutritional value of GF foodstuffs. One of the most promising, in the development of GF bread, seems to be the use of sourdough. This has been used since ancient times for the elaboration of wheat and rye bread, but nowadays is adjusted for GF raw materials. The technique is based on the fermentation of bread through a mixture of flour and water that is fermented by lactic bacteria and yeast that can improve the quality and nutritional value of food. In fact, in a study comparing breads made with sourdough and semolina durum wheat (the gluten was removed), gluten-containing wheat breads, and GF commercial breads, the bread with sourdough had a better availability of free fatty acids and higher protein digestibility. Additionally, breads with sourdough showed similar values of minerals, vitamins, and fiber than gluten-containing breads (even in the case of thiamine and niacin the values were higher) [[65\]](#page-81-0). Meanwhile, Wolter et al. (2014) investigated the potential uses of sourdough for reducing the predicted glycemic index [[66\]](#page-81-0). According to their results, this technique can be effective for reducing the above-mentioned index for teff and sorghum breads, but not for those of quinoa or buckwheat (the use of buckwheat elevates the index).

Another potentially effective method for improving the nutritional value of GF foods is germination. Cornejo et al. (2015), saw how brown rice germination at different times varies the amount of macronutrients, as well as that of lipids or proteins [\[67](#page-81-0)]. According to their results, 48 h of germination provided a high content of lipids and proteins for brown rice bread. Furthermore, 2 days' germination resulted in higher antioxidant power (high levels of polyphenols and gamma-aminobutiric acid), a decrease in the phytic acid level (this anti-nutrient has a chelating effect on some minerals, and decreases the absorption of protein and starch), and a reduction of the glycemic index [\[67](#page-81-0)].

Gluten-containing foodstuffs' fortification is an open possibility in order to raise the nutritional value of GF foods. Taking into account the deficiencies shown by celiac patients in iron and calcium (among others) [\[68](#page-81-0)], studies on fortified GF bread [[69,](#page-81-0) [70\]](#page-81-0) began to be carried out. .

Except for the pasta category, any other food group among GF foodstuffs showed fiber deficiencies. However, several investigations have focused on making suitable bread for celiac patients as well as for people suffering from type 2 diabetes. In this kind of formulation, inulin, oligofructose, and *Psyllium* and beta-glucans have been used to improve the technological or sensory properties and nutritional qualities of GF foodstuffs. As a result, breads fortified in fiber $(0.75 \text{ g beta-glucans and } 4 \text{ g of } 6)$ inulin type fructansin 50 g of bread) were obtained [\[3](#page-78-0)]. It is important to point out that to achieve functional effects, such as reduced postprandial blood glucose and cholesterol levels or prebiotic effects, the recommended daily intake of these compounds is between 3 and 5 g.

5.6 Conclusions

There are marked nutritional differences between GF foodstuffs and glutencontaining counterparts. These differences are mainly due to higher lipid and lower protein content, but are also due to reduced amounts of micronutrients or fiber found in GF foods. Other characteristics, such as physicochemical properties, digestibility, or glycemic index, also diverge between GF and gluten-containing products. In view of this scenario, several strategies are being carried out to improve the nutritional value and other characteristics of GF foodstuffs. The use of alternative cereals instead of traditional ones is an interesting proposal that many publications postulate. However, there are also other options, such as the introduction of other ingredients in the formulation (hydrocolloids and other sources of protein, among others), or the use of sourdough, which can balance the reduced amounts in nutrient content.

References

- 1. Sciarini LS, Ribotta PD, León AE, Pérez GT. Influence of gluten-free flours and their mixtures on batter properties and bread quality. Food Bioproc Tech. 2010;3:577–85.
- 2. Matos ME, Rosell CM. Understanding gluten-free dough for reaching breads with physical quality and nutritional balance. J Sci Food Agric. 2015;95:653–61.
- 3. Capriles VD, dos Santos FG, Arêas JAG. Gluten-free breadmaking: improving nutritional and bioactive compounds. J Cereal Sci. 2016;67:83–91.
- 4. Sciarini LS, Ribotta PD, León AE, Pérez GT. Effect of hydrocolloids on gluten-free batter properties and bread quality. Int J Food Sci Technol. 2010;45
- 5. Sumnu G, Koksel F, Sahin S, Basman A, Meda V. The effects of xanthan and guar gums on staling of gluten-free rice cakes baked in different ovens. Int JFood SciTech. 2010;45:87–93.
- 6. Araújo HM, Araújo WM. Coeliac disease. Following the diet and eating habits of participating individuals in the Federal District, Brazil. Appetite. 2011;57:105–9.
- 7. Zannini E, Jones JM, Renzetti S, Arendt EK. Functional replacements for gluten. Annu Rev Food Sci Technol. 2012;3:227–45.
- 8. United States Department of Agriculture. Agricultural research service. USDA food composition databases. Available from: [https://ndb.nal.usda.gov/ndb/.](https://ndb.nal.usda.gov/ndb/)
- 9. Bean SR, Schober TJ, Arendt E, Fenster C. Use of sorghum flour in bakery products. AIB Tech Bull. 2006;28(3):1–6.
- 10. Gebremariam MM, Zarnkow M, Becker T. Teff (*Eragrostis tef*) as a raw material for malting, brewing and manufacturing of gluten-free foods and beverages: a review. J Food Sci Technol. 2014;51:2881–95.
- 11. Jukanti AK, Gowda CLL, Rai KN, Manga VK, Bhatt RK. Crops that feed the world 11. Pearl Millet (*Pennisetum glaucum* L.): an important source of food security, nutrition and health in the arid and semi-arid tropics. Food Sec. 2016;8:307–29.
- 12. Sharma S, Sharma N, Handa S, Pathania S. Evaluation of health potential of nutritionally enriched Kodo millet (*Eleusine coracana*) grown in Himachal Pradesh, India. Food Chem. 2017;214:162–8.
- 13. Arentz-Hansen H, Fleckenstein B, Molberg Ø, Scott H, Koning F, Jung G, et al. The molecular basis for oat intolerance in patients with celiac disease. PLoS Med. 2004;1:e1.
- 14. Real A, Comino I, de Lorenzo L, Merchán F, Gil-Humanes J, Giménez MJ, et al. Molecular and immunological characterization of gluten proteins isolated from oat cultivars that differ in toxicity for celiac disease. PLoS One. 2012;7:e483e65.
- 15. Comino I, Real A, de Lorenzo L, Cornell H, López-Casado M, Barro F, et al. Diversity in oat potential immunogenicity: basis for the selection of oat varieties with no toxicity in celiac disease. Gut. 2011;60(7):915–22.
- 16. Comino I, Moreno ML, Real A, Rodríguez-Herrera A, Barro F, Sousa C. The gluten-free diet: testing alternative cereals tolerated by celiac patients. Nutrients. 2013;5:4250–68.
- 17. Thompson T, Lee AR, Grace T. Gluten contamination of grains, seeds, and flours in the United States: a pilot study. J Am Diet Assoc. 2010;110:937–40.
- 18. Steinert RE, Raederstorff D, Wolever TM. Effect of consuming oat bran mixed in water before a meal on glycemic responses in healthy humans − a pilot study. Nutrients. 2016;8(9):524.
- 19. Hüttner EK, Bello FD, Arendt EK. Rheological properties and bread making performance of commercial whole grain oat flours. J Cereal Sci. 2010;52(1):65–71.
- 20. Caselato-Sousa VM, Amaya-Farfán J. State of knowledge on Amaranth grain: a comprehensive review. J Food Sci. 2012;77:R93–R104.
- 21. Escudero NL, de Arellano ML, Luco JM, Giménez MS, Mucciarelli SI. Comparison of the chemical composition and nutritional value of *Amaranthus cruentus* flour and its protein concentrate. Plant Foods Hum Nutr. 2004;59:15–21.
- 22. Singhal RS, Kulkarni PR. Amaranths an underutilized resource. Int J Food SciTech. 1988;23:125–39.
- 23. Alvarez-Jubete L, Wijngaard H, Arendt EK, Gallagher E. Polyphenol composition and in vitro antioxidant activity of amaranth, quinoa, buckwheat and wheat as affected by sprouting and baking. Food Chem. 2010;119:770–8.
- 24. Vega-Gálvez A, Miranda M, Vergara J, Uribe E, Puente L, Martínez EA. Nutrition facts and functional potential of quinoa (*Chenopodium quinoa* willd.), an ancient Andean grain: a review. J Sci Food Agric. 2010;90:2541–7.
- 25. do Nascimento AB, Fiates GM, Dos Anjos A, Teixeira E. Analysis of ingredient lists of commercially available gluten-free and gluten-containing food products using the text mining technique. Int J Food Sci Nutr. 2013;64:217–22.
- 26. Arendt EK, Moroni A, Zannini E. Medical nutrition therapy: use of sourdough lactic acid bacteria as a cell factory for delivering functional biomolecules and food ingredients in gluten-free bread. Microb Cell Fact. 2011;10:1–9.
- 27. Segura ME, Rosell CM. Chemical composition and starch digestibility of different gluten-free breads. Plant Foods Hum Nutr. 2011;66:224–30.
- 28. Scherer P. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55(6):1537–45.
- 29. Mazzeo T, Cauzzi S, Brighenti F, Pellegrini N. The development of a composition database of gluten-free products. Public Health Nutr. 2015;18:1353–7.
- 30. Missbach B, Schwingshackl L, Billmann A, Mystek A, Hickelsberger M, Bauer G, et al. Gluten-free food database: the nutritional quality and cost of packaged gluten-free foods. PeerJ. 2015;3:e1337.
- 31. Kulai T, Rashid M. Assessment of nutritional adequacy of packaged gluten-free food products. Can J Diet Pract Res. 2014;75:186–90.
- 32. Wu JH, Neal B, Trevena H, Crino M, Stuart-Smith W, Faulkner-Hogg K, et al. Are glutenfree foods healthier than non-gluten-free foods? An evaluation of supermarket products in Australia. Br J Nutr. 2015;114:448–54.
- 33. Miranda J, Lasa A, Bustamante MA, Churruca I, Simon E. Nutritional differences between a gluten-free diet and a diet containing equivalent products with gluten. Plant Foods Hum Nutr. 2014;69:182–7.
- 34. Pellegrini N, Agostoni C. Nutritional aspects of gluten-free products. J Sci Food Agric. 2015;95(12):2380–5.
- 35. Houben A, Höchstötter A, Becker T. Possibilities to increase the quality in gluten-free bread production: an overview. Eur Food Res Tech. 2012;235:195–208.
- 36. Marti A, Pagani MA. What can play the role of gluten in gluten-free pasta? Trends Food Sci Technol. 2013;31:63–71.
- 37. Kinsey L, Burden ST, Bannerman E. A dietary survey to determine if patients with celiac disease are meeting current healthy eating guidelines and how their diet compares to that of the British general population. Eur J Clin Nutr. 2008;62:1333–42.
- 38. Wild D, Robins GG, Burley VJ, Howdle PD. Evidence of high sugar intake, and low fibre and mineral intake, in the gluten-free diet. Aliment Pharmacol Ther. 2010;32:573–81.
- 39. Thompson T. Folate, iron, and dietary fiber contents of the gluten-free diet. J Am Diet Assoc. 2000;100:1389–96.
- 40. Thompson T. Thiamin, riboflavin, and niacin contents of the gluten-free diet: is there cause for concern? J Am Diet Assoc. 1999;99:858–62.
- 41. Yazynina E, Johansson M, Jägerstad M, Jastrebova J. Low folate content in gluten-free cereal products and their main ingredients. Food Chem. 2008;111:236–42.
- 42. Suliburska J, Krejpcio Z, Reguła J, Grochowicz A. Evaluation of the content and the potential bioavailability of minerals from gluten-free products. Acta Sci Pol Technol Aliment. 2013;12:75–9.
- 43. Churruca I, Miranda J, Lasa A, Bustamante M, Larretxi I, Simon E. Analysis of body composition and food habits of Spanish celiac women. Nutrients. 2015;7:5515–31.
- 44. Bardella MT, Fredella C, Prampolini L, Molteni N, Giunta AM, Bianchi PA. Body composition and dietary intakes in adult celiac disease patients consuming a strict gluten-free diet. Am J Clin Nutr. 2000;72:937–9.
- 45. Martin U, Mercer SW. A comparison of general practitioners prescribing of gluten-free foods for the treatment of celiac disease with national prescribing guidelines. J Hum Nutr Diet. 2014;27(1):96–104.
- 46. Burden M, Mooney PD, Blanshard RJ, White WL, Cambray-Deakin DR, Sanders DS. Cost and availability of gluten-free food in the UK: in store and online. Postgrad Med J. 2015;91(1081):622–6.
- 47. Carini E, Scazzina F, Curti E, Fattori F, Mazzeo T, Vittadini E. Physicochemical, sensory properties and starch in vitro digestion of gluten-free breads. Int J Food Sci Nutr. 2015;66:867–72.
- 48. Flores-Silva PC, Rodriguez-Ambriz SL, Bello-Pérez LA. Gluten-free snacks using plantainchickpea and maize blend: chemical composition, starch digestibility, and predicted glycemic index. J Food Sci. 2015;80:C961–6.
- 49. Berti C, Riso P, Monti LD, Porrini M. In vitro starch digestibility and in vivo glucose response of gluten-free foods and their gluten counterparts. Eur J Nutr. 2004;43:198–204.
- 50. Jenkins DJ, Thorne MJ, Wolever TM, Jenkins AL, Rao AV, Thompson LU. The effect of starch-protein interaction in wheat on the glycemic response and rate of in vitro digestion. Am J Clin Nutr. 1987;45:946–51.
- 51. Packer SC, Dornhorst A, Frost GS. The glycemic index of a range of gluten-free foods. Diabet Med. 2000;17:657–60.
- 52. Alvarez-Jubete L, Arendt EK, Gallagher E. Nutritive value of pseudo-cereals and their increasing use as functional gluten-free ingredients. Trends Food Sci Technol. 2010;21:106–13.
- 53. Alvarez-Jubete L, Arendt EK, Gallagher E. Nutritive value and chemical composition of pseudo-cereals as gluten-free ingredients. Int J Food Sci Nutr. 2009;60(Suppl 4):240–57.
- 54. Gambuś H, Gambuś F, Pastuszka D, Wrona P, Ziobro R, Sabat R, et al. Quality of gluten-free supplemented cakes and biscuits. Int J Food Sci Nutr. 2009;60(Suppl 4):31–50.
- 55. Rybicka I, Krawczyk M, Stanisz E, Gliszczyńska-Świgło A. Selenium in gluten-free products. Plant Foods Hum Nutr. 2015;70:128–34.
- 56. Altındağ G, Certel M, Erem F, İlknur KÜ. Quality characteristics of gluten-free cookies made of buckwheat, corn, and rice flour with/without transglutaminase. Food Sci Technol Int. 2015;21(3):213–20.
- 57. Rai S, Kaur A, Singh B. Quality characteristics of gluten-free cookies prepared from different flour combinations. J Food Sci Technol. 2014;51:785–9.
- 58. Lemos AR, Capriles VD, Pinto e silva MEM, Arêas JAG. Effect of incorporation of amaranth on the physical properties and nutritional value of cheese bread. Food Sci Tech (Campinas). 2012;32:427–31.
- 59. Tsatsaragkou K, Yiannopoulos S, Kontogiorgi A, Poulli E, Krokida M, Mandala I. Mathematical approach of structural and textural properties of gluten-free bread enriched with carob flour. J Cereal Sci. 2012;56(3):603–9.
- 60. Giménez MA, Drago SR, Bassett MN, Lobo MO, Sammán NC. Nutritional improvement of corn pasta-like product with broad bean (*Vicia faba*) and quinoa (*Chenopodium quinoa*). Food Chem. 2016;199:150–6.
- 61. Padalino L, Mastromatteo M, Lecce L, Spinelli S, Conte A, Del Nobile MA. Optimization and characterization of gluten-free spaghetti enriched with chickpea flour. Int J Food Sci Nutr. 2015;66:148–58.
- 62. Pineli LL, de Aguiar LA, de Oliveira GT, Botelho RB, Ibiapina MD, de Lima HC, et al. Use of baru (Brazilian almond) waste from physical extraction of oil to produce gluten-free cakes. Plant Foods Hum Nutr. 2015;70(1):50–5.
- 63. Korus J, Juszczak L, Ziobro R, Witczak M, Grzelak K, Sójka M. Defatted strawberry and blackcurrant seeds as functional ingredients of gluten-free bread. J Texture Stud. 2012;43:29–39.
- 64. O'Shea N, Doran L, Auty M, Arendt E, Gallagher E. The rheology, microstructure and sensory characteristics of a gluten-free bread formulation enhanced with orange pomace. Food Funct. 2013;4:1856–63.
- 65. Rizzello CG, Montemurro M, Gobbetti M. Characterization of the bread made with durum wheat semolina rendered gluten free by sourdough biotechnology in comparison with commercial gluten-free products. J Food Sci. 2016;81:H2263–72.
- 66. Wolter A, Hager AS, Zannini E, Arendt EK. Influence of sourdough on in vitro starch digestibility and predicted glycemic indices of gluten-free breads. Food Funct. 2014;5:564–72.
- 67. Cornejo F, Caceres PJ, Martínez-Villaluenga C, Rosell CM, Frias J. Effects of germination on the nutritive value and bioactive compounds of brown rice breads. Food Chem. 2015;173:298–304.
- 68. Welstead L.The gluten-free diet in the 3rd millennium: rules, risks and opportunities. Diseases. 2015;3(3):136–49.
- 69. Kiskini A, Kapsokefalou M, Yanniotis S, Mandala I. Effect of different iron compounds on wheat and gluten-free breads. J Sci Food Agric. 2010;90:1136–45.
- 70. Krupa-Kozak U, Wronkowska M, Soral-Smietana M. Effect of buckwheat flour on microelements and proteins contents in gluten-free bread. Czech J Food Sci. 2011;29(3):103–8.

Chapter 6 Gluten-Free Diet: Nutritional Status and Dietary Habits of Celiac Patients

Itziar Churruca, Idoia Larretxi, and Arrate Lasa

Abbreviations

- BMI Body mass index
- CD Celiac disease
- CH Carbohydrate
- FFM Fat-free mass
- FM Fat mass
- GF Gluten-free
- GFD Gluten-free diet
- GFP Gluten-free product
- ppm Parts per million

6.1 Introduction

A strict, lifelong, gluten-free diet (GFD) is currently the only effective treatment for celiac disease (CD); it consists of the total elimination of all products containing gluten from the diet. As explained in previous chapters, gluten protein is present in some of the cereals from the *Triticeae* family such as wheat, barley, rye, triticale, kamut, spelt, and probably oats. Actually, the consumption of oats by celiac patients is controversial, and there is no unanimity to consider it as a safe protein. Even though the prolamin content in this cereal is much lower than in the other cereals recognized as toxic, many products containing oats are contaminated by traces of flours in cereals containing gluten, which represents a limitation for its use. Because of this, the most widespread recommendation is to discourage oat consumption.

Following a GFD means avoiding the toxic prolamin in order to guarantee celiac patients' health and well-being. For that purpose, it is essential to know which foods contain or may contain gluten, and which do not. According to its gluten content, a food is classified into one of three categories: foods that contain gluten, foods that do not contain gluten, and foods that may contain gluten.

Foods that contain gluten are considered harmful for celiac patients' health. This group includes cereals containing toxic prolamins and all their derivatives. Cerealbased products for specific use in celiac patients (gluten-free products (GFPs)) are excluded from this list as long as it is specified on the label.

Foods that do not contain gluten are adequate and secure foods in a GFD because they do not contain any toxic prolamin. This group includes cereals that do not contain gluten per se (rice, maize, quinoa, buckwheat, millet or sorghum), and foods that are not cereal derivatives (fruits, vegetables, fish, meat, etc.). There are also some cereal-based products which, even though they originally contained the toxic prolamin, have had it almost totally removed during the elaboration process and the final product does not exceed the content authorized by legislation. Thus they are suitable for celiac patients.

Foods that may contain gluten belong to a group that includes certain products that in their original composition did not have gluten, but which during the elaboration process, wheat or other harmful cereal derivatives could have been added (either deliberately or accidentally).

Table [6.1](#page-84-0) shows a classification of the different food groups according to their potential presence of gluten [\[1](#page-94-0)]

It is quite remarkable that almost all fresh foods, except for certain cereals, are gluten-free. On the contrary, many processed products include or may include gluten in their composition. Actually, flours and wheat starches are widely used by food industries and certain products, such as cold meats or other manufactured products, which originally did not contain gluten, but can result in final products containing it. Therefore, labels need to be carefully read, and special attention paid to the ingredient list and to certification marks that ensure the absence of gluten. Moreover, any cross-contamination of gluten should be avoided during storage, preparation, and cooking. These rules are essential for celiac patients because even the tiniest quantities of gluten can cause damage to their intestinal villi.

It must be pointed out that the correct GFD has to be not only safe for celiac patients, but also nutritionally balanced. A balanced diet involves fulfilling all energy and nutrient requirements, avoiding nutrient deficiencies, and ensuring a healthful status. In general terms, balanced energy distribution in a diet is obtained when 55% of the energy comes from carbohydrates, 30% from fats, and 15% from protein, and when all vitamin and mineral recommendations, as well as those of water, fiber, or other compounds, are fulfilled.

When the nutritional composition of GFD has been assessed, unbalanced proportions of macronutrients and several deficiencies in vitamin and mineral content have been observed. This could be for several reasons: on the one hand, celiac patients who strictly adhere to a GFD have to exclude gluten-containing grains from their diets; this means that foods such as bread, flour, pasta, breakfast cereals, or biscuits are eliminated. These products are the major source of energy: protein, carbohydrates and micronutrients, such as iron, zinc, calcium, magnesium, and the

	Foods containing gluten	Foods that do not contain gluten	Foods that may contain gluten
Cereals and tubers	Wheat, oats, barley, rye, spelt, triticale, wild wheat, kamut, green spelt grain, bulgur, semolina and all their flours. Other foods made with those flours (porridges, battered foods, biscuits)	Corn, rice, millet grain, wheat, buckwheat, quinoa, amaranth beans, flour carob, tapioca, manioc and potato, and all their derivatives	Processed products (chips, mashed potatoes), cornmeal, rice flour (pollution crusade) and their derivatives
Vegetables	Breaded or floured vegetables	All natural vegetables	Pre-cooked dishes
Fruit and nuts	Floured dry fruits (figs)	All raw fruits and nuts	Toasted nuts with salt,
Dairies	Yogurt with cereals or biscuits	Milk and dairy products: cured cheeses, cottage cheese, cream, natural yogurt and junket	creams, puddings and custards, milkshakes, prepared dairy desserts, flavored yogurt and with pieces of fruit, powered junket, processed cheese
Protein foods	Breaded or floured meat. and fish and with gluten-containing sauces	All kinds of meats and fresh viscera, cured meat. Serrano ham. Fresh/frozen fish without breading, fresh seafood and oil/natural tinned fish and shellfish. Eggs Natural legumes	Cold meat, canned meat and fish with sauces, various patés and cooked ham
Miscellaneous	Béchamel sauce	Vegetable oils, butter, margarine, lard, vinegar, pure spices	Prepared sauces, soy sauces, spices preparations, bouillon cubes, dried powder or granulated barm and yeast extracts, peppers
Foods that have to be consumed sparingly	Chocolate cereals containing gluten, bakery products, beer, coffee substitutes with barley or malt, oats beverages	Honey and sugar soft drinks, coffee, tea, natural juices, fruit nectars, cava, wines, grape juice	Chocolate, candy and gumdrops, cocoa cream. Chocolate and coffee substitutes, combined drinks, liqueurs

Table 6.1 Classification of foods from different food groups according to their gluten content [\[1\]](#page-94-0)

B vitamins [\[2](#page-94-0), [3](#page-95-0)]. Moreover, it has been reported that wheat, rye, and barley supply approximately 35% of the dietary fiber intake in healthy children [\[4](#page-95-0)]. The restrictions on the cereals mentioned can compromise the nutritional status of celiac children and make the implementation of the recommendations for a varied and balanced diet difficult sometimes.

On the other hand, celiac patients tend to consume refined gluten-free cereal products, which do not have the same nutritional composition as their unrefined analogues. Studies aimed at analyzing the nutritional composition of GFP have reported differences in calories, macronutrients, fiber, sodium, salt and cholesterol content between some gluten-free rendered and gluten-containing foodstuffs [\[5](#page-95-0)]. Moreover, whereas wheat flour products are usually enriched, gluten-free cereal products are not, and therefore they often do not contain the same levels of micronutrients, such as thiamine, riboflavin, niacin, folate, vitamin D, calcium and iron [[6,](#page-95-0) [7](#page-95-0)].

In this sense, people with celiac disease following GFDs develop complications such as anemia, which is related to a lack of iron and folic acid, or osteoporosis, associated with a lack of calcium and vitamin D, among others [\[8](#page-95-0), [9](#page-95-0)]. In the following sections we explain the most important outcomes from studies on celiac adults and children, especially results obtained when their nutritional status and dietary intakes have been assessed.

6.2 GFD in Adult Celiac Patients: Nutritional Status and Dietary Habits

Studies of adult celiac patients show that nutritional deficiencies (low vitamin and mineral plasma levels) due to the malabsorption caused by intestinal atrophy are common. It has been known for a long time that newly diagnosed celiac patients suffer from malnutrition, but what is not so widely analyzed is whether this situation persists when these patients start following a GFD, which is, as mentioned above, the unique treatment for celiac disease.

Non-treated celiac patients regularly develop diseases such as anemia (caused by iron deficiency), retinopathy (vitamin A deficiency), systemic and peripheral neuropathy (vitamins B12 and E), complications of pregnancy (iron or folic acid), dental disease, limited joint motility, osteopenia, and osteoporosis [[8\]](#page-95-0). In fact, there have been several studies of newly diagnosed celiac adults that point out iron and copper deficiencies, as well as vitamins A and D, with the E and B groups (folate, B12 and B6) as the most common ones [[10,](#page-95-0) [11](#page-95-0)]. Moreover, when the nutritional status of these patients was analyzed with anthropometric data, adult celiac patients generally showed lower body weight, BMI, fat mass (FM) and fat-free mass (FFM) than control subjects [[12–16\]](#page-95-0). This makes an evaluation of the nutritional status and metabolic aspects of celiac patients essential at the time of diagnosis in order to detect possible malnutrition.

It could be thought that the situation at diagnosis would be recovered when patients begin a GFD; indeed, it has been shown that when celiac patients begin one, intestinal atrophy improves and there is a remission of symptoms. Thus, vitamin and mineral absorption should be improved in the intestinal villi. Nevertheless, there has been recent evidence that nutritional deficiencies are not completely normalized after GFD follow-up [\[12](#page-95-0), [13](#page-95-0), [17](#page-95-0)] and Capristo et al. [[18\]](#page-95-0). For instance, the metabolic variables of celiac patients who had a marked improvement in the duodenal mucosa after following a GFD were compared with those of recently diagnosed patients and the control population. As a result, they found that hemoglobin,

hematocrit, iron, and transferrin serum concentrations were lower in all celiac patients (treated and newly diagnosed). Hallert et al. [\[19](#page-95-0)] measured total plasma homocysteine levels (as the metabolic marker of folate), and vitamins B6 and B12 in 30 adults with celiac disease who had followed a GFD for 8–12 years. At this period, a third of the subjects showed higher plasma homocysteine levels and lower B6 and folate content; thus, authors concluded that vitamin status should be regularly reviewed in the follow-up of adult celiac patients.

Even though anthropometric data in patients going on a GFD improve when compared to those from a baseline, they are no better than those of the control population. In a study by Smecuol et al. [[20\]](#page-95-0), 25 newly diagnosed patients were recruited, presenting low percentages of fat, lean tissue, and bone compartments. However, after 37 months of GFD, body weight, BMI, fat mass and bone mass had significantly increased. Along these lines, Ukkola et al. [\[21](#page-95-0)] observed that patients who were underweight at diagnosis increased their body weight after 1 year of GFD, and that those who were overweight or obese lost weight. By contrast, when Churruca et al. [\[22](#page-95-0)] analyzed anthropometric measurements of a cohort of adult celiac women and compared them to those of Spanish control women, most of them showed lower body weight and fat mass than the women in the control group.

In another study carried out by Bardella et al. [\[23](#page-95-0)], similar results were observed: lower values of body weight, FM, lean mass and bone mass of celiac adult patients compared to those of the control subjects. These results as a whole suggest that even if an improvement of the nutritional status is achieved with GFD, it still does not reach the situation found in the control population. There can be two explanations for this: on the one hand, the pathological situation that going on a GFD still provokes a low bioavailability of nutrients, and on the other, these patients are more concerned about their dietary habits and hence lower weight, BMI, and fat mass values. In fact, it is remarkable that not all authors comparing data from baseline with those after following GFD show an amelioration of the nutritional status. For instance, Capristo et al. [[17\]](#page-95-0), observed that anthropometric data on patients going on a GFD were as bad as those of the newly diagnosed, which were, altogether, worse than those observed in the control population. They therefore concluded that GFD does not improve the nutritional status of adult celiac patients. A summary of the studies demonstrating biochemical and anthropometric characteristics of newly diagnosed celiac patients and those starting a GFD are shown in Table [6.2.](#page-87-0)

In view of all this, following a GFD does not seem to fulfill all the nutritional requirements of adult celiac patients. In fact, it has been shown that the nutritional composition of GFD is unbalanced in terms of energy requirements, macronutrient distribution, and micronutrient intake. For instance, when Churruca et al. [\[22](#page-95-0)] analyzed the eating patterns and diet composition of 54 adult celiac women, they found that their energy intake was slightly lower than the dietary reference intakes. Moreover, excessive protein intake and over-consumption of fat was observed. Carbohydrate and fiber consumption was below the recommended levels, and vitamin D, iron, and iodine had a low percentage of compliance to the recommendations.

Other researchers have also assessed the nutritional composition of GFD followed by adult celiac patients, and similar results have been obtained: a lower

Table 6.2 Biochemical and anthropometric data of celiac adult subjects at diagnosis and after following a GFD **Table 6.2** Biochemical and anthropometric data of celiac adult subjects at diagnosis and after following a GFD

(continued)

 $(continued)$

NA not analyzed *NA* not analyzed

Table 6.2 (continued) **Table 6.2** (continued)

	Adults		Children and adolescents	
	Deficiencies	Excesses	Deficiencies	Excesses
Energy	Energy		Energy	
Macronutrients	Complex	Total protein	Complex	Simple carbohydrates
	carbohydrates	Total fat	carbohydrates	Total protein
			Unsaturated	Total fat
			fatty acids	Saturated fatty acids
Fiber	Fiber		Fiber	
Micronutrients	D, E, Folic Acid,		D vitamin	
Vitamins	B1, B2, B6		C vitamin	
			Thiamine	
Minerals	Mg, Fe, Ca, I, Se		Calcium	
			Magnesium	
			Selenium	
			Iron	

Table 6.3 Nutrition errors in GFD of adult people, children and adolescents [[18](#page-95-0), [22](#page-95-0)–[24](#page-96-0), [28](#page-96-0), [29](#page-96-0), [34](#page-96-0), [36–41, 43,](#page-96-0) [45](#page-96-0)]

consumption of energy than control subjects, a high percentage of fat, and a low percentage of CH and protein [\[23](#page-95-0), [24](#page-96-0)]. Capristo et al. [[18](#page-95-0)] saw that although patients had similar energy intake to that of the control patients, the macronutrient distribution was unbalanced: a high percentage of fat and CH and low consumption of protein. The enhanced dietary consumption of fats accompanied by a reduction in protein content could be related to the GFP and, concretely, to their formulations (Table 6.3).

Commonly, lipid-rich ingredients, such as animal or vegetable oils and emulsifiers (mono- and diglycerides of fatty acids) are added in order to improve the palatability and texture of GF foodstuffs [[25–27\]](#page-96-0). Moreover, these products have a lower protein content due to the use of starches, flours from low-protein cereals such as rice or corn, or the use of gums or enzymes in their elaboration [\[25](#page-96-0)]. The discrepancies observed in CH intake could be due to the differences seen between the composition of GFP, which have higher amounts than their analogues [[5,](#page-95-0) [25](#page-96-0)], and the reported low intake of non-starch carbohydrates among people following a GFD [\[25](#page-96-0)].

Data on fiber intake in people on a GFD also show that the requirements for this nutrient are not fulfilled [\[22](#page-95-0), [24](#page-96-0)] (Table 6.3). In order to argue this fact, two causes have to be taken into consideration: first, the gluten-containing cereals provide nearly a third of all the recommended dietary fiber [\[4](#page-95-0)], and second, refined glutenfree cereal products' composition supplies less fiber than their not-refined analogues because they are not as enriched or fortified [[5,](#page-95-0) [28\]](#page-96-0). Regarding the micronutrient intake in GFD, Martin et al. indicated that the vitamin B1, B2, B6, folic acid, magnesium and iron intake were lower among adult celiac patients than those observed among the general population [[22,](#page-95-0) [24\]](#page-96-0). These nutritional deficiencies can be due to the exclusion of gluten-containing grains and foods from the GFD, which are a major source of micronutrients $[2, 3]$ $[2, 3]$ $[2, 3]$, and to the consumption in a GFP, which often does not contain the same levels of micronutrients as their counterparts – e.g., thiamine, riboflavin, niacin, folate, vitamin D, calcium, or iron [\[6](#page-95-0), [28](#page-96-0), [29](#page-96-0)].

Data on the food consumption indicate as well that people following GFDs do not adhere to adequate eating plans. In the study carried out by Churruca et al. [[22\]](#page-95-0), the group observed that whereas recommendations for dairy products and fruit intake were followed, vegetable consumption was not enough for the vast majority of adult celiac women. Moreover, more than three-quarters of the participants consumed excessive amounts of meat. It must be kept in mind that the observed eating patterns and energy and nutrient intakes of celiac women from that study did not differ very much from those of the women in the control group; despite this, the authors concluded that some considerations, such as reducing fat and protein consumption and increasing fiber intake, should be taken into account.

6.3 GFDs in Celiac Children and Adolescents: Nutritional Status and Dietary Habits

Among children, CD is one of the most common food-related chronic diseases. The incidence of CD in European children is about 1%. However, it is increasing continuously [\[30](#page-96-0), [31\]](#page-96-0) and there is a significant percentage of patients still undiagnosed [[32](#page-96-0)]; indeed, a Swedish screening study put the figure at 3% in children aged 12–14 [[33](#page-96-0)].

As mentioned, a GFD must ensure the absence of gluten in the diet, but it must also be nutritionally balanced, covering all energy and nutrient requirements. This is even more important in the case of children and adolescents, whose diets must also ensure adequate growth and development to prevent deficiencies and promote healthy lives. Celiac children usually have lower weight, height, and BMIs than ageand sex-matched controls, leading to less overweight and obesity and more underweight children. Nevertheless, some authors have reported that following a GFD may contribute to undesirable weight gain due to the imbalance in its composition [\[28](#page-96-0), [34](#page-96-0), [35](#page-96-0)].

Several studies have found unbalanced dietary intakes [[28,](#page-96-0) [29\]](#page-96-0) due to a reduced energy intake [\[36](#page-96-0)], low intakes of complex carbohydrates and fibers [\[34](#page-96-0), [37](#page-96-0), [38\]](#page-96-0), and subsequent higher protein [[36\]](#page-96-0) and fat intakes [[34, 36](#page-96-0), [38](#page-96-0), [39\]](#page-96-0). With regard to lipids, the intake of fatty acids is also unbalanced, and celiac children and adolescents show a high consumption of saturated fats and low consumption of unsaturated fats [[38,](#page-96-0) [40\]](#page-96-0) (Table [6.3](#page-90-0)).

These dietary habits are similar to those observed in non-celiac children and adolescents [[38](#page-96-0), [40](#page-96-0)]. Nevertheless, different results have been reported when comparing the GFDs of celiac children and adolescents to that of the general population. Zuccoti et al. [[41](#page-96-0)] reported that although both celiac and non-celiac children showed higher protein, fat, and sugar intake than was recommended in Italy, celiac children presented higher energy and carbohydrate intakes and lower fat intakes, without differences in protein-derived energy. In a study conducted on celiac children in Spain to assess whether there was any change in the diet with gluten prior to diagnosis and the glutenfree diet one year after diagnosis, an increase in the ingestion of monounsaturated fatty acid and a decrease of saturated ones in GFDs was observed [\[42](#page-96-0)]. In contrast, Babio et al. [\[43](#page-96-0)] observed higher consumption of added sugar, total fat, and foods rich in protein, such as meat, fish, and eggs, and lower amounts of foods rich in starch in celiacs than in the control group in people aged 10–23.

With regard to fiber, its intake in celiac children is below the recommendation, as occurs in the general population [[34,](#page-96-0) [38](#page-96-0), [43](#page-96-0)]. Some researchers have not observed differences in fiber content in celiac and non-celiac children's diets [[38,](#page-96-0) [43\]](#page-96-0), but Mariani and colleagues showed a lower consumption of carbohydrates, and in particular a low fiber content, in the diets of celiac adolescents as compared to healthy adolescents [\[34](#page-96-0)]; this could be explained, as mentioned above, by the lack of cereals rich in fiber and the presence of refined cereals in the GFD [\[4](#page-95-0), [28](#page-96-0)].

GFDs also lead to micronutrient deficiencies in celiac children; these deficiencies include vitamins D, A, K, and E, as well as folic acid, vitamin B12, zinc, iron, and calcium- related ones [\[38](#page-96-0), [41](#page-96-0), [43–45\]](#page-96-0) (Table [6.3\)](#page-90-0). Most of them are first associated with untreated celiac disease due to malabsorption caused by the atrophy of intestinal villi. However, it has been reported that among celiac adults and children on GFDs, some micronutrient deficiencies may persist as well [[7,](#page-95-0) [28, 29\]](#page-96-0). Concerning vitamins, several researchers have observed insufficient intakes of vitamins D [\[38](#page-96-0)] and C [\[40](#page-96-0)] as well as thiamine [\[40](#page-96-0)] in celiac children. Similar results have been observed regarding minerals, such as calcium [\[41](#page-96-0)], magnesium [\[38](#page-96-0), [41\]](#page-96-0), selenium [\[38](#page-96-0)] and iron [[41\]](#page-96-0). Therefore, as proposed for adults, the serum levels of some of these micronutrients should be checked in all children with celiac disease who follow a GFD [[44\]](#page-96-0). Although many researchers have found diminished micronutrient intake among celiac children, it must be pointed out that Ohlund et al. [\[38](#page-96-0)] observed an increase in the intake of iron and calcium in celiac with respect to participants in the control group.

As to the dietary habits of celiac children and adolescents, the consumption of food groups shows a low adherence to pyramid guidelines. Celiac children consume a very low amount of cereals as a way to avoid gluten. Babio et al. [\[43](#page-96-0)] found that celiac patients consume less starch (pasta, bread, and pastries) and more proteinrich foods (meat, fish, eggs) than the non-celiac population. Moreover, celiac children do not fulfill the recommendations for foods rich in fiber, such as legumes, vegetables, and fruits. Thus, as proposed for adults, reducing protein consumption and increasing fiber intake should be also considered [[22\]](#page-95-0).

6.4 Strategies and New Proposals for Improving the Nutritional Status of Celiac Patients and Making GFDs More Balanced

Generally speaking, all the studies previously mentioned show that celiac patients on GFDs do not fulfill energy recommendations, that macronutrient distribution is unbalanced, and that the consumption of certain micronutrients and fibers is inadequate. Considering that the GFD has to be maintained for a lifetime, it will be

Nutrient	Sources
Iron	Meats (beef, liver), fish (sardines, clams, oysters), beans (white, lentil, chickpea), grains (quinoa, buckwheat, teff), dark green leafy vegetables, seeds and nuts
Calcium	Dairy products (milk, yogurt, cheese), fortified milk substitutes and juices Fish (sardines, salmon with bones, trout, perch), dark green leafy vegetables (spinach, dandelion and turnip greens, kale), beans, grains (quinoa, buckwheat, millet)
B Complex vitamins	Grains (quinoa, buckwheat, millet, brown rice, amaranth) dark green leafy vegetables, legumes, meats and dairy products
Fiber	Beans (navy, kidney, split pea, lentils, black beans, pinto beans, chickpeas) sweet potato with skin, grains (quinoa, buckwheat, millet, brown rice, amaranth, flax seed meal, rice bran) raw fruits and vegetables; stewed prunes, dried figs, nuts

Table 6.4 Natural dietary sources that may help fulfill the requirements of vitamins and minerals that are commonly lacking in celiac patients

necessary to make efforts and design new strategies to be followed by celiac patients in order to improve diet quality and their nutritional status. Some of these strategies could include the following features:

- (a) The consumption of cereals other than rice and corn that are free of gluten per se should be encouraged [\[28](#page-96-0)]. This is the situation with quinoa and amaranth, which are good sources of vitamins (riboflavin, folic acid, vitamin C and vitamin E). Moreover, the appropriate consumption of other foods (apart from cereals), such as, fish, meat, and mainly fruits and vegetables, should be potentiated, due to their containing the vitamins and minerals that celiac patients lack [[29\]](#page-96-0). Table 6.4 shows a few strategies that can be followed with natural products in order to fulfill micronutrient recommendations.
- (b) GF products' fortification: Despite the traditional, yet unusual fortification in order to avoid potential contamination, it seems that gluten-free products are now being fortified [[7\]](#page-95-0). This fortification should be one of the main objectives of the food industry's GFPs' specialized manufacturing.
- (c) The use of supplements in a GFD: It has been shown that the regular use of supplements can improve the nutritional deficiencies that were observed. For instance, B-vitamin supplements have been shown to be effective in reducing homocysteine levels in patients with celiac disease, and they have been proposed as a possible tool to be considered for disease management [[46\]](#page-96-0).
- (d) Nutrition education for celiac patients: Education on nutrition should become part of the therapeutic pathway, above all in childhood [\[28](#page-96-0)], and specific dietetic recommendations have to be developed for people on GFDs. In fact, dietetic and celiac associations have published nutritional guides that alert patients to the potential nutritional deficiencies resulting from a nutritionally unbalanced GFD [[1\]](#page-94-0). Moreover, specific tools to evaluate and design gluten-free diets are needed because those available on the market do not contain the nutritional composition of gluten-free products.
- (e) Increasing the adherence to GFDs among celiac patients: Adherence to the diet has been described as a crucial factor for the achievement of total correction of body composition, the minimization of symptoms, and the healing of intestinal mucosa. Prospective studies of newly diagnosed celiac adults with dietary assessments after 1 and 5 years, have shown that those patients who strictly complied with GFDs were the ones whose intestinal lesions and body composition became normal more quickly [[20,](#page-95-0) [47\]](#page-97-0). However, patients with no adherence to the diet or, as the authors classified, those with regular gluten intake episodes, did not improve.
- (f) Reducing the incidence of gluten transgressions: Some patients who strictly adhere to GFDs still suffer from digestive pain and discomfort; this can be due to the ingestion of traces of gluten, which is known as gluten transgression. Consuming gluten traces even for one day leads to an accumulation of small amounts that can result in the appearance of symptoms. Along these lines, it has been found that exposure to less than 10 mg/day is unlikely to cause histological changes in the intestinal mucosa, and that exposures to 50 mg/day or more is likely to do so [\[48–50](#page-97-0)]. For this reason, the acceptable gluten threshold for foodstuffs has progressively declined over the last few years, to 20 mg/kg or ppm. Understanding that total gluten intake must be limited to less than 50 mg/ day, it would be possible to consume a large amount of these foods on a daily basis. Higher ingestions, either by a high rate of transgression or low adherence to the GFD could explain the lack of the symptoms' disappearance or of the nutritional status improvement among celiac patients following GFD.

Unintentional transgressions are also usual in celiac patients who "eat out," due to the fact that kitchen staff could have limited knowledge of the disease and often are not qualified enough to produce GF meals, so celiac patients usually avoid eating in restaurants. Therefore, it is necessary to improve the understanding of CD in food services and to ensure safe food consumption for celiac sufferers [\[51](#page-97-0)].

(g) A regular follow-up of celiac patients on a GFD: These regular tests should include measuring serum antibodies, body composition, and a detailed dietary history, as well as checking for symptoms of nutritional deficiencies, the presence of malignancies, and other autoimmune diseases [\[8](#page-95-0)].

References

- 1. Lasa A, Churruca I, Miranda J, Larretxi I, Bustamante MA, Simón E. Guía de alimentación equilibrada para las personas celiacas. Departamento de Salud de Gobierno Vasco, asociación de Celiacos de Euskadi y Laboratorio de Análisis de Gluten de la Universidad del País Vasco. 2014. ISBN: 978–84–695-9829-0.
- 2. Whitton C, Nicholson SK, Roberts C, Prynne CJ, Pot GK, Olson A, et al. National diet and nutrition survey: UK food consumption and nutrient intakes from the first year of the rolling programme and comparisons with previous surveys. Br J Nutr. 2011;106:1899–914.
- 3. Størsrud S, Hulthén LR, Lenner RA. Beneficial effects of oats in the gluten-free diet of adults with special reference to nutrient status, symptoms and subjective experiences. Br J Nutr. 2003;90:101–7.
- 4. Enghardt BH, Pearson M, Becker W. Dietary habits and nutrient intake in Swedish children 4 years old and school children in grades 2 and 5 (Riksmaten – barn 2003). Uppsala: Uppsala, National Food Administration (Livsmedelsverket); 2006.
- 5. Miranda J, Lasa A, Bustamante MA, Churruca I, Simon E. Nutritional differences between a gluten-free diet and a diet containing equivalent products with gluten. Plant Foods Hum Nutr. 2014;69:182–7.
- 6. Thompson T. Thiamin, riboflavin, and niacin contents of the gluten-free diet: is there cause for concern? J Am Diet Assoc. 1999;99:858–62.
- 7. Saturni L, Ferretti G, Bacchetti T. The gluten-free diet: safety and nutritional quality. Forum Nutr. 2010;2:16–34.
- 8. Pietzak MM. Follow-up of patients with celiac disease: achieving compliance with treatment. Gastroenterology. 2005;128(4 Suppl 1):S135–41.
- 9. Valdimarsson T, Toss G, Löfman O, Ström M. Three years' follow-up of bone density in adult celiac disease: significance of secondary hyperparathyroidism. Scand J Gastroenterol. 2000;35:274–80.
- 10. Wierdsma NJ, van Bokhorst-de van der Schueren MA, Berkenpas M, Mulder CJ, van Bodegraven AA. Vitamin and mineral deficiencies are highly prevalent in newly diagnosed celiac disease patients. Forum Nutr. 2013;5:3975–92.
- 11. Malandrino N, Capristo E, Farnetti S, Leggio L, Abenavoli L, Addolorato G, et al. Metabolic and nutritional features in adult celiac patients. Dig Dis. 2008;26:128–33.
- 12. Corazza GR, Di Sario A, Sacco G, Zoli G, Treggiari EA, Brusco G, et al. Subclinical celiac disease: an anthropometric assessment. J Intern Med. 1994;236:183–7.
- 13. Capristo E, Mingrone G, Addolorato G, Greco AV, Corazza GR, Gasbarrini G. Differences in metabolic variables between adult celiac patients at diagnosis and patients on a gluten-free diet. Scand J Gastroenterol. 1997;32:1222–9.
- 14. Bodé S, Hassager C, Gudmand-Høyer E, Christiansen C. Body composition and calcium metabolism in adult treated celiac disease. Gut. 1991;32:1342–5.
- 15. Mazure RM, Vazquez H, Gonzalez D, Mautalen C, Soifer G, Cataldi M, et al. Early changes of body composition in asymptomatic celiac disease patients. Am J Gastroenterol. 1996;91:726–30.
- 16. Capristo E, Addolorato G, Greco AV, Gasbarrini G. Body composition and energy metabolism in celiac disease. Am J Gastroenterol. 1998;93:1596–7.
- 17. Capristo E, Addolorato G, Mingrone G, De Gaetano A, Greco AV, Tataranni PA, et al. Changes in body composition, substrate oxidation, and resting metabolic rate in adult celiac disease patients after a 1-y gluten-free diet treatment. Am J Clin Nutr. 2000;72:76–81.
- 18. Capristo E, Malandrino N, Farnetti S, Mingrone G, Leggio L, Addolorato G, et al. Increased serum high-density lipoprotein-cholesterol concentration in celiac disease after gluten-free diet treatment correlates with body fat stores. J Clin Gastroenterol. 2009;43:946–9.
- 19. Hallert C, Grant C, Grehn S, Grännö C, Hultén S, Midhagen G, et al. Evidence of poor vitamin status in celiac patients on a gluten-free diet for 10 years. Aliment Pharmacol Ther. 2002;16:1333–9.
- 20. Smecuol E, Gonzalez D, Mautalen C, Siccardi A, Cataldi M, Niveloni S, Mazure R, Vazquez H, Pedreira S, Soifer G, Boerr LA, Mauriño E, Bai JC. Longitudinal study on the effect of treatment on body composition and anthropometry of celiac disease patients. Am J Gastroenterol. 1997;92:639–43.
- 21. Ukkola A, Mäki M, Kurppa K, Collin P, Huhtala H, Kekkonen L, et al. Changes in body mass index on a gluten-free diet in celiac disease: a nationwide study. Eur J Intern Med. 2012;23:384–8.
- 22. Churruca I, Miranda J, Lasa A, Bustamante M, Larretxi I, Simon E. Analysis of body composition and food habits of Spanish celiac women. Forum Nutr. 2015;7:5515–31.
- 23. Bardella MT, Fredella C, Prampolini L, Molteni N, Giunta AM, Bianchi PA. Body composition and dietary intakes in adult celiac disease patients consuming a strict gluten-free diet. Am J Clin Nutr. 2000;72:937–9.
- 24. Martin J, Geisel T, Maresch C, Krieger K, Stein J. Inadequate nutrient intake in patients with celiac disease: results from a German dietary survey. Digestion. 2013;87:240–6.
- 25. Pellegrini N, Agostoni C. Nutritional aspects of gluten-free products. J Sci Food Agric. 2015;95(12):2380–5.
- 26. Houben A, Höchstötter A, Becker T. Possibilities to increase the quality in gluten-free bread production: an overview. Eur Food Res Technol. 2012;235:195–208.
- 27. Marti A, Pagani MA. What can play the role of gluten in gluten-free pasta? Trends Food Sci Technol. 2013;31:63–71.
- 28. Vici G, Belli L, Biondi M, Polzonetti V. Gluten-free diet and nutrient deficiencies: a review. Clin Nutr. 2016; doi[:10.1016/j.clnu.2016.05.002](http://dx.doi.org/10.1016/j.clnu.2016.05.002).
- 29. Penagini F, Dilillo D, Meneghin F, Mameli C, Fabiano V, Zuccotti GV. Gluten-free diet in children: an approach to a nutritionally adequate and balanced diet. Forum Nutr. 2013;5:4553–65.
- 30. Fasano A, Catassi C. Celiac disease in children. Best Pract Res Clin Gastroenterol. 2005;19:467–78.
- 31. Telega G, Bennet TR, Werlin S. Emerging new clinical patterns in the presentation of celiac disease. Arch Pediatr Adolesc Med. 2008;162:164–8.
- 32. Catassi C, Gatti S, Fasano A. The new epidemiology of celiac disease. J Pediatr Gastroenterol Nutr. 2014;59(Suppl 1):S7–9.
- 33. Myléus A, Ivarsson A, Webb C, Danielsson L, Hernell O, Högberg L, et al. Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J Pediatr Gastroenterol Nutr. 2009;49(2):170–6.
- 34. Mariani P, Viti MG, Montuori M, La Vecchia A, Cipolletta E, Calvani L, et al. The gluten-free diet: a nutritional risk factor for adolescents with celiac disease? J Pediatr Gastroenterol Nutr. 1998;27:519–23.
- 35. Valletta E, Fornaro M, Cipolli M, Conte S, Bissolo F, Danchielli C. Celiac disease and obesity: need for nutritional follow-up after diagnosis. Eur J Clin Nutr. 2010;64:1371–2.
- 36. Dell'Olio D, Palma L, Malorgio E, AnsaldiBalocco N. What do celiac children eat? Dietary analysis of a group of children with celiac disease on a diet. Minerva Gastroenterol Dietol. 1995;41:269–73.
- 37. Hopman EG, le Cessie S, von Blomberg BM, Mearin ML. Nutritional management of the gluten-free diet in young people with celiac disease in The Netherlands. J Pediatr Gastroenterol Nutr. 2006;43:102–8.
- 38. Ohlund K, Olsson C, Hernell O, Ohlund I. Dietary shortcomings in children on a gluten-free diet. J Hum Nutr Diet. 2010;23:294–300.
- 39. Ferrara P, Cicala M, Tiberi E, Spadaccio C, Marcella L, Gatto A, et al. High fat consumption in children with celiac disease. Acta Gastroenterol Belg. 2009;72:296–300.
- 40. Kautto E, Ivarsson A, Norström F, Högberg L, Carlsson A, Hörnell A. Nutrient intake in adolescent girls and boys diagnosed with celiac disease at an early age is mostly comparable to their non-celiac contemporaries. J Hum Nutr Diet. 2014;27:41–53.
- 41. Zuccotti G, Fabiano V, Dilillo D, Picca M, Cravidi C, Brambilla P. Intakes of nutrients in Italian children with celiac disease and the role of commercially available gluten-free products. J Hum Nutr Diet. 2013;26:436–44.
- 42. Salazar J, Espín B, Rodríguez A, Argüelles F, García R, Rubio M, et al. Valoración nutricional de la dieta sin gluten. ¿Es la dieta sin gluten deficitaria en algún nutriente? An Pediatr. 2015;83:33–9.
- 43. Babio N, Alcázar M, Castillejo G, Recasens M, Martínez-Cerezo F, Gutiérrez-Pensado V, et al. Patients with coeliac disease reported highter consumption of added sugar and total fat than healthy individuals. J Pediatr Gastroenterol Nutr. 2017;64(1):63–9.
- 44. Erdem T, Ferat Ç, Nurdan YA, Halime E, Muhammed Selçuk S, Hamza K, et al. Vitamin and mineral deficiency in children newly diagnosed with celiac disease. Turk J Med Sci. 2015;45:833–6.
- 45. García-Manzanares A, Lucendo AJ. Nutritional and dietary aspects of celiac disease. Nutr Clin Pract. 2011;26:163–73.
- 46. Hadithi M, Mulder CJ, Stam F, Azizi J, Crusius JB, Peña AS, et al. Effect of B vitamin supplementation on plasma homocysteine levels in celiac disease. World J Gastroenterol. 2009;15:955–60.
- 47. Newnham ED, Shepherd SJ, Strauss BJ, Hosking P, Gibson PR. Adherence to the gluten-free diet can achieve the therapeutic goals in almost all patients with celiac disease: a 5-year longitudinal study from diagnosis. J Gastroenterol Hepatol. 2016;31:342–9.
- 48. Catassi C, Fabiani E, Iacono G, D'Agate C, Francavilla R, Biagi F, et al. A prospective, doubleblind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007;85:160–6.
- 49. Akobeng AK, Thomas AG. Systematic review: tolerable amount of gluten for people with celiac disease. Aliment Pharmacol Ther. 2008;27:1044–52.
- 50. La Vieille S, Dubois S, Hayward S, Koerner TB. Estimated levels of gluten incidentally present in a Canadian gluten-free diet. Forum Nutr. 2014;6:881–96.
- 51. Oliveira OMV, Zandonadi RP, Gandolfi L, de Almeida RC, Almeida LM, Pratesi R. Evaluation of the presence of gluten in beans served at self-service restaurants: a problem for celiac disease carriers. J Culinary Sci Tech. 2014;12:22–33.
- 52. Hallert C, Tobiasson P, Walan A. Serum folate determinations in tracing adult coeliacs. Scand J Gastroenterol. 1981;16:263–7.
- 53. Stene-Larsen G, Mosvold J, Ly B. Selective vitamin B12 malabsorption in adult celiac disease. Report on three cases with associated autoimmune diseases. Scand J Gastroenterol. 1988;23:1105–8.
- 54. Kemppainen T, Uusitupa M, Janatuinen E, Jarvinen R, Julkunen R, Pikkarainen P. Intakes of nutrients and nutritional status in coeliac patients. Scand J Gastroenterol. 1995;30:575–9.
- 55. Kemppainen TA, Kosma VM, Janatuinen EK, Julkunen RJ, Pikkarainen PH, Uusitupa MI. Nutritional status of newly diagnosed celiac disease patients before and after the institution of a celiac disease diet—Association with the grade of mucosal villous atrophy. Am J Clin Nutr. 1998;67:482–7.
- 56. Alwitry A. Vitamin A deficiency in coeliac disease. Br J Ophthalmol. 2000;84:1079–80.
- 57. Dahele A, Ghosh S. Vitamin B12 deficiency in untreated celiac disease. Am J Gastroenterol. 2001;96:745–50.
- 58. Dickey W. Low serum vitamin B12 is common in coeliac disease and is not due to autoimmune gastritis. Eur J Gastroenterol Hepatol. 2002;14:425–7.
- 59. Hozyasz KK, Chelchowska M, Laskowska-Klita T. Vitamin E levels in patients with celiac disease. Med Wieku Rozwoj. 2003;7:593–604.
- 60. Harper JW, Holleran SF, Ramakrishnan R, Bhagat G, Green PH. Anemia in celiac disease is multifactorial in etiology. Am J Hematol. 2007;82:996–1000.
- 61. Dickey W, Ward M, Whittle CR, Kelly MT, Pentieva K, Horigan G, Patton S, McNulty H. Homocysteine and related B-vitamin status in coeliac disease: effects of gluten exclusion and histological recovery. Scand J Gastroenterol. 2008;43:682–8.
- 62. Henri-Bhargava A, Melmed C, Glikstein R, Schipper HM. Neurologic impairment due to vitamin E and copper deficiencies in celiac disease. Neurology. 2008;71:860–1.
- 63. Bergamaschi G, Markopoulos K, Albertini R, Di Sabatino A, Biagi F, Ciccocioppo R, Arbustini E, Corazza GR. Anemia of chronic disease and defective erythropoietin production in patients with celiac disease. Haematologica. 2008;93:1785–91.
- 64. Lerner A, Shapira Y, Agmon-Levin N, Pacht A, Ben-Ami Shor D, Lopez H, Sanchez-Castanon M, Shoenfeld Y. The clinical significance of 25OH-vitamin D status in celiac disease. Clin Rev Allergy Immunol. 2013;42:322–30.